Table of Contents Welcome...... 2 Acknowledgements...... 3 About MDS...... 6 MDS Committees and Task Forces...... 10 International Congress Registration and Venue...... 13 International Congress Information...... 14 Evaluations...... 14 Opening Ceremony and Welcome Reception...... 15 Press Room...... 15 Poster Sessions and Speaker Ready Room Hours...... 16 Continuing Medical Education...... 20 Program-at-a-Glance...... 21 Scientific Session Definitions...... 23 Scientific Program Schedule...... 24 Faculty...... 36 Exhibitor Information...... 39 Exhibitor Directory...... 40 Exhibit Hall Floor Plan...... 45 Istanbul Convention and Exhibition Centre Floor Plans...... 46 Map of Istanbul...... 48 Junior Awards...... 50 Social Events...... 50 Satellite Symposia...... 51 Oral Platform Presentations...... 53 Poster Session 1...... 57 Poster Session 2...... 72 Poster Session 3...... 88 Membership Information...... 103

The Movement Disorder Society’s 11th International Congress of Parkinson’s. Disease and Movement Disorders June 3-7, 2007 • Istanbul, Turkey

555 East Wells Street, Suite 1100 Milwaukee, WI 53202 USA Tel: +1 414-276-2145 Fax: +1 414-276-3349 Web site: www.movementdisorders.org E-mail: [email protected] Welcome Letter Dear Colleagues,

On behalf of The Movement Disorder Society (MDS), we are pleased to welcome you to Istanbul, Turkey for the 11th International Congress of Parkinson’s Disease and Movement Disorders. The 11th International Congress has been designed to provide an innovative and comprehensive overview of the latest perspectives and research developments in the field of Movement Disorders.

We encourage you to take every opportunity to participate in the Scientific Program which has drawn world renowned speakers and foremost experts in their respective fields. In the next days, the latest research regarding Movement Disorders will be presented and discussed in an open format, offering unique educational opportunities for all delegates.

The International Congress convenes with a series of Opening Symposia and then continues with an array of Plenary, Parallel, Poster and Video Sessions, as well as Controversies, Skills Workshops and Meet the Expert sessions. New this year are How-To-Do-It sessions, which will bring a unique dynamic to the program.

Please save time in your schedule to participate in the Opening Ceremony and Welcome Reception on Sunday evening, as well as the Gala Event on Wednesday evening. These social events will celebrate the unique culture of Istanbul, and will incorporate some of the stunning views the city has to offer.

On behalf of The Movement Disorder Society, we would like to welcome you to Istanbul and thank you for your participation in this auspicious event.

With best regards,

Anthony E. Lang, MD, FRCPC President, The Movement Disorder Society, 2007-2008

Eduardo Tolosa, MD Chair, 2007 Congress Scientific Program Committee

Murat Emre, MD Chair, 2007 Congress Local Organizing Committee

 Acknowledgements The International Congress Oversight Committee of the 11th International Congress of Parkinson’s Disease and Movement Disorders wishes to acknowledge and thank the following companies for their support: Double Platinum Level

Platinum Level

Gold Level

Silver Level

Bronze Level



About MDS The Movement Disorder Society (MDS) is an international, professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic Movement Disorders, and abnormalities in muscle tone and motor control. The spectrum of clinical disorders represented by the Society includes, but is not limited to: Blepharospasm Dysphonia Dystonic disorders Gait disorders Huntington’s disease Parkinson’s disease Restless legs syndrome Spasticity Tardive Tics and Tourette syndrome The Movement Disorder Society (MDS) was founded in 1985 on the initiative of Professors Stanley Fahn and . C. David Marsden, whose leadership and vision guided the expansion of clinical expertise and research in this field. The organization merged in 1988 with the International Medical Society for Motor Disturbances.

PURPOSE, MISSION AND GOALS Purpose: The object and mission of the Society shall be to advance the neurological sciences pertaining to Movement Disorders; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

 About MDS Mission and Goals: To disseminate knowledge about Movement Disorders by: To formulate and promote public policy that will • Providing educational programs for clinicians, favorably affect the care of patients with Movement scientists and the general public designed to advance Disorders by: scientific and clinical knowledge about Movement • Working with regulatory agencies to assist them Disorders in the approval process of safe and effective • Sponsoring congresses and symposia on Movement therapeutic interventions Disorders • Informing the public (media) and patient support • Collaborating with other international organizations and groups of new research and therapeutic advances lay groups • Playing a proactive role in the development • Publishing journals, videotapes and other collateral of policies that affect support of research and materials committed to high scientific standards and patient care peer review • Developing standards of training in the specialty To promote research into causes, prevention and treatment of Movement Disorders by: • Using the Society’s influence and resources to enhance support for research • Facilitating the dissemination of information about research • Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders

MDS OFFICERS (2007-2008) MDS INTERNATIONAL President EXECUTIVE COMMITTEE Anthony E. Lang, Canada Giovanni Abbruzzese, Italy Alim L. Benabid, France President-Elect Philip D. Thompson, Australia Shu-Leong Ho, China Karl D. Kieburtz, USA Secretary Irene Litvan, USA Olivier Rascol, France Demetrius M. Maraganore, USA Secretary-Elect Marcelo Merello, Argentina Matthew B. Stern, USA John C. Rothwell, United Kingdom Cristina Sampaio, Portugal Treasurer Claudia M. Trenkwalder, Yoshikuni Mizuno, Japan International Congress Treasurer-Elect Oversight Committee Oscar S. Gershanik, Argentina Chair: Werner Poewe, Austria Past President Murat Emre, Turkey Andrew J. Lees, United Kingdom Anthony E. Lang, Canada. Andrew J. Lees, United Kingdom Yoshikuni Mizuno, Japan C. Warren Olanow, USA Philip D. Thompson, Australia  About MDS Congress Scientific Program Committee International Medical Society Chair: Eduardo Tolosa, Spain for Motor Disturbances Co-Chair 2007: Murat Emre, Turkey Past Presidents Alfredo Berardelli, Italy 1993-1994 C. Warren Olanow, USA Anders Björklund, Sweden 1991-1992 Bastian Conrad, Germany David John Burn, United Kingdom 1989-1990 Mark Hallett, USA Piu Chan, China 1987-1988 Mario Manfredi, Italy Cynthia L. Comella, USA 1985-1986 C. David Marsden, United Kingdom Günther Deuschl, Germany Thomas Gasser, Germany MDS International Secretariat Oscar S. Gershanik, Argentina The Movement Disorder Society Christopher G. Goetz, USA 555 East Wells Street, Suite 1100 John Hardy, USA Milwaukee, WI 53202-3823 USA Joseph Jankovic, USA Tel: +1 414-276-2145 Ryuji Kaji, Japan Fax: +1 414-276-3349 Anthony E. Lang, Canada E-mail: [email protected] Irene Litvan, USA Web site: www.movementdisorders.org Andres Lozano, Canada Werner Poewe, Austria Serge Przedborski, USA Bhim Singhal, India Oksana Suchowersky, Canada Congress Local Organizing Committee Chair: Murat Emre, Turkey Raif Çakmur, Turkey Okan Dogu, Turkey Bulent Elibol, Turkey Hakan Gürvit, Turkey Hasmet A. Hanagasi, Turkey Jale Yazici, Turkey Past Presidents 2005-2006 Andrew J. Lees, United Kingdom 2003-2004 C. Warren Olanow, USA 2001-2002 Werner Poewe, Austria 1999-2000 Mark Hallett, USA 1997-1998 Eduardo Tolosa, Spain 1995-1996 Joseph Jankovic, USA 1991-1994 C. David Marsden, United Kingdom 1988-1991 Stanley Fahn, USA



MDS Committees and Task Forces Archives Education Liaison/Public Relations Chair: Andres M. Lozano Chair: Cynthia L. Comella Chair: Regina Katzenschlager Bastiaan R. Bloem Co-Chair: Daniel Tarsy James Bower David John Burn Joaquim Ferreira Francisco Cardoso Stanley Fahn Susan Fox Andrew Evans Christopher G. Goetz Donald Grosset Neziha Gouider-Khouja Mark Hallett Andrew Hughes Robert Hauser Peter Jenner Kelly Lyons Alexander Muenchau Amos Korczyn Marcelo Merello Philippe Remy Michael Schulder Austen Peter Moore Daniel Truong William Weiner Anette Schrag Membership Awards Oksana Suchowersky Chair: Francisco Cardoso Chair: Stanley Fahn Louis Tan K. Ray Chaudhuri Robert Burke Claudia M. Trenkwalder Shengdi Chen Nir Giladi Jens Volkmann Hubert Fernandez Ryuji Kaji Financial Affairs Chafiq Hicham Federico Micheli Chair: Yoshikuni Mizuno Regina Katzenschlager Niall Quinn Kailash Bhatia Chin Song Lu Anette Schrag Mohit Bhatt Uday Muthane Matthew B. Stern Murat Emre Yoshikazu Ugawa A. Jon Stoessl Oscar Gershanik Publications Oversight Bylaws Andrew J. Lees Chair: Andrew J. Lees Chair: David Riley J. Martin Rabey Roger Barker Charles Adler Matthew B. Stern Günther Deuschl Andrew Hughes A. Jon Stoessl Thomas Gasser Petr Kanovsky Industrial Relations Christopher G. Goetz Janis Miyasaki Chair: Kapil Sethi Regina Katzenschlager Olivier Rascol Co-Chair: Murat Emre Tomoyoshi Kondo Continuing Medical Education Shengdi Chen Anthony E. Lang Chair: Ronald Pfeiffer Nobutaka Hattori Irene Litvan Cynthia L. Comella Shu-Leong Ho John C. Rothwell Philippe Damier Michael Okun Steven Schwid Irene Litvan C. Warren Olanow Philip D. Thompson Janis Miyasaki William Ondo Scientific Issues Michael Okun Anthony Schapira Chair: Thomas Gasser David Riley Mark Stacy David John Burn Robert Rodnitzky Matthew B. Stern Vincenzo Bonifati Lisa Shulman Fabrizio Stocchi Günther Deuschl Andrew Siderowf Hubert Fernandez Michele Tagliati David Eidelberg Etienne Hirsch Vladimir Kostic Andres M. Lozano Eng King Tan

10 Strategy and Planning Task Force on UPDRS Revision Task Force Chair: C. Warren Olanow Chair: Andres M. Lozano Chair: Christopher G. Goetz Anthony E. Lang Keyoumars Ashkan UPDRS Part I Andrew J. Lees Alim L. Benabid Chair: Werner Poewe Philip D. Thompson Robert Coffey Bruno Dubois Web Site Michael Dogali Anette Schrag Kelly Foote Chair: Olivier Rascol UPDRS Part II Robert Gross Co-Chair: Matthew Stern Chair: Matthew B. Stern Marwan I. Hariz Madhuri Behari Anthony E. Lang Zvi Francisco Cardoso Peter Le Witt Günther Deuschl Joachim K. Krauss UPDRS Part III Joaquim Ferreira Paul Larson Chair: Stanley Fahn Thomas Gasser Efstathios Papavassiliou Joseph Jankovic Christopher G. Goetz Hiroki Toda C. Warren Olanow Joseph Jankovic Ali T. Zirh Andrew J. Lees Task Force on PD Dementia UPDRS Part IV Irene Litvan Co-Chair: Bruno Dubois Chair: Pablo Martinez-Martín Kelly Lyons Co-Chair: Murat Emre Andrew J. Lees Philip D. Thompson Dag Aarsland Olivier Rascol Bob Van Hilten Task Force on Epidemiology G.A. Broe Chair: Caroline M. Tanner Richard Brown Scale Development Standards Yoav Ben-Shlomo David John Burn Chair: Glenn Stebbins Nadir Bharucha Jeffrey L. Cummings Robert Holloway James Bower Dennis Dickson David Nyenhuis Piu Chan Charles Duyckaerts Appendices Dusan Flisar Serge G. Gauthier Chair: Cristina Sampaio Amos D. Korczyn Christopher G. Goetz Richard Dodel Mathilde Leonardi Amos D. Korczyn Jaime Kulisevsky Andrew J. Lees Elan D. Louis Statistical Testing Zvezdan Pirtosek Richard Levy Irene Litvan Chair: Barbara C. Tilley Gustavo Roman Sue Leurgans Webster Ross Yoshikuni Mizuno C. Warren Olanow Jean Teresi Task Force on Evidence Based Werner Poewe Medicine in Movement Disorders Niall P. Quinn MDS Committee and Task Force Chair: Cristina Sampaio Cristina Sampaio Chairs and members will meet dur- Francisco Cardoso Eduardo Tolosa ing the International Congress. A Carl Clarke schedule of these meetings will be Christopher G. Goetz Task Force on Rating Scales for PD provided to the Committee and Task Austen Peter Moore Steering Committee Force members. The Committee and Werner Poewe Chair: Christopher G. Goetz Task Force schedule of meetings will Olivier Rascol Werner Poewe also be displayed on signage in the Bob Van Hilten Olivier Rascol Society’s Exhibit Booth, located on the Cristina Sampaio first floor of the Istanbul Convention Glenn Stebbins and Exhibition Centre.

11

International Congress Registration and Venue

Badges Language All International Congress attendees will receive a name The official language of the International Congress is badge with their registration materials. Badges should be English. worn at all times as they will be used to control access Registration Desk into all International Congress sessions and activities. Location: Main Entrance, First Floor, Istanbul Convention Individuals will be identified as follows: and Exhibition Centre Red = Delegate Name badges, session tickets, special event tickets and Yellow = Exhibitor International Congress registration bag tickets can be Orange = Exhibitor Delegate collected at the International Congress Registration Desk Green = Guest located in the Main Entrance of the Istanbul Convention Purple = Press and Exhibition Centre. Black = Staff Registration Desk Hours Dates Saturday, June 2...... 4:00 p.m. to 8:00 p.m. Sunday, June 3, 2007 through Thursday, June 7, 2007 Sunday, June 3...... 7:00 a.m. to 8:30 p.m. Hotel Information Monday, June 4...... 7:00 a.m. to 9:00 p.m. Hilton Tuesday, June 5...... 7:00 a.m. to 7:00 p.m. Cumhuriyet Caddesi Wednesday, June 6...... 7:00 a.m. to 7:30 p.m. Harbiye-Istanbul 34367 Thursday, June 7...... 7:00 a.m. to 5:00 p.m. Turkey Venue Tel: +90 212 315 6000 Istanbul Convention and Exhibition Centre (ICEC) Fax: +90 212 240 4165 Istanbul Lutfi Kirdar Convention and Exhibition Centre Hyatt Regency Lutfi Kirdar Uluslararasi Kongre ve Sergi Sarayi Taskisla Caddesi, Taksim Harbiye 80230 Istanbul Istanbul, 34437 Turkey Turkey Tel: + 90 212 296 3055 Tel: +90 212 368 1234 Fax: + 90 212 224 0878 Fax: +90 212 368 1000 http://www.icec.org/en/index.asp Topkon Congress Services Topkon is the 11th International Congress Housing Bureau. If you have any concerns regarding your hotel accommodations, please contact Topkon or visit their booth located on the main level of the Istanbul Convention and Exhibition Centre. Topkon Congress Services Headquarter Office Zühtü Pasa Mah. Rifat Bey Sokak No: 24 PK. 34724 Kalamis-Kadiköy, Istanbul Turkey Tel: + 90 216 330 90 20 Fax: + 90 216 330 90 05 E-mail: [email protected] Web Site: www.topkon.com

13 International Congress Information Abstract Volume of this policy is not to prevent a speaker with a potential All abstracts accepted for poster presentation have been conflict of interest from making a presentation. It is mere- published in an abstract supplement to the MDS Journal, ly intended that any potential conflict should be identified Movement Disorders. Each delegate should have received openly so that the listeners may form their own judgments one copy with their registration materials. MDS members about the presentation with the full disclosure of the facts. will receive an additional copy with an MDS Journal issue. It remains for the audience to determine whether the speaker’s outside interest may reflect a possible bias in Abstracts-On-CD-ROM either the exposition or the conclusions presented. All abstracts published in the supplement to the MDS Journal are available by Abstracts-On-CD-ROM sponsored Faculty financial disclosure information will be provided to by MDS and supported by an unrestricted educational participants onsite in Istanbul. grant from Medtronic. To obtain a copy, please visit the Please see the program addendum in your International Medtronic Booth (# 109) located in the Rumeli Building, Congress registration bag for complete information re- upper floor. garding faculty disclosure of commercial relationships. Continuing Medical Education Faculty Disclosure of Unlabeled Product Use Discussion Objectives Presentations which provide information in whole or As a result of participating in this activity, the attendee in part related to non-approved uses for drug products should be better able to: and/or devices must clearly acknowledge the unlabeled • Describe the pathophysiology and neurobiology of indications or the investigative nature of their proposed Parkinson’s disease and other Movement Disorders; uses to the audience. Speakers who plan to discuss non- • Discuss the diagnostic approaches and tools available approved uses for commercial products and/or devices for Parkinson’s disease and other Movement Disorders; must advise the International Congress audience of their • Discuss the pharmacological and non-pharmacological intent. Please see the program addendum in your Interna- treatment options available for Parkinson’s disease tional Congress registration bag for complete information and other Movement Disorders. regarding faculty disclosure of unlabeled product use discussion. Target Audience The target audience of the 11th International Congress Evaluations of Parkinson’s Disease and Movement Disorders includes Please take time to complete the evaluation forms provid- clinicians, researchers, post-doctoral fellows, medical ed for each session you attend. Your input and comments residents, medical students and other healthcare pro- are essential in planning future educational programs for fessionals with an interest in the current research and MDS. approaches for the diagnosis and treatment of Movement When completed, evaluations may be returned to your Disorders. meeting room attendants, the evaluation drop boxes or to the MDS Registration Desk. Faculty Financial Disclosure Information It is the policy of The Movement Disorder Society (MDS) to Internet Café ensure balance, independence, objectivity and scientific Location: Istanbul Convention and Exhibition Centre, rigor in all sponsored educational activities. All faculty Second Floor and Rumeli Building, First Level participating in any MDS sponsored activities are required Internet access is available to meeting attendees in to disclose to the activity audience any real or apparent two convenient locations, the ICEC and Rumeli Building. conflict(s) of interest that may have a direct bearing on Please limit your Internet use to 15 minutes to allow other the subject matter of the Continuing Medical Education attendees use of this service. This service is supported (CME) activity. This pertains to relationships with pharma- through an unrestricted educational grant from Lundbeck ceutical companies, biomedical device manufacturers, or Turkey. other corporations whose products or services are related to the subject matter of the presentation topic. The intent 14 International Congress Information MDS Exhibit and Information Booth Optional Tours Desk Location: Main Lobby, First Floor, Istanbul Convention and Location: Main Lobby, First Floor, Istanbul Convention and Exhibition Centre Exhibition Centre The Movement Disorder Society (MDS) is an International Tours have been arranged by Topkon Congress Services. Society of healthcare professionals committed to research Please visit the Tours Desk located near the Registration and patient care in the fields of Parkinson’s disease and Area in the Main Lobby on the first floor of the Istanbul other disorders of movement and motor control. Convention and Exhibition Centre to check in for the tours. Created not only to further the goals and objectives of Additional tour tickets may be purchased at the desk, MDS International, The Movement Disorder Society’s based on availability. regional sections, the Asian and Oceanian Section and Press Room European Section, strive to increase the interest, educa- Location: Office I, Istanbul Convention and Exhibition tion and participation of neurologists, Movement Disorder Centre specialists, non-Movement Disorder specialists, trainees, Members of the working media receive waived registra- allied health professionals and scientists in the Asian, tion fees for the 11th International Congress. Journalists Oceanian and European regions. and writers should report to the Press Room with their MDS supports and promotes a wide range of educational credentials to register for the International Congress and programming and other initiatives to advance scientific wear their name badge for admittance into MDS sessions. understanding and standards of care as they pertain to The Press Room will be open during the following hours: Movement Disorders. For this, MDS provides forums such Sunday, June 3 8:00 a.m. to 5:00 p.m. as a high ranking journal, scientific symposia and Interna- Monday, June 4 8:00 a.m. to 5:00 p.m. tional Congresses. Tuesday, June 5 8:00 a.m. to 5:00 p.m. Attendees are invited to take advantage of MDS member Wednesday, June 6 8:00 a.m. to 5:00 p.m. benefits by applying to the Society. Learn more about MDS Thursday, June 7 8:00 a.m. to 5:00 p.m. initiatives and speak with a representative at the MDS Exhibit and Information Booth located in the main lobby of the Istanbul Convention and Exhibition Centre during the following hours: Sunday, June 3 12:00 p.m. to 7:00 p.m. Monday, June 4 8:00 a.m. to 7:00 p.m. Tuesday, June 5 8:00 a.m. to 7:00 p.m. Wednesday, June 6 8:00 a.m. to 7:00 p.m. Thursday, June 7 8:00 a.m. to 4:30 p.m. No Cameras Cameras are not permitted in any 11th International Con- gress educational sessions or in the poster areas. Opening Ceremony and Welcome Reception Location: Istanbul Convention and Exhibition Centre, First Floor and the Rumeli Gardens The Opening Ceremony will take place on Sunday, June 3, at 7:30 p.m. The Welcome Reception will immediately fol- low the Opening Ceremony in the Rumeli Gardens. These events are open to all delegates and registered guests.

15 International Congress Information Scientific Sessions Poster Session 1 The 2007 Scientific Program incorporates Opening Sym- Location: Rumeli Hall, Lower Level posia, Plenary and Parallel Sessions, Skills Workshops, Tuesday, June 5 Video Sessions, How-To-Do-It Sessions, Meet the Expert Poster Viewing: 9:00 a.m. to 4:00 p.m. Sessions, Poster Sessions, and Controversies and Skills Authors Present: 12:30 p.m. to 2:30 p.m. Workshops. Abstracts: 33-345, and poster 683 Although the ever popular Opening Symposia and Plenary Poster Session 2 Sessions follow a style similar to the 2004 Rome and Location: Rumeli Hall, Lower Level 2005 New Orleans International Congresses, meet the Expert Sessions, Parallel Sessions and Skills Workshops Wednesday, June 6 are designed to meet the need for smaller, more focused Poster Viewing: 9:00 a.m. to 4:00 p.m. sessions. These sessions are offered to an audience size Authors Present: 12:30 p.m. to 2:30 p.m. of 50-200 participants resulting in greater opportunities Abstracts: 346-662, and Poster 788 for audience participation. Poster Session 3 Tickets are required for admission into all Parallel Ses- Location: Rumeli Hall, Lower Level sions, Video and Meet the Expert Sessions, Skills Work- Thursday, June 7 shops and How-To-Do-It Sessions. There is no additional Poster Viewing: 9:00 a.m. to 4:00 p.m. fee for tickets to these sessions. Please check the onsite Authors Present: 12:30 p.m. to 2:30 p.m. Registration Desk for availability of these tickets. Abstracts: 663-973 Poster Sessions Speaker Ready Room Location: Rumeli Hall, Lower Level Location: Sultan II, Ground Floor, Istanbul Convention and Delegate feedback from past International Congresses Exhibition Centre has indicated great interest in Poster Sessions. Poster All speakers must check in at the Speaker Ready Room Sessions are featured each day based upon the following with presentation materials on the day prior to their schedule: scheduled presentation. Equipment is available to allow faculty to review their presentations. Audiovisual person- nel will be available for assistance. The Speaker Ready Room hours are as follows: Visit us on the Web at Saturday, June 2 4:00 p.m. to 8:00 p.m. Sunday, June 3 7:00 a.m. to 8:30 p.m. www.movementdisorders.org Monday, June 4 7:00 a.m. to 9:00 p.m. Tuesday, June 5 7:00 a.m. to 7:00 p.m. For further information, please contact: Wednesday, June 6 7:00 a.m. to 7:00 p.m. The Movement Disorder Society Thursday, June 7 7:00 a.m. to 4:30 p.m. International Secretariat 555 East Wells Street, Suite 1100 Milwaukee, WI 53202 USA Tel: + 1 414-276-2145 Fax: + 1 414-276-3349 E-mail: [email protected] Web site: www.movementdisorders.org

16

Continuing Medical Education Information

Learning Objectives Requesting CME Credits/Certificates of Attendance As a result of participating in this activity, the attendee To receive a CME Certificate or Certificate of Attendance should be better able to: authenticating participation in this educational activity, • Describe the pathophysiology and neurobiology of International Congress participants must complete and Parkinson’s disease and other Movement Disorders; submit an online CME Request Form following their • Discuss the diagnostic approaches and tools available participation in the International Congress. To do so, for Parkinson’s disease and other Movement Disorders; participants may visit the CME Kiosks near the Registration • Discuss the pharmacological and non-pharmacological Area, available on Wednesday, June 6, and Thursday, June treatment options available for Parkinson’s disease and 7. Participants may also visit the Web site from their own other Movement Disorders. computer by logging on to www.movementdisorders. org/congress/congress07/cme. CME Certificates and Availability of CME Credits Certificates of Attendance can be printed directly from the This activity has been planned and implemented in Kiosks onsite or your personal computer, or e-mailed to accordance with the Essential Areas and policies of the yourself from the CME Kiosks. Accreditation Council for Continuing Medical Education Participants will need their MDS ID Number and password (ACCME) through the sponsorship of The Movement to claim credit. This information can be found on the Disorder Society. The Movement Disorder Society is bottom of your registration confirmation form (found in accredited by the ACCME to provide continuing medical your registration packet). It will also be e-mailed to all education for physicians. International Congress participants upon the completion The Scientific Program of the 11th International Congress of the 11th International Congress. of Parkinson’s Disease and Movement Disorders has been reviewed and approved for Category 1 credit toward Target Audience the American Medical Association (AMA) Physician’s The target audience of the 11th International Congress Recognition Award. The Movement Disorder Society is of Parkinson’s Disease and Movement Disorders includes accredited by the Accreditation Council for Continuing clinicians, researchers, post-doctoral fellows, medical Medical Education to provide continuing medical education residents, medical students and other healthcare to physicians. professionals with an interest in the current research and approaches for the diagnosis and treatment of Movement The Movement Disorder Society designates this educational activity for a maximum of 37 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

20 11th International Congress Program-at-a-Glance Sunday Monday Tuesday Wednesday Thursday 7:00 AM 7:00 AM Committee Meetings Committee Committee Meetings Committee Meetings Committee Meetings Meetings

8:00 AM 8:00 AM

Plenary Session 1 Plenary Session 2 Plenary Session 3 9:00 AM 9:00 AM Opening Symposia C. David Marsden . Junior Award . Stanley Fahn. Lecture Lectures Lecture 10:00 AM 10:00 AM

Parallel Parallel Sessions Plenary Session 4 11:00 AM Sessions 11:00 AM

12:00 PM 12:00 PM

Committee Meetings Lunch and Lunch and MDS Lunch 1:00 PM Poster. Poster. Business . and 1:00 PM Opening Symposia Session Session Meeting Poster. Committee Session Meetings Committee Committee 2:00 PM Meetings Meetings 2:00 PM

Oral Platform Oral Platform Plenary Session 5: 3:00 PM Presentations, Video Presentations, Video Controversies 3:00 PM Sessions, Meet the Sessions, Meet the Expert Sessions, Expert Sessions, Skills Workshop, Skills Workshop, 4:00 PM How-To-Do-It How-To-Do-It 4:00 PM Sessions Sessions

5:00 PM 5:00 PM Highlights of Posters Highlights of Posters Sessions Sessions

6:00 PM 6:00 PM

7:00 PM 7:00 PM

Opening Ceremony 8:00 PM 8:00 PM Gala Event 8:00 p.m. - midnight Welcome Reception 9:00 PM 9:00 PM

10:00 PM 10:00 PM

21

Scientific Session Definitions Opening Symposia: These sessions will provide the latest Skills Workshops: This clinic-based training session information regarding research and treatment options provides an educational illustration of treatment for Parkinson’s disease and other Movement Disorders. procedures through live demonstrations utilizing patients Planned by a subcommittee of the Congress Scientific and proper equipment to further develop practitioners’ Program Committee, these sessions are supported skills and knowledge within the field of treatment of through educational grants from Industry Supporters and Movement Disorders. are didactic in presentation format with time allotted for Controversies: This Plenary Session is designed to discussion. Continuing Medical Education credits are bring together a larger audience by incorporating all offered for these sessions. International Congress attendees. Content is prepared Parallel Sessions: These concurrent sessions are to stimulate interest and debate among a panel of designed to provide an in-depth report of the latest pre-selected experts. Views from several angles will be research findings, state-of-the-art treatment options, as addressed as discussion of pre-selected “hot” topics will well as involve a discussion of future strategies. Sessions be open for debate among the panelists. will have evidence-based components and incorporate the Highlights of Poster Sessions: These sessions are “hot” issues in Parkinson’s disease and other Movement designed to highlight the top-ranking abstracts of the Disorders. International Congress. Session content will be divided Plenary Sessions: Designed to bring together a large into two categories for review of the abstracts: Clinical audience by incorporating all International Congress and Basic. The Chair of each category will select several attendees, these sessions will provide a broad overview of interesting abstracts and obtain one or more summary the latest clinical and basic science research findings and slides of their abstracts for use in these sessions. state-of-the-art information. How-To-Do-It Sessions: These sessions are practical Video Sessions: Designed to provide a broad overview of interactive sessions focusing on illustration and will related Movement Disorders, the video sessions will focus incorporate what clinicians use, how to use it, and what on the phenomenology covering the many different kinds they watch for. of Movement Disorders affecting the population today. Meet the Expert Sessions: These interactive sessions provide attendees the opportunity to bring their case studies analysis and discussions in a smaller setting. These sessions are designed to cover treatment and management of Movement Disorders through the discussion of relevant real-life cases brought for peer review and recommendation. Attendees will be invited to share their cases at the session.

23 Scientific Program Schedule for 2007 Istanbul Congress Sunday, June 03, 2007

12:00 PM Lunch will be provided 4:00 PM to 5:00 PM Location: Halic Foyer 2012 Opening Symposium: Issues in cognitive dysfunction in Parkinson’s disease 1:00 PM to 3:00 PM Supported by an educational grant from Merck 2010 Opening Symposium: Benefits and issues in Serono the use of long lasting agonists Location: Marmara Room Location: Anadolu Auditorium Chair: Fabrizio Stocchi Chair: Howard Hurtig Roma, Italy Philadelphia, PA, USA 4:00 PM Cognitive dysfunction in Parkinson’s disease Chair: Werner Poewe David John Burn Innsbruck, Austria Newcastle upon Tyne, United Kingdom 1:00 PM Long acting agonists - Is there an advantage? 4:30 PM Treatment of cognitive dysfunction and dementia Oscar S. Gershanik in Parkinson’s disease Buenos Aires, Argentina Murat Emre 1:30 PM Combination therapy - Is there a role? Capa Istanbul, Turkey Wolfgang H. Oertel Marburg, Germany 5:00 PM to 7:00 PM 2:00 PM Update on cardiac valvulopathy with the use of 2013 Opening Symposium: Levodopa - Still dopamine agonists the one Yoshikuni Mizuno Supported by an educational grant from Novartis Tokyo, Japan Pharma/Orion Pharma 2:30 PM Panel Discussion Location: Anadolu Auditorium 3:00 PM to 4:00 PM Chair: Niall P. Quinn London, United Kingdom 2011 Opening Symposium: Imaging the Chair: Philip D. Thompson dopamine system Adelaide, Australia Supported by an educational grant from GE 5:00 PM History of levodopa Healthcare Andrew J. Lees Location: Marmara Room London, United Kingdom Chair: Andrew J. Lees 5:30 PM Levodopa - Advantages and disadvantages in the London, United Kingdom treatment of Parkinson’s disease 3:00 PM Imaging the dopamine system - Techniques John G. Nutt and methods Portland, OR, USA Joel S. Perlmutter 6:00 PM Role of COMT inhibitors St. Louis, MO, USA Eduardo Tolosa 3:30 PM Imaging the dopamine system in the diagnosis Barcelona, Spain of Parkinson’s disease 6:30 PM New concepts in the use of levodopa Kenneth Marek C. Warren Olanow New Haven, CT, USA New York, NY, USA 7:30 PM to 10:00 PM Opening Ceremony Location: Anadolu Auditorium Welcome Reception Location: Rumeli Gardens

24 Monday, June 04, 2007

8:00 AM Breakfast will be provided 12:30 PM Dopamine agonists and the treatment of Location: Halic Foyer Parkinson’s disease - Motor complications and neuroprotection 9:00 AM to 10:00 AM Anthony H.V. Schapira 3015 Opening Symposium: Transdermal therapy London, United Kingdom for Parkinson’s disease 1:00 PM Dopamine agonists and Restless Legs Syndrome Supported by an educational grant from Schwarz Claudia M. Trenkwalder Pharma AG Kassel, Germany Location: Marmara Room 1:30 PM Dopamine agonists - Adverse effects, new Chair: Yoshikuni Mixuno considerations, sleep, impulsive disorders, Tokyo, Japan edema, heart valve 9:00 AM Patch technology in the treatment of Janis Miyasaki Parkinson’s disease Toronto, ON, Canada Peter LeWitt Southfield, MI, USA 2:00 PM to 3:00 PM 9:20 AM Transdermal administration of 3017 Opening Symposium: Botulinum toxin - dopaminergic agents Clinical indications in the treatment of Werner Poewe dystonia 2007 Innsbruck, Austria Supported by an educational grant from 9:40 AM Panel Discussion Allergan, Ltd. Location: Marmara Room 10:00 AM to 2:00 PM Chair: Cynthia L. Comella 3016 Opening Symposium: A decade of non-ergot Chicago, IL, USA dopamine agonists 2:00 PM What factors influence outcome following Supported by an educational grant from Boehringer botulinum toxin therapy? Ingelheim Giovanni Abbruzzese Location: Anadolu Auditorium Genova, Italy Chair: C. Warren Olanow 2:30 PM Safety and efficacy studies with different New York, NY, USA botulinum toxin formulations Chair: Matthew B. Stern Daniel Tarsy Philadelphia, PA, USA Boston, MA, USA 10:00 AM Dopamine systems - Anatomy Yoland Smith Atlanta, GA, USA 10:30 AM Dopamine systems in Parkinson’s disease - What goes wrong? Anthony A. Grace Pittsburgh, PA, USA 11:00 AM Why are the dopamine neurons vulnerable in Parkinson’s disease Etienne C. Hirsch Paris, France 11:30 AM Dopamine agonists - Their development and history Donald B. Calne Vancouver, BC, Canada 12:00 PM Lunch will be provided Location: Halic Foyer

25 Monday, June 04, 2007

3:00 PM to 4:00 PM 7:00 PM to 8:00 PM 3018 Opening Symposium: Issues in the 3020 Opening Symposium: Manipulating the management of Parkinson’s disease dopamine system Supported by an educational grant from Teva Supported by an educational grant from Valeant Pharmaceutical Industries, Ltd. And H. Lundbeck A/S Pharmaceuticals Location: Marmara Room Location: Anadolu Auditorium Chair: Anthony E. Lang Chair: Eldad Melamed Toronto, ON, Canada Petah Tiqva, Israel 3:00 PM Attempts to obtain neuroprotection in Parkinson’s 7:00 PM MAO-B-zydis delivery of selegiline - disease Current status C. Warren Olanow Kapil D. Sethi New York, NY, USA Augusta, GA, USA 3:20 PM Issues to consider in the early management of 7:30 PM COMT - Current status of tolcapone Parkinson’s disease Wolfgang Oertel Olivier Rascol Marburg, Germany Toulouse, France 3:40 PM Issues to consider in the management of 8:00 PM to 9:00 PM moderate to advanced Parkinson’s disease 3021 Opening Symposium: Infusion therapies Matthew B. Stern Supported by an educational grant from Solvay Philadelphia, PA, USA Pharmaceuticals GmbH Location: Marmara Room 4:00 PM to 6:00 PM Chair: Murat Emre 3019 Opening Symposium: Long acting Capa Istanbul, Turkey dopamine agonists 8:00 PM CDS Supported by an educational grant from Fabrizio Stocchi GlaxoSmithKline UK Limited Roma, Italy Location: Anadolu Auditorium 8:30 PM Duodopa Chair: David J. Brooks To be announced London, United Kingdom 9:00 PM to 10:00 PM Chair: Ray L. Watts Birmingham, AL, USA 3022 Opening Symposium: Surgical therapy for 4:00 PM Importance of compliance in the management of Parkinson’s disease Parkinson’s disease Supported by an educational grant from Medtronic, Donald Grosset Inc. Glasgow, United Kingdom Location: Anadolu Auditorium 4:30 PM Rationale and clinical results for a long acting Chair: Alim L. Benabid dopaminergic therapy in Parkinson’s disease Grenoble, France Ray L. Watts 9:00 PM Candidates for DBS - Indications and Birmingham, AL, USA contraindications 5:00 PM Long term results and future opportunities Paul Krack Robert Hauser Grenoble, France Tampa, FL, USA 9:30 PM DBS for Parkinson’s disease - Long term motor 5:30 PM Panel Discussion and neurobehavioral outcomes Anthony E. Lang 6:00 PM to 7:00 PM Dinner will be provided Toronto, ON, Canada Location: Halic Foyer

26 Tuesday, June 05, 2007

8:30 AM to 10:00 AM 10:30 AM Outcome measures for disease progression 4051 Plenary Session 1 Joel Perlmutter Location: Anadolu Auditorium St. Louis, MO, USA Chair: Murat Emre 11:00 AM The placebo effect in PD trials Capa Istanbul, Turkey Christopher G. Goetz Chair: Anthony E. Lang Chicago, IL, USA Toronto, Canada 11:30 AM Clinical trials and drug development in PD - 8:30 AM Mechanisms of neurodegeneration in Parkinson’s Current needs and regulatory road blocks disease Cristina Sampaio Serge Przedborski Lisboa, Portugal New York, NY, USA 12:00 PM Discussion 9:00 AM Imaging of neurodegeneration in 4103 Parallel Session: Parkinson’s disease: Parkinson’s disease Outcome measures and scales David J. Brooks London, United Kingdom Location: Mini-Auditorium Chair: Pablo Martinez-Martín Madrid, Spain 9:30 AM C. David Marsden Lecture: Evolution of MSA Co-Chair: Ergun Uc as an entity Iowa City, IA, USA Location: Anadolu Auditorium 10:30 AM Why should we switch from the old to the new Niall P. Quinn UPDRS? London, United Kingdom Pablo Martinez-Martín Madrid, Spain 10:30 AM to 12:30 PM 11:00 AM Which imaging markers predict the progression 4101 Parallel Session: Genetics of Parkinson’s of Parkinson’s disease? disease Philippe Remy Creteil Cedex, France Location: Topkapi A 11:30 AM Non-motor scales of Parkinson’s disease Chair: Thomas Gasser K. Ray Chaudhuri Tübingen, Germany London, United Kingdom Co-Chair: Enza Maria Valente 12:00 PM Discussion Rome, Italy 10:30 AM The dominant 4104 Parallel Session: Movement Disorders Vincenzo Bonifati surgery meets , Location: Dolmabahce A 11:00 AM The recessive Chair: Andres Lozano Matthew J. Farrer Toronto, ON, Canada Jacksonville, FL, USA Co-Chair: Cenk Akbostanci 11:30 AM The complex Ankara, Turkey Thomas Gasser 10:30 AM Cognitive and psychiatric aspects of Parkinson’s Tübingen, Germany disease surgery 12:00 PM Discussion Paul Krack 4102 Parallel Session: Clinical trials in Grenoble, France Parkinson’s disease 11:00 AM Surgery for Tourettes and OCD Virlee Visser-Vandewalle Location: Anadolu Auditorium Maastricht, Netherlands Chair: Christopher G. Goetz 11:30 AM Other emerging indications Chicago, IL, USA Thomas Schlaepfer Co-Chair: To be announced Baltimore, MD, USA 12:00 PM Discussion

27 Tuesday, June 05, 2007

4105 Parallel Session: What do the basal 11:30 AM The paroxysmal ganglia do? Meltem Demirkiran Location: Halic Room Adana, Turkey Chair: John C. Rothwell 12:00 PM Discussion London, United Kingdom 4108 Parallel Session: Current treatment of Co-Chair: Jose Martin Rabey Zerifin, Israel Parkinson’s disease: Motor symptoms – 10:30 AM Motor functions Teaching Course John C. Rothwell Location: Marmara Room London, United Kingdom Chair: Oksana Suchowersky 11:00 AM Cognitive functions Calgary, AB, Canada Peter L. Strick Co-Chair: Fabrizio Stocchi Pittsburgh, PA, USA Roma, Italy 11:30 AM Limbic functions 10:30 AM When to start treatment? Jose Martin Rabey Anthony H.V. Schapira Zerifin, Israel London, United Kingdom 12:00 PM Discussion 11:00 AM Initial treatment in mild Parkinson’s disease Oksana Suchowersky 4106 Parallel Session: Facial Movement Calgary, AB, Canada Disorders 11:30 AM Treatment of moderate to severe Parkinson’s Location: Dolmabahce B disease Chair: Alfredo Berardelli Fabrizio Stocchi Roma, Italy Roma, Italy Co-Chair: Joseph Jankovic 12:00 PM Discussion Houston, TX, USA 10:30 AM Functional organization of facial movements 4109 Parallel Session: Intersection of sleep Robert Morecraft and Movement Disorders: Evaluation and Vermillion, SD, USA treatment - Teaching Course 11:00 AM Clinical aspects and pathophysiology of Location: Topkapi B cranial dystonia Chair: Cynthia L. Comella Alfredo Berardelli Chicago, IL, USA Roma, Italy Co-Chair: Alesandro Iranzo de Riquer 11:30 AM Non-dystonic involuntary facial movements Barcelona, Spain Philip D. Thompson 10:30 AM REM sleep behavior disorder Adelaide, Australia Carlos Schenck 12:00 PM Discussion Minneapolis, MN, USA 11:00 AM Restless Leg Syndrome/PLMS 4107 Parallel Session: Paroxysmal Movement Richard Allen Disorders Baltimore, MD, USA Location: Dolmabahce C 11:30 AM Disorders of sleep in Parkinson’s disease Chair: Kailash Bhatia Cynthia L. Comella London, United Kingdom Chicago, IL, USA Co-Chair: Mitsutoshi Yamamoto 12:00 PM Discussion Takamatsu, Japan 10:30 AM Ion channel disorders as a model for paroxysmal or episodic neurologic phenomena Dimitri M. Kullman London, United Kingdom 11:00 AM The episodic Kailash Bhatia London, United Kingdom 28 Tuesday, June 05, 2007

Poster Presentations Admission to this session is by delegate name badge. No ticket 4401 Meet the Expert Session: Management of is required for admission to Poster Presentations. Parkinson’s disease: Case presentations Location: Topkapi A Poster Session 1 Eldad Melamed Location: Lower Level, Rumeli Hall Petah Tiqva, Israel Poster Viewing: 9:00 AM - 4:00 PM Eduardo Tolosa Authors Present 12:30 PM - 2:30 PM Barcelona, Spain Poster Numbers: 33-345 and 683 4402 Meet the Expert Session: Focal dystonias 2:30 PM to 4:30 PM Location: Dolmabahce C 4201 Skills Workshop: DBS - Basic programming Alberto Albanese challenges and target identification Milano, Italy Location: Mini-Auditorium Francisco Eduardo C. Cardoso Satoshi Goto Belo Horizonte, Brazil Tokushima City, Japan 4601 Oral Platform Presentations 1 Jens Volkmann Location: Marmara Room Kiel, Germany Chair: Daniel Tarsy Jonathan O. Dostrovsky Boston, MA, USA Toronto, ON, Canada Chair: John Hardy 4202 Skills Workshop: Botulinum toxin - Basic Bethesda, MD, USA techniques and special applications 4602 Oral Platform Presentations 2 Location: Dolmabahce A Location: Halic Room Raif Çakmur Chair: Carlo Colosimo Izmir, Turkey Rome, Italy Dirk W. Dressler Chair: Erik Ch. Wolters Rostock, Germany Amsterdam, The Netherlands 4301 Video Session: Movement Disorders 4701 How-To-Do-It Session: How to examine functional surgery - Unique complications Movement Disorder patients and responses Location: Topkapi B Location: Dolmabahce B Roger Barker Boulos-Paul W. Bejjani Cambridge, United Kingdom Byblos, Lebanon Pierre Pollak Patricia Limousin-Dowsey Grenoble, France London, United Kingdom 5:00 PM to 6:30 PM 4302 Video Session: Uncommon hyperkinetic 4901 Highlights of Poster Sessions 1-Basic Movement Disorders Location: Anadolu Auditorium Location: Anadolu Auditorium Chair: Rosario Luquin Kailash P. Bhatia Pamplona, Spain London, United Kingdom Chair: Eldad Melamed Kapil D. Sethi Petah Tiqva, Israel Augusta, GA, USA 4902 Highlights of Poster Sessions 2-Clinical Location: Marmara Room Chair: Piu Chan Beijing, China Chair: David J. Brooks London, United Kingdom

29 Wednesday, June 06, 2007

8:30 AM to 10:00 AM 5102 Parallel Session: Spasticity and spastic 5051 Plenary Session: Treatment of Parkinson’s disease Location: Dolmabahce A Location: Anadolu Auditorium Chair: Alexandra Durr Chair: Joseph Jankovic Paris, France Houston, TX, USA Co-Chair: Philip D. Thompson Chair: Eduardo Tolosa Adelaide, Australia Barcelona, Spain 10:30 AM Phenotypes and genotypes of Hereditary Spastic 8:30 AM Disease modification: Pipeline or pipe dream? Paraplegia (HSP) Olivier Rascol Alexandra Durr Toulouse, France Paris, France 8:50 AM What’s new in the treatment of Parkinson’s 11:00 AM The role of axonal transport in the pathogenesis disease? of HSP Anthony E. Lang Rebeca Schüle Toronto, ON, Canada Tübingen, Germany 9:10 AM What’s next in the treatment of Parkinson’s 11:30 AM Update on the pathophysiology and management disease? of spasticity Werner Poewe Reiner Benecke Innsbruck, Austria Rostock, Germany 12:00 PM Discussion 9:30 AM Junior Award Lectures 5103 Parallel Session: Lower body parkinsonism Location: Anadolu Auditorium, First Floor, Istanbul Convention and gait disorders and Exhibition Centre Location: Halic Room Chairs: Joseph Jankovic Chair: Bastiaan R. Bloem Houston, TX, USA Nijmegen, Netherlands Eduardo Tolosa Co-Chair: Nir Giladi Barcelona, Spain Tel Aviv, Israel 10:30 AM Motor and cognitive mechanisms of gait and 10:30 AM to 12:30 PM its disorders 5101 Parallel Session: Update on the molecular Bastiaan R. Bloem pathogenesis and protein interactions in Nijmegen, Netherlands Parkinson’s disease 11:00 AM Vascular parkinsonism Jan C.M. Zijlmans Location: Anadolu Auditorium Breda, Netherlands Chair: Valina Dawson 11:30 AM Pathophysiology and treatment of Idopathic NPH Baltimore, MD, USA Richard Penn Co-Chair: Serge Przedborski Chicago, IL, USA New York, NY, USA 12:00 PM Discussion 10:30 AM Synuclein and protein aggregation Leonidas Stefanis 5104 Parallel Session: Not to be forgotten Papagou, Greece Movement Disorders 11:00 AM The bulky parkinsonian kinase LRRK2 Location: Dolmabahce B Valina Dawson Chair: Hiroshi Shibasaki Baltimore, MD, USA Kyoto, Japan 11:30 AM PINK1, a mitochondrial kinase Co-Chair: Wolfgang Oertel Enza Maria Valente Marburg, Germany Rome, Italy 10:30 AM Immunological Movement Disorders 12:00 PM Discussion Gavin Giovannoni London, United Kingdom

30 Wednesday, June 06, 2007

11:00 AM Peripherally induced Movement Disorders 10:30 AM Parkinsonian emergencies Angelo Quartarone Oscar S. Gershanik Messina, Italy Buenos Aires, Argentina 11:30 AM Myoclonus 11:00 AM Neuroleptic malignant syndrome Hiroshi Shibasaki Sadako Kuno Kyoto, Japan Tokyo, Japan 12:00 PM Stereotypies and catatonia 11:30 AM Hyperkinetic emergencies Kapil Sethi François Tison Atlanta, GA, USA Pessac, France 12:00 PM Discussion 5105 Parallel Session: Update on Tauopathies Location: Dolmabahce C 5108 Parallel Session: Current management of Chair: Irene Litvan Parkinson’s disease: Non-motor symptoms Louisville, KY, USA - Teaching Course Co-Chair: Andrew Lees Location: Marmara Room London, United Kingdom Chair: David John Burn 10:30 AM Lessons from familial tauopathies and Newcastle Upon Tyne, United Kingdom genetic studies Co-Chair: Hasmet A. Hanagasi Zbigniew K. Wszolek Kozyatagi, Turkey Jacksonville, FL, USA 10:30 AM Cognitive impairment and dementia 11:00 AM PSP David John Burn David R. Williams Newcastle Upon Tyne, United Kingdom Melbourne, Australia 11:00 AM Depression and other psychiatric manifestations 11:30 AM CBD Paolo Barone Irene Litvan Napoli, Italy Louisville, KY, USA 11:30 AM Autonomic dysfunction 12:00 PM Discussion Jacobus J. van Hilten Leiden, Netherlands 5106 Parallel Session: Ataxia: What’s new? 12:00 PM Discussion Location: Mini-Auditorium Chair: Mark Hallett 5109 Parallel Session: Pediatric Movement Bethesda, MD, USA Disorders in an office setting: Diagnosis Co-Chair: Ryuji Kaji and treatment - Teaching Course Tokushima City, Japan Location: Topkapi B 10:30 AM What does the cerebellum do? Chair: Emilio Fernandez-Alvarez Mark Hallett Barcelona, Spain Bethesda, MD, USA Co-Chair: Aikaterini Kompoliti 11:00 AM Genetic ataxias Chicago, IL, USA Ludger Schoels 10:30 AM An approach to the child with Tübingen, Germany Movement Disorders 11:30 AM Secondary ataxias Padraic James Grattan-Smith Thomas Klockgether Sydney, Australia Bonn, Germany 11:00 AM Cerebral palsy look-alike Movement Disorders 12:00 PM Discussion Emilio Fernandez-Alvarez 5107 Parallel Session: Movement Disorder Barcelona, Spain emergencies 11:30 AM Tics and Tourette Aikaterini Kompoliti Location: Topkapi A Chicago, IL, USA Chair: Oscar S. Gershanik 12:00 PM Discussion Buenos Aires, Argentina Co-Chair: Bhim Singhal Mumbai, India 31 Wednesday, June 06, 2007

Poster Presentations 5402 Meet the Expert Session: Evaluation of Admission to this session is by delegate name badge. No ticket eye movements is required for admission to Poster Presentations. Location: Dolmabahce C Poster Session 2 R. John Leigh Location: Lower Level, Rumeli Hall Cleveland, OH, USA David Zee Poster Viewing: 9:00 AM - 4:00 PM Ellilott City, MD, USA Authors Present 12:30 PM - 2:30 PM Poster Numbers: 346-662 and 788 5601 Oral Platform Presentations 1 Location: Marmara Room 2:30 PM to 4:30 PM Chair: Rivka Inzelberg 5201 Skills Workshop: Parenteral administration Kfar Saba, Israel of Parkinson’s disease medication Chair: Vladimir Kostic Location: Mini-Auditorium Belgrade, Serbia and Montenegro Maria Jose Marti Domenec Barcelona, Spain 5602 Oral Platform Presentations 2 Giovanni Fabbrini Location: Dolmabahce A Rome, Italy Chair: Bluent Elibol Ankara, Turkey 5202 Skills Workshop: Sleep studies in Chair: Heinz Reichmann Movement Disorders Dresden, Germany Location: Topkapi B Birgit Högl 5701 How-To-Do-It Session: How to examine Innsbruck, Austria mental function in patients with Alex Iranzo Riquer Movement Disorders Barcelona, Spain Location: Topkapi A Dag Aarsland 5301 Video Session: Unusual phenotypes of Stavanger, Norway defined genetic diseases Murat Emre Location: Halic Capa Istanbul, Turkey Emilio Fernandez-Alvarez Barcelona, Spain 5:00 PM to 6:30 PM Marie-Jose Vidailhet 5901 Highlights of Poster Sessions 1-Clinical Paris, France Location: Anadolu Auditorium Chair: Okan Dogu 5302 Video Session: Psychogenic Movement Mersin, Turkey Disorders that look real and real Movement Chair: James Leverenz Disorders that look psychogenic Seattle, WA, USA Location: Anadolu Auditorium 5902 Highlights of Poster Sessions 2-Clinical Anette Schrag Location: Marmara Room London, United Kingdom Chair: Jamie Kulisevsky John G.L. Morris Barcelona, Spain Sydney, Australia Chair: Marcelo Merello Buenos Aires, Argentina 5401 Meet the Expert Session: Iatrogenic Movement Disorders Location: Dolmabahce B Pierre J. Blanchet Montreal, PQ, Canada William J. Weiner Baltimore, MD, USA 32 Thurssday, June 07, 2007

8:30 AM to 10:00 AM Poster Presentations 6051 Plenary Session 3 Admission to this session is by delegate name badge. No ticket Location: Anadolu Auditorium is required for admission to Poster Presentations. Chair: Günther Deuschl Poster Session 3 Kiel, Germany Location: Lower Level, Rumeli Hall Chair: Yoshikuni Mizuno Poster Viewing: 9:00 AM - 4:00 PM Tokyo, Japan Authors Present 12:30 PM - 2:30 PM 8:30 AM Essential Tremor Poster Numbers: 663 - 973 Joseph Jankovic Houston, TX, USA 9:00 AM Huntington’s disease 2:30 PM to 4:30 PM M. Flint Beal New York, NY, USA 6501 Controversies Location: Anadolu Auditorium Chair: Amos D. Korczyn 9:30 AM Stanley Fahn Lecture: DBS for Parkinson’s Ramat-Aviv, Israel disease 30,000 patients later. What have we Chair: Serge Przedborski learned and what remains to be done? New York, NY, USA Pierre Pollak Grenoble, France Early surgery for Parkinson’s disease vs late? 2:30 PM Early Andres M. Lozano 10:30 AM to 12:30 PM Toronto, ON, Canada 6052 Plenary Session 4: Dystonia 2:45 PM Late Location: Anadolu Auditorium Paul E. Greene Chair: Giovanni Abbruzzese New York, NY, USA Genova, Italy Is there evidence for genetic/environmental interactions Chair: Andrew J. Lees in Parkinson’s disease? London, United Kingdom 3:00 PM Yes 10:30 AM Update on clinical features of sporadic and Caroline M. Tanner familial dystonia Sunnyvale, CA, USA Thomas T. Warner 3:15 PM No London, United Kingdom John A. Hardy 11:00 AM Update on the pathogenesis: Role of plasticity in Bethesda, MD, USA the evolution and devolution of dystonia Hartwig R. Siebner Is Braak staging valid? Kiel, Germany 3:30 PM Yes 11:30 AM Update on the molecular genetics of Howard Hurtig familial dystonia Philadelphia, PA, USA Laurie J. Ozelius 3:45 PM No New York, NY, USA Wolfgang H. Oertel 12:00 PM Update on the management of dystonia: DBS, Marburg, Germany intrathecal baclofen, b-toxin, and medication Does proteosome inhibition cause Parkinson’s disease? Ryuji Kaji 4:00 PM Yes Tokushima City, Japan C. Warren Olanow New York, NY, USA 4:15 PM No Jeffrey Kordower Chicago, IL, USA

33

Faculty Dag Aarsland David J. Brooks Bulent Elibol Hasmet A. Hanagasi Stavanger, Norway London, United Kingdom Ankara, Turkey Istanbul, Turkey 5701 3019, 4051, 4902 5602 5108 Giovanni Abbruzzese David John Burn Murat Emre John A. Hardy Genova, Italy Newcastle Upon Tyne, United Capa Istanbul, Turkey Bethesda, MD, USA 3017, 6052 Kingdom 2012, 3021, 4051, 5701 4601, 6501 Cenk Akbostanci 2012, 5108 Giovanni Fabbrini Etienne C. Hirsch Istanbul, Turkey Raif Çakmur Rome, Italy Paris, France 4104 Izmir, Turkey 5201 3016 Alberto Albanese 4202 Matthew J. Farrer Birgit Hogl Milano, Italy Donald B. Calne Jacksonville, FL, USA Innsbruck, Austria 4402 Vancouver, BC, Canada 4101 5202 Richard P. Allen 3016 Emilio Fernandez-Alvarez Howard Hurtig Baltimore, MD, USA Francisco Eduardo C. Barcelona, Spain Philadelphia, PA, USA 4109 Cardoso 5109, 5301 2010, 6501 Roger Barker Belo Horizonte, Brazil Thomas Gasser Rivka Inzelberg Cambridge, United Kingdom 4402 Tübingen, Germany Kfar Saba, Israel 4701 Piu Chan 4101 5601 Paolo Barone Beijing, China Oscar S. Gershanik Alex Iranzo De Riquer Napoli, Italy 4902 Buenos Aires, Argentina Barcelona, Spain 5108 K. Ray Chaudhuri 2010, 5107 4109, 5202 M. Flint Beal London, United Kingdom Nir Giladi Joseph Jankovic New York, NY, USA 4103 Tel Aviv, Israel Houston, TX, USA 6051 Carlo Colosimo 5103 4106, 5051, 6051 Boulos-Paul W. Bejjani Rome, Italy Gavin Giovannoni Ryuji Kaji Byblos, Lebanon 4602 London, United Kingdom Tokushima City, Japan 4301 Cynthia L. Comella 5104 5106, 6052 Alim L. Benabid Chicago, IL, USA Christopher G. Goetz Thomas Klockgether Grenoble, France 3017, 4109 Chicago, IL, USA Bonn, Germany 3022 Valina Dawson 4102 5106 Reiner Benecke Baltimore, MD, USA Satoshi Goto Aikaterini Kompoliti Rostock, Germany 5101 Tokushima City, Japan Chicago, IL, USA 5102 Meltem Demirkiran 4201 5109 Alfredo Berardelli Adana, Turkey Anthony A. Grace Amos D. Korczyn Roma, Italy 4107 Pittsburgh, PA, USA Ramat-Aviv, Israel 4106 Günther Deuschl 3016 6501 Kailash P. Bhatia Kiel, Germany Padraic James Grattan-Smith Vladimir Kostic London, United Kingdom 6051 Sydney, Australia Belgrade, Serbia and 4107, 4302 Okan Dogu 5109 Montenegro Pierre J. Blanchet Mersin, Turkey Paul E. Greene 5601 Montreal, PQ, Canada 5901 New York, NY, USA Paul Krack 5401 Jonathan O. Dostrovsky 6501 Grenoble, France Bastiaan R. Bloem Toronto, ON, Canada Donald G. Grosset 3022, 4104 Nijmegen, Netherlands 4201 Glasgow, United Kingdom Jamie Kulisevsky 5103 Dirk W. Dressler 3019 Barcelona, Spain Vincenzo Bonifati Rostock, Germany Mark Hallett 5902 Rotterdam, Netherlands 4202 Bethesda, MD, USA Dimitri M. Kullman 4101 Alexandra Durr 5106 London, United Kingdom Paris, France 4107 5102 36 Saduko Kuno John G. Nutt Thomas E. Schlaepfer Eduardo Tolosa Tokyo, Japan Portland, OR, USA Baltimore, MD, USA Barcelona, Spain 5107 2013, 3014 4104 2013, 4401, 5051 Anthony E. Lang Wolfgang H. Oertel Ludger Schoels Claudia M. Trenkwalder Toronto, ON, Canada Marburg, Germany Tübingen, Germany Kassel, Germany 3018, 3022, 4051, 5051 2010, 3020, 5104, 6501 5106 3016 Andrew J. Lees C. Warren Olanow Anette Schrag Ergun Yasar Uc London, United Kingdom New York, NY, USA London, United Kingdom Iowa City, IA, USA 2011, 2013, 5105, 6052 2013, 3016, 3018, 6501 5302 4103 R. John Leigh Laurie J. Ozelius Rebeca Schüle Enza Maria Valente Cleveland, OH, USA New York, NY, USA Tübingen, Germany Rome, Italy 5402 6052 5102 4101, 5101 Peter A. LeWitt Joel S. Perlmutter Kapil D. Sethi Jacobus J. Van Hilten Southfield, MI, USA St. Louis, MO, USA Augusta, GA, USA Leiden, Netherlands 3015 2011, 4102 3020, 4302, 5104 5108 Patricia Limousin-Dowsey Werner Poewe Hiroshi Shibasaki Marie-Jose Vidailhet London, United Kingdom Innsbruck, Austria Kyoto, Japan Paris, France 4301 2010, 3015, 5051 5104 5301 Irene Litvan Pierre Pollak Hartwig R. Siebner Veerle Visser-Vandewalle Louisville, KY, USA Grenoble, France Kiel, Germany Maastricht, Netherlands 5105 4701, 6051 6052 4104 Andres M. Lozano Serge Przedborski Bhim S. Singhal Jens Volkmann Toronto, ON, Canada New York, NY, USA Mumbai, India Kiel, Germany 4104, 6501 4051, 5101, 6501 5107 4201 Maria Rosario Luquin Angelo Quartarone Yoland Smith Thomas T. Warner Pamplona, Spain Messina, Italy Atlanta, GA, USA London, United Kingdom 5901 5104 3016 6052 Kenneth Marek Niall P. Quinn Leonidas Stefanis Ray L. Watts New Haven, CT, USA London, United Kingdom Papagou, Greece Birmingham, AL, USA 2011 4051 5101 3019 Maria Jose Marti Domenec Jose Martin Rabey Matthew B. Stern William J. Weiner Barcelona, Spain Zerifin, Israel Philadelphia, PA, USA Baltimore, MD, USA 5201 4105 3016, 3018 5401 Pablo Martinez-Martín Olivier Rascol Fabrizio Stocchi David R. Williams Madrid, Spain Toulouse, France Roma, Italy Melbourne, Australia 4103 3014, 3018, 5051 2012, 3021, 4108 5105 Eldad Melamed Heinz Reichmann Peter L. Strick Erik Ch. Wolters Petah Tiqva, Israel Dresden, Germany Pittsburgh, PA, USA Amsterdam, Netherlands 3020, 4401, 4901 5602 4105 4602 Marcelo Merello Philippe Remy Oksana Suchowersky Zbigniew K. Wszolek Buenos Aires, Argentina Creteil Cedex, France Calgary, AB, Canada Jacksonville, FL, USA 5902 4103 4108 5105 Janis Miyasaki John C. Rothwell Caroline M. Tanner Mitsutoshi Yamamoto Toronto, ON, Canada London, United Kingdom Sunnyvale, CA, USA Takamatsu, Japan 3016 4105 6501 4107 Yoshikuni Mizuno Cristina Sampaio Daniel Tarsy David Zee Tokyo, Japan Lisboa, Portugal Boston, MA, USA Ellilott City, MD, USA 2010, 3015, 6051 4102 4601 5402 Robert J. Morecraft Anthony H.V. Schapira Philip D. Thompson Jan C.M. Zijlmans Vermillion, SD, USA London, United Kingdom Adelaide, Australia Breda, Netherlands 4106 3016, 4108 2013, 4106, 5102 5103 John G.L. Morris Carlos Schenck François Tison Sydney, Australia Minneapolis, MN, USA Pessac, France 5302 4109 5107 37

Exhibitor Information General Information and Exhibit Hours Exhibitor Badge Policy Please allow adequate time in your daily schedule to visit Admission to the Exhibit Hall will be by name badge only. the Exhibit Hall, located in the Rumeli Building, upper Security guards will monitor Exhibit Hall entrances for floor which is directly next to the Istanbul Convention proper identification. Exhibit stand personnel must show and Exhibition Centre (ICEC). The exhibition is an integral an official MDS exhibitor name badge in order to gain component of your International Congress experience, access to the Exhibit Hall during installation, show, or offering you the opportunity to speak with representatives dismantlement hours. Independent contractor personnel, of companies providing services or marketing products hired by an exhibitor to install and dismantle their display, directly related to Movement Disorders. Delegates may should register on-site for a temporary name badge valid visit the Exhibit Hall during the following hours: for only installation and dismantlement hours. Monday, June 4.. . . 9:00 a.m. to 5:00 p.m. Exhibitor Badge (Yellow): Allows admittance to the exhibit Tuesday, June 5.. . . 9:00 a.m. to 5:00 p.m. hall area only. Wednesday, June 6 9:00 a.m. to 5:00 p.m. Exhibitor Delegate Badge (Orange): Allows the delegate to Thursday, June 7 9:00 a.m. to 4:00 p.m. enter the Exhibit hall as an exhibitor and attend scientific Exhibitor Registration sessions (requiring a ticket) and the Welcome Reception. Location: Rumeli Building foyer Endorsement Disclaimer Exhibitors must register at the Exhibitor Registration Desk Products and services displayed in the Exhibit Hall or located inside the entrance of the Rumeli Building during advertised in the program occur by contractual business the following hours: arrangements between MDS and participating companies Saturday, June 2 4:00 p.m. to 8:00 p.m. and organizations. These arrangements do not constitute Sunday, June 3 9:00 a.m. to 8:30 p.m. nor imply an endorsement by MDS of these products and Monday, June 4.. . . 7:00 a.m. to 6:00 p.m. services. Tuesday, June 5.. . . 7:00 a.m. to 6:00 p.m. Wednesday, June 6 7:00 a.m. to 6:00 p.m. Thursday, June 7 7:00 a.m. to 5:00 p.m.

39 Exhibitor Directory Allergan, Ltd. Britannia Pharmaceuticals Limited Marlow International, the Parkway. 41-51 Brighton Road Marlow, Bucks. Redhill, Surrey RH1 6YS SL7 1YL. United Kingdom UK Telephone: +44-1737-773-741 Telephone: +44-1628-494-444 Web site: www.britannia-pharm.co.uk Fax: +44-1628-494-449 Booth #: 119 Web site: www.allergan.co.uk Britannia Pharmaceuticals Ltd. is a UK-based company Booth #: 110 which markets a range of Apo-go (apomorphine Hcl) With more than 55 years of experience providing high- products for the treatment of disabling motor fluctuations quality, science-based products, Allergan, Inc., with UK in Parkinson’s disease patients which persist, despite in- offices in Marlow, Bucks and worldwide headquarters in dividually titrated treatment with oral Parkinson’s disease Irvine, California, USA, discovers, develops and commer- medications. cializes products in the ophthalmology, neurosciences, GE Healthcare medical dermatology, medical aesthetics, obesity inter- Pollards Wood, Nightingales Lane vention and other specialty markets that deliver value to Chalfont St. Giles, Bucks HP8 4SP its customers, satisfy unmet medical needs, and improve United Kingdom patients’ lives Telephone: +44 1494-54-4000 Boehringer Ingelheim GmbH Fax: +44 1494-49-8234 Binger Str. 173 Web site: www.gehealthcare.com Ingelheim, Rheinland-Pfalz 55216 Booth #: 108 Germany GE Healthcare is dedicated to helping you transform Telephone: +49-6132-77-0 healthcare delivery by driving critical breakthroughs in Fax: +49-6132-72-0 biology and technology. Our expertise in medical imag- Web site: www.boehringer-ingelheim.com ing is enabling healthcare professionals around the world Booth #: 101 discover new ways to predict, diagnose and treat disease Pramipexole (known in Europe under the trade names earlier. While at MDS, please visit our stand to learn more Sifrol® and Mirapexin®, in the U.S.A. as Mirapex® and in about DaTSCAN. Turkey as Pexola®) is a compound from Boehringer Ingel- heim research first approved in 1997 for the treatment of the of idiopathic Parkinson’s disease, as monotherapy or in combination with levodopa. Prami- pexole is approved throughout the European Union, in the U.S.A. and in several other countries for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS).

40 GlaxoSmithKline plc H. Lundbeck A/S 980 Great West Road Ottiliavej 9, Brentford, Middlesex TW8 9GS Copenhagen – Valby DK-2500 United Kingdom Denmark Telephone: +44-20-8047-5000 Telephone: + 45-36-30-13-11 Web site: www.gsk.com Fax: + 45-36-30-19-40 Booth #: 102 Web site: www.lundbeck.com GlaxoSmithKline (GSK) is a research-based pharmaceuti- Booth #: 105 cal company with a mission to improve the quality of Azilect – a new treatment for Parkinson’s disease both as human life by enabling people to do more, feel better and monotherapy in early disease and as adjunctive therapy in live longer. GSK makes medicines, vaccines and consum- more advanced disease. Several large clinical trials dem- er healthcare products. Its business accounts for 6.3% of onstrated Azilect’s high efficacy, together with good safety the world’s pharmaceutical market. In 2006, GSK invested profile and high tolerability including in elderly patients £3.5 billion and employed over 15,000 people in research and convenient dosing – once daily, no titration. and development with the aim of building the best product Medtronic, Inc. pipeline in the industry. GSK donates money, medicines, 710 Medtronic Parkway NE time and equipment to help improve health and education Minneapolis, MN 55432 in under-served communities. GSK supports public health USA initiatives and local community projects around the world Telephone: +1 763-514-4000 and donates medicines to support disaster relief efforts Fax: +1 763-514-4879 and impoverished communities. Web site: www.medtronic.com Ipsen Booth #: 109 42 rue du Docteur Blanche Medtronic is the global leader in medical technology Paris 75016 – alleviating pain, restoring health and extending life for France millions of people around the world. Activa® Deep Brain Telephone: +33-1-44-30-43-15 Stimulation Therapy, exhibited, has been used in more Fax: +33-1-44-30-42-00 than 35,000 patients worldwide for the treatment of the Web site: www.ipsen.com three most common movement disorders: Parkinson’s Booth #: 118 disease, essential tremor and dystonia. Ipsen is a European pharmaceutical group with over 20 Merck Serono products on the market and a total worldwide staff of nearly 9, Chemin des Mines 4,000. The company’s development strategy is based on Geneva 1211 a combination of products in targeted therapeutic areas Switzerland (oncology, endocrinology and neuromuscular disorders), Telephone: +41-22-414-3600 which are growth drivers and primary care products which Fax: + 41-22-414-3085 contribute significantly to its research financing. This strat- Web site: www.merckserono.net egy is also supported by an active policy of partnerships. The location of its four R&D centres (Paris, Boston, Barce- Booth #: 112 lona, London) gives the Group a competitive edge in gaining Merck Serono, a division of Merck KGaA, Darmstadt, access to leading university research teams and highly Germany, is a global business focusing on innovative pre- qualified personnel. In 2005, Research and Development scription pharmaceuticals with headquarters in Geneva. expenditure reached €169.0 million, i.e. 20.9% of con- The entity has leading brands serving patients in the ar- solidated sales, which amounted to €807.1 million in the eas of Oncology (Erbitux®), (Rebif®) and other Group’s pro forma accounts set up according to the IFRS. therapeutic areas. Merck Serono‘s research programs are Nearly 700 people in R&D are dedicated to the discovery focused on establishing new therapeutic agents in other and development of innovative drugs for patient care. areas, including Parkinson‘s disease.

41 Merz Pharmaceuticals GMBH Orion Corporation Orion Pharma Eckenheimer Landstrase 100 Orionintie 1 Frankfurt 60318 FI-02101 Espoo Germany Finland Telephone: +49-69-1503-0 Telephone: + 358-10-4261 Fax: +49-69-1503-200 Fax: +358-10-426-3815 Web site: www.merz.de Web site: www.orion.fi/english Booth #: 116 Booth #: 103 Product Name: Xeomin Orion Corporation (OMX Helsinki, ORNAV, ORNBV) is a Eu- Active substance: Clostridium Botulinum neurotoxin Type ropean, R&D-based, business-driven pharmaceuticals and diagnostics company with special emphasis on develop- A (150 KD), free of complexing proteins 100 LD50 units per vial ing innovative treatments and diagnostic tests for global markets. Noldus Information Technology b.v. Please feel invited to visit the combined exhibition of Nieuwe Kanaal 5 Novartis and Orion Wageningen 6709 PA The Netherlands For further information please visit the companies’ Web Telephone: +31-317-473-300 sites. Fax: +31-317-424496 Pfizer Inc Web site: www.noldus.com 235 East 42nd Street Booth #: 121 New York, NY 10017 Noldus Information Technology develops and supports USA professional software and instrumentation for behavioral Telephone: +1 212-733-2323 research. Our product range includes several products Web site: www.pfizer.com especially developed for neuroscience research. Or latest Booth #: 104 product, CatWalk, is the ultimate system to dynamically Cabaser is approved for the symptomatic treatment of measure footprints of rodents on basis of which locomotor Parkinson’s disease (PD). deficits and pain syndromes can be assessed. Pfizer Inc, founded in 1849, is dedicated to better health Novartis Pharma AG and greater access to healthcare. Our purpose is help- Lichtstr. 35 ing people live longer, healthier, happier lives. Our route Basel CH-4002 to that purpose is through discovering and developing Switzerland breakthrough medicines; providing information on preven- Telephone: + 41-61-324-1111 tion, wellness, and treatment; consistent high-quality Fax: + 41-61-324-6652 manufacturing of medicines, consumer products; and Web site: www.novartis.com global leadership in corporate responsibility. Booth #: 103 Novartis AG is a world leader in pharmaceuticals and consumer health, headquartered in Basel, Switzerland. Novartis researches, develops, manufacturers and mar- kets leading innovative prescription drugs used to treat a number of diseases and conditions and has been a leader in the Neuroscience area for more than 50 years. Please feel invited to visit the combined exhibition of Novartis and Orion.

42 Schwarz Pharma AG Teva Pharmaceutical Industries Ltd. Alfred-Nobel-Strasse 10 P.O. Box 3190 Monheim 40789 Petah Tiqva 49131 Germany Israel Telephone: +49 2173-48-0 Telephone: + 972-3-926-7267 Fax: +49 2173-48-1608 Fax: + 972-3-923-4050 Web site: www.schwarzpharma.com Web site: www.tevapharm.com Booth #: 106 Booth #: 105 Schwarz Pharma AG (Monheim, Germany) is a publicly Azilect – a new treatment for Parkinson’s disease both as traded company, which develops and markets innova- monotherapy in early disease and as adjunctive therapy in tive drugs with the focus on Central Nervous System more advanced disease. Several large clinical trials dem- (CNS) as well as cardiovascular and gastro-intestinal onstrated Azilect’s high efficacy, together with good safety diseases. These drugs are manufactured and marketed by profile and high tolerability including in elderly patients SCHWARZ PHARMA affiliates in Europe, USA and Asia. and convenient dosing – once daily, no titration. Solstice Neurosciences, Inc. The Movement Disorder Society 40 General Warren Blvd., Suite 160 International Secretariat Malvern, PA 19355 555 East Wells Street, Suite 1100 USA Milwaukee, WI 53202-3823 Telephone: +1 267-620-8000 USA Fax: +1 267-620-8190 Telephone: +1 414-276-2145 Web site: http://www.solsticeneuro.com/ Fax: +1 414-276-3349 Booth #: 117 www.movementdisorders.org Solstice Neurosciences, Inc. is a specialty biopharmaceu- Booth: Located in the Istanbul Convention and Exhibition tical company focused on the development, manufactur- Centre (main building) ing, sales and marketing of specialty products. Solstice’s The Movement Disorder Society is an international, first product, Myobloc® (Botulinum Toxin Type B) Inject- professional society of clinicians, scientists, and other able Solution, represents the only Botulinum Toxin Type B healthcare professionals, who are interested in Parkin- currently available to physicians and patients worldwide. son’s disease, related neurodegenerative and neurode- velopmental disorders, hyperkinetic Movement Disorders, Solvay Pharmaceuticals GmbH and abnormalities in muscle tone and motor control. Visit Hans-Böckler-Allee 20 our exhibit booth to learn more about MDS and member- Hannover 30173 ship opportunities. Germany Telephone: +49 511-857-0 Valeant Pharmaceuticals International Fax: +49 511-857-2294 One Enterprise Web site: www.solvaypharmaceuticals.com Aliso Viejo, CA 92656 Booth #: 111 USA Telephone: +1 949-461-6000 Solvay Pharmaceuticals is a global player in selected Fax: +1 949-461-6609 disease target areas. One of the strong focuses concen- Web site: www.valeant.com trates research and development efforts in Neurology, where doctors and patients may count with new and Booth #: 107 better therapies to choose from. Duodopa represents a Valeant Pharmaceuticals International (NYSE: VRX) is a new concept in the treatment of PD patients, assuring global specialty pharmaceutical company that develops, constant and stable plasma levodopa concentrations. manufactures and markets a broad range of pharmaceuti- Duodopa increases ON time, is suitable as monotherapy cal products primarily in the areas of neurology, infectious and improves quality of life. disease and dermatology. More information about Valeant can be found at www.valeant.com.

43 Vernalis Pharmaceuticals Inc. 1140 Headquarters Plaza 2nd Floor, West Tower Morristown, NJ 07960 USA Telephone: +1 973-867-5555 Fax: +1 973-867-5524 Web site: www.vernalis.com Booth #: 120 Vernalis is a specialty bio-pharmaceutical company with two marketed products: Apokyn® (apomorphine hydro- chloride injection) and Frova® (frovatriptan). The company has a broad development pipeline focused on neurology and central nervous system disorders. Wiley-Blackwell 111 River Street Hoboken, NJ 07030 USA Telephone: +1 201-748-6000 Fax: +1 201-748-6088 Web site: www.wiley.com Booth #: 122 Wiley-Blackwell is proud to publish Movement Disorders on behalf of The Movement Disorder Society. Wiley-Black- well (formed in 2007) combines two of the most re- spected publishers in the world: Blackwell and John Wiley & Sons. Wiley-Blackwell’s portfolio now includes 1,250 scholarly journals, many society-owned, and numerous books with global appeal.

44 Exhibit Hall Floor Plan

45 Istanbul Convention and Exhibition Centre Floor Plans

1st Floor

Ground Floor

46 Istanbul Convention and Exhibition Centre Floor Plans

2nd Floor 3rd Floor

47 Map of Istanbul

48

Junior Awards Social Events Two Junior Awards will be presented for outstanding SUNDAY, JUNE 3, 2007 abstracts of The Movement Disorder Society’s 11th Opening Ceremony and Welcome Reception International Congress of Parkinson’s Disease and 7:30 p.m. to 10:00 p.m. Movement Disorders. One award will be presented for excellence in clinical research, and another for excellence Location: Istanbul Convention and Exhibition Centre and in basic research. Eligible individuals for the Junior the Rumeli Gardens Awards must be forty (40) years of age or less, or within All International Congress attendees are warmly invited five years of completion of training and the first author on to meet friends and colleagues during the traditional the abstract. The Movement Disorder Society’s Awards International Congress Opening Ceremony, which will Committee selects the two award recipients from those feature a unique cultural dance show on Sunday evening, who applied. Please refer to the flyer highlighting the June 3, at the Istanbul Convention and Exhibition Centre. 2007 Junior Awards recipients and their topics, in your A Welcome Reception, accompanied by food, beverage registration bag. and entertainment, in the Rumeli Gardens will directly follow the Opening Ceremony. Each paid registrant is able to bring one guest to the Welcome Reception only. Guest WEDNESDAY, JUNE 6, 2007 badges will be available in the registration packet onsite 9:30 a.m.-10:30 a.m. for those who requested one. 4103 Junior Award Lectures Location: Anadolu Auditorium, First Floor, Istanbul WEDNESDAY, JUNE 6, 2007 Convention and Exhibition Centre Chairs: Joseph Jankovic Gala Event Houston, TX, USA 8:00 p.m. to midnight Eduardo Tolosa Location: Ciragan Palace Barcelona, Spain All participants of the 11th International Congress are invited to attend the Gala Event at the spectacular Ciragan Palace located by the shores of the Bosphorus for an evening of cultural performances, entertainment and Turkish cuisine. Transportation will be departing from the Hilton, Hyatt, and Istanbul Convention and Exhibition Centre at 7:00 p.m. and suggested attire is smart casual. The cost for one Gala Event ticket is $100 USD. A ticket is required for entrance to the Gala Event and will be enclosed in delegates’ registration materials. If you have not already purchased a Gala Event ticket and would like to do so, please visit the Registration Desk to inquire about availability.

50 Satellite Symposia

Sunday, June 3, 2007 11:30 a.m.-1:00 p.m. Restorative Neurology Facts or Fiction? For further information please contact: Ann Marie Janson Lang Phone: +468 58583733 Fax: +468 7116659 [email protected] http://www.swemodis.se

Monday, June 4, 2007 2:30 p.m.-4:30 p.m. Parkinson’s disease Nurse Specialist-a British Perspective, Four Nations One Aim For further information please contact: Mrs. Linda Caie Phone: + 01224 556854 [email protected]

51

Oral Platform Presentations 4601 Oral Platform Presentations 4602 Tuesday, June 5, 2007 - 2:30 PM - 4:30 PM Tuesday, June 5, 2007 - 2:30 PM - 4:30 PM Room: Marmara Room Room: Halic Room Chair: John Hardy, Bethesda, MD, USA Chairs: Carlo Colosimo, Rome, Italy Daniel Tarsy, Boston, MA, USA Erik Ch. Wolters, Amsterdam, The Netherlands

Restless legs syndrome and other movement disorders Atypical parkinsonism and Dystonia 1 Evidence for linkage of Restless legs syndrome to 9 Effect of disease duration on the pattern of chromosome 9p: Are there two distinct loci? cerebral glucose metabolism in patients with K. Lohmann-Hedrich, A. Ziegler, A. Neumann, A. multiple system atrophy Kleensang, T. Lohnau, H. Muhle, A. Djarmati, I.R. J.H. Lee, C.H. Lyoo, S.H. Oh, M.S. Lee (Seoul, Konig, P.L. Kramer, U. Stephani, C. Klein (Luebeck, Republic of Korea) Germany) 10 Neuroprotection and Natural History in Parkinson 2 RLS patients can also develop compulsions on Plus Syndromes (NNIPPS): Results of a dopaminergic agonists randomized placebo-controlled trial of riluzole in E. Pourcher, H. Cohen (Quebec, Quebec, Canada) PSP and MSA 3 Transcranial sonography in Restless legs P.N. Leigh, A. Ludolph, Y. Agid, G. Bensimon, The syndrome NNIPPS Consortium (London, United Kingdom) J. Godau, A.-K. Wevers, A. Gaenslen, A. Di Santo, 11 Degeneration of cardiac sympathetic nerve can E. Caliskan-Erle, T. Gasser, D. Berg (Tübingen, occur in multiple system atrophy Germany) S. Orimo, T. Kanazawa, A. Nakamura, T. Uchihara, F. 4 Original clinical and biological findings in 3 new Mori, A. Kakita, K. Wakabayashi, H. Takahashi (Tokyo, mutations of the senataxin gene Japan) M. Anheim, M.C. Fleury, J. Franques, J.-P. Delaunoy, 12 Correlates of side-to-side symmetry of motor M. Moreira, M. Koenig, C. Tranchant (Strasbourg, manifestations in Parkinsonian disorders France) R.P. Munhoz, H.A. Teive, L.C. Werneck (Curitiba, PR, 5 Silver syndrome variant of hereditary spastic Brazil) paraplegia: Identification of a novel locus 13 The dystonia-associated protein torsinA A. Orlacchio, C. Patrono, F. Gaudiello, V. Moschella, modulates synaptic vesicle recycling A. Borreca, A. Orlacchio, R. Floris, G. Bernardi, T. A. Granata, G. Schiavo, T.T. Warner (London, United Kawarai (Rome, Italy) Kingdom) 6 Spectrum of gait impairments in presymptomatic 14 Pallidal deep brain stimulation improves quality and symptomatic Huntington’s disease: Cross of life in segmental and generalized dystonia: sectional data Results from a prospective, randomized sham- A.K. Rao, L.M. Muratori, E.D. Louis, C.B. Moskowitz, controlled trial K.S. Marder (New York, New York, USA) J. Mueller, I.-M. Skogseid, R. Benecke, W. Poewe, 7 Frequency of dementia in FMR1 premutation G. Deuschl, A. Kupsch, T. Trottenberg, J. Volkmann carriers (Innsbruck, Austria) M. Peller, K. Zeuner, M. Weiss, A. M. Sevin, Z. Kutalik, P. Damier, M. Vercelletto, P. Knutzen, M. Hallett, G. Deuschl, H.R. Siebner (Kiel, Renou, P. Boisseau, S. Bergmann, J.-M. Rival, S. Schleswig-Holstein, Germany) Jacquemont (Nantes, France) 16 Clinical and electrophysiological phenotype of 8 Intrafusal effects of botulinum toxin injection in myoclonus dystonia due to epsilon sarcoglycan patients with upper motor neuron syndrome gene mutations C. Trompetto, G. Francavilla, C. Ogliastro, L. E. Apartis, E. Roze, F. Clot, I. Guyon-Marechal, S. Avanzino, M. Bove, A. Berardelli, G. Abbruzzese Thobois, C. Tranchant, P. Damier, Y. Beaugendre, A. (Genova, Italy) Durr, M. Vidailhet (Paris, France)

53 Oral Platform Presentations 5601 24 Neuropathological characteristics of Parkinson’s disease associated with LRRK2 I2020T Wednesday, June 6, 2007 - 2:30 PM - 4:30 PM (Sagamihara family) Room: Marmara Room S. Ujiie, Y. Ogino, M. Ogino, T. Uchihara, S. Yagishita, Chairs: Vladimir Kostic, Belgrade, Serbia/Montenegro K. Hasegawa, H. Kowa, F. Sakai (Sagamihara, Rivka Inzelberg, Kfar Saba, Israel Kanagawa, Japan) Parkinson’s disease Oral Platform Presentations 5602 17 The physiological effects of pedunculopontine Wednesday, June 6, 2007 - 2:30 PM - 4:30 PM stimulation in patients with Parkinson’s disease Room: Dolmabahce A S. Tisch, J.C. Rothwell, V. Di Lazzaro, M. Dileone, F. Chairs: Bulent Elibol, Ankara, Turkey Capone, P. Profice, A. Insola, P. Mazzone (London, Heinz Reichmann, Dresden, Germany United Kingdom) 18 Clinimetric testing of the new UPDRS (MDS- Clinical Electrophysiology and Imaging UPDRS) vs. original version 25 Probing a heterosynaptic manifestation of C.G. Goetz, B.C. Tilley, S. Shaftman, G.T. Stebbins, homeostatic plasticity in the intact human motor S. Fahn, P. Martinez-Martín, W. Poewe, C. Sampaio, cortex M.B. Stern, R. Dodel, B. Dubois, R. Holloway, J. M. Poetter, S. Fischer, G. Deuschl, A. Quartarone, H. Jankovic, J. Kulisevsky, A.E. Lang, A. Lees, S. Siebner (Kiel, Germany) Leurgans, P.A. LeWitt, D. Nyenhuis, C.W. Olanow, O. 26 Impaired temporal preparation in Parkinson’s Rascol, A. Schrag, J. Teresi, J.J. van Hilten (Chicago, disease: Slow brain potential and oscillatory Illinois, USA) manifestations 19 The 2 adrenergic antagonist fipamezole prolongs P. Praamstra, P. Pope (Birmingham, United Kingdom) the anti-parkinsonian actions of L-DOPA in the 27 Simultaneous EMG-fMRI; relating movement and MPTP-lesioned macaque brain activity in tremor T.H. Johnston, J.-M. Savola, S.H. Fox, J.M. Brotchie A.-F. van Rootselaar, N.M. Maurits, R. Renken, (Toronto, Ontario, Canada) J.H.T.M. Koelman, J.M. Hoogduin, K.L. Leenders, 20 Topography of -synuclein pathology in M.A.J. Tijssen (Amsterdam, Netherlands) Parkinson’s disease 28 Change in water diffusion MRI following repetitive M.E. Kalaitzakis, M.B. Graeber, S.M. Gentleman, transcranial magnetic stimulation R.K.B. Pearce (London, United Kingdom) M. Abe, T. Mima, N. Sawamoto, S. Urayama, T. Aso, 21 Prospective comparison of weight gain and energy H. Fukuyama (Kyoto, Japan) intake after subthalamic (STN), pallidal (GPi) and 29 White matter changes in the diagnosis of thalamic (VIM) deep brain stimulation (DBS) in presymptomatic neurodegenerative diseases: The Parkinson’s disease example of Huntington’s disease S. Blanchard, G. Drillet, P. Sauleau, S. Drapier, A.-S. S. Kloppel, B. Draganski, S.J. Tabrizi, R.S.J. Gillioz, T. Rouaud, J. Peron, M. Verin (Rennes, France) Frackowiak (London, United Kingdom) 22 Staging of lewy-related pathology in a community- 30 Hyposmia, midbrain hyperechogenity and based sample of dementia: Evidence for disease- Parkinson’s disease: Findings in a population- dependent anatomic distribution based study J.B. Leverenz, E.B. Larson, D. Vavrek, E.R. Peskind, K. Seppi, H. Stockner, S. Kiechl, J. Schwaiger, M. J.D. Bowen, W.C. McCormick, L. Teri, W.A. Kukull, T.J. Sawires, J. Willeit, W. Poewe (Innsbruck, Austria) Montine, D.W. Tsuang (Seattle, Washington, USA) 31 Firing patterns of STN in early stage PD patients 23 Neuropsychological and psychiatric sequelae of implanted with DBS deep-brain stimulation for Parkinson’s disease – a C.H. Harrison, N.D. Manus, C.E. Gill, C.C. Kao, M.S. randomized controlled multicenter study Remple, T.L. Davis, J.S. Neimat, P.E. Konrad, P.D. C. Daniels, K. Witt, J. Reiff, P. Krack, M. Krause, Charles (Nashville, Tennessee, USA) K. Boetzel, A. Schnitzler, L. Wojtecki, R. Hilker, E. Kalbe, G.H. Schneider, A. Kupsch, G. Deuschl, for the German Parkinson Study Group, Neurostimulation Section (Kiel, Germany) 54 32 Connections between premotor and motor cortex in healthy subjects and in patients with Parkinson’s disease A. Suppa, M. Bologna, C. Lorenzano, F. Gilio, M. Napoletani, A. Berardelli (Rome, Italy)

CME and Certificates of Attendance

To claim CME Credits or to receive a Certificate of Attendance for participation in this educational activity, International Congress participants must complete and submit an online CME Request Form following their participation in the International Congress. This can be done onsite at the CME Kiosk, or online from your own computer. CME Kiosk Hours 7:00 AM – 7:00 PM Wednesday, June 6 7:00 AM – 6:00 PM Thursday, June 7 The CME Kiosk is located in the Main Lobby behind the registration area, near the stairs.

Online: Visit www.movementdisorders.org/congress/congress07/cme and follow the on-screen instructions to claim your CME Credit or Certificate of Attendance. You can print the certificate directly from your computer or a send it to your personal e-mail address.

CME/Certificate of Attendance Online Instructions: You will need your MDS ID Number and password to claim credit. This information can be found on the bottom of your registration confirmation form (found in your registration packet). It will also be e-mailed to all International Congress participants upon the completion of the 11th International Congress.

MDS-0407-024

55

Poster Session 1 42 Different metabolic pattern in SCA 1,2,3 and 6 in FDG-PET and correlation with clinical parameters Tuesday, June 5, 2007 - 12:30 PM - 2:30 PM M. Minnerop, E. Rota Kops, H. Herzog, E. Brunt, K.L. Rumeli Hall, Lower Level Leenders, T. Klockgether, U. Wüllner (Bonn, Germany) Poster Viewing 9:00 a.m. to 4 p.m. 43 SCA 12 – with the identification of novel Authors Present 12:30 p.m. to 2:30 p.m. intermediate allele Poster numbers 33-345 and Poster 683 A.K. Srivastava, M. Mukerji, M.V. Padma, K. Prasad, Ataxia M. Behari (New Delhi, India) Poster numbers 33-52 44 SCA 7 with late retinal degeneration from India 33 High field proton MR spectroscopy of sporadic and A.K. Srivastava, M. Mukerji, M.B. Singh, M. Tripathi, hereditary spinocerebellar ataxias R. Bhatia, M.V. Padma, K. Prasad, M. Behari (New G. Oz, I. Iltis, D. Hutter, C.M. Gomez (Minneapolis, Delhi, India) Minnesota, USA) 45 Cognitive dysfunctions in spinocerebellar ataxia 34 Frequency of the MCP sign in FMR1 premutation type 1 and 2 carriers and FXTAS E. Pastorello, S. Lombardi, F. Cappa, M. Clementi, P. M.A. Leehey, D. Rubinstein, A.G. Brega, D. Hall, F. Bisiacchi, D. Paganini, C.P. Trevisan (Padova, Italy) Tassone, L. Zhang, R. Hagerman, P.J. Hagerman, J. 46 Characteristics of cortical excitability revealed Grigsby (Denver, Colorado, USA) by transcranial magnetic stimulation in 35 NARP-MILS syndrome caused by 8993T>G spinocerebellar ataxias type 1, type 2 and mitochondrial DNA mutation showing ragged-red idiopathic sporadic fibers S. Radovanovic, N. Dragasevic, J. Maric, M. Svetel, J. Youn, J.Y. Kim, W.Y. Lee, E.J. Chung, W.T. Yoon, Y.- V.S. Kostic (Belgrade, Serbia) L. Suh, C.S. Ki (Seoul, Republic of Korea) 47 Human recombinant erythropoietin increases 36 Gordon Holmes spinocerebellar ataxia with retinal frataxin in Friedreich ataxia dystrophy S. Boesch, B. Sturm, S. Hering, H. Goldenberg, B. S.-J. Kim, E.J. Chung, J-H. Joo (Busan, Korea) Scheiber-Mojdehkar, W. Poewe (Innsbruck, Austria) 37 Ataxin-2 localizes at the Endoplasmic reticulum 48 Novel compound heterozygous mutations in SACS and co-sediments with polysomes gene in autosomal recessive spastic ataxia of S. van de Loo, J. Nowock, R. Hilker, G. Auburger Charlevoix-Saguenay (ARSACS) (Frankfurt/Main, Germany) I. Toyoshima, S. Kamada, S. Okawa, M. Sugawara, C. 38 A phase III double-blind, randomised, placebo- Wada (Akita, Japan) controlled study of the efficacy, safety and 49 Potassium channel blocker 4-aminopyridine is tolerability of idebenone in the treatment of effective in late onset episodic ataxia type 2 (EA2) Friedreich’s ataxia patients – a video case report P. Giunti, J. Gray, N.W. Wood (London, United M. Löhle, W. Schrempf, M. Wolz, H. Reichmann, A. Kingdom) Storch (Dresden, Saxony, Germany) 39 The natural history of multiple system atrophy 50 Correlation between clinical tests and K. Arai, Y. Yoshiyama, K. Ogawara, C. Ishikawa, K. Ito accelerometry in the assessment of cerebellar (Chiba, Japan) tremor in multiple sclerosis 40 Clinical relevance of “bulging eyes” for the S. Seidel, D. Samal, J. Zezula, K. Vass, E. Auff differential diagnosis of spinocerebellar ataxias (Vienna, Austria) H.A.G. Teive, R.P. Munhoz, S. Raskin, W.O. Arruda, 51 Spinocerebellar ataxia type 7 in Venezuela L.C. Werneck (Curitiba, PR, Brazil) M. Gallardo, A. Soto, G. Orozco, M. Camacaro 41 Involuntary movements in ataxia-telangiectasia: (Caracas, Miranda, Venezuela) Natural history and quantitative characteristics 52 Usefulness of the scale for assessment and rating A.G. Shaikh, D.S. Zee, A.E. Meyer, H.M. Lederman, of ataxia (SARA) T.O. Crawford (Baltimore, Maryland, USA) I. Yabe, M. Matsushima, H. Soma, H. Sasaki (Sapporo, Japan)

57 Basic Science 64 Reflex control of jaw movement Poster numbers 53-83 K.S. Türker (Adelaide, SA, Australia) 53 Vacuous chewing movements are related to 65 No age-related loss or morphological changes in striosome-dominant activity in ventrolateral nigral neurons of pars compacta striatum of normal Indian human brains: A stereological B. Bastan, G. Sahin, M. Hayran, E. Saka, B. Elibol study (Lund, Sweden) P.A. Alladi, A. Mahadevan, T.C. Yasha, T.R. Raju, S.K. 54 LRRK2 binds to membrane Shankar, U. Muthane (Bangalore, Karnataka, India) T. Hatano, S.-I. Kubo, Y. Mizuno, N. Hattori (Bunkyo, 66 Expression of MT1 MT2 receptors in human Tokyo, Japan) postmortem amygdala and substantia nigra of 55 The GTPase and kinase activity of the LRRK2 Parkinson’s disease and controls subjects protein are both required for inclusion formation N. Adi, L. Shehadeh, D.C. Mash, C. Singer, S. and cell toxicity in cell culture models Papapetropoulos (Miami, Florida, USA) D. Schweiger, M. van Doeselaar, B. Oostra, V. Bonifati 67 Human uncoupling-protein-4 protects neuronal (Rotterdam, Netherlands) cell death from MPP+ induced toxicity by 56 Potency of CNBTX-A substantially exceeds labeled regulating mitochondrial membrane potential, units in standard potency test reducing generating ROS and maintaining ATP T. Hunt, K. Clarke (Irvine, California, USA) levels 57 MPTP-lesioned mouse model of the beginning-of- C.Y. Chu, W.L. Ho, H.H. Kwok, Y.J. Wang, D.B. dose inhibitory effect in Parkinson’s disease Ramsden, S.L. Ho (Hong Kong, China) S.A. Gunzler, S. Shakil, N.E. Carlson, J.G. Nutt, C.K. 68 Role of Neu4L sialidase and its substrate Meshul (Portland, Oregon, USA) ganglioside GD3 in neuronal apoptosis induced by 58 PYM50028, a novel, orally active neurotrophic catechol metabolites factor inducer, protects and reverses the neuronal T. Hasegawa, N. Sugeno, A. Takeda, M. Matsuzaki- damage induced by MPP+ in mesencephalic Kobayashi, A. Kikuchi, K. Furukawa, T. Miyagi, Y. neuronal cultures and by MPTP in a mouse model Itoyama (Sendai, Miyagi, Japan) of Parkinson’s disease 69 Vesicular dysfunction may trigger dopaminergic N.P. Visanji, T.H. Johnston, N. Callizot, A. Orsi, D. cell death Rees, J.M. Brotchie (Toronto, Ontario, Canada) M. Kobayashi, T. Hasegawa, A. Takeda, N. Sugeno, Y. 59 Evaluation of gastrointestinal function in a mouse Itoyama (Sendai, Miyagi, Japan) model of Parkinson’s disease 70 Glucocerebrosidase mutations promote - G. Anderson, G. Taylor, D. Bernhard, M. Anitha, S. synuclein aggregation Srinivasan, J.G. Greene (Atlanta, , USA) O. Goker-Alpan, D. Urban, B.K. Stubblefield, M.R. 60 Stability of Xeomin®, a preparation of botulinum Cookson, E. Sidransky (Bethesda, Maryland, USA) neurotoxin type A, free of complexing proteins 71 Leucine-rich repeat kinase 2 binds to lipid rafts in S. Grein, G.J. Mander, S. Grafe (Frankfurt, Germany) synaptic terminals 61 Modulation of Akt signaling pathway by the S.-I. Kubo, T. Hatano, Y. Mizuno, N. Hattori (Bunkyo, interaction of DJ-1 with PTEN Tokyo, Japan) C.Y. Kim, H. Kitaura, S.M.M. Iguchi-ArigaSanae, H. 72 Pleiotrophin over-expression after intrastriatal Ariga (Sapporo, Hokkaido, Japan) and intranigral administration of a recombinant 62 Decreased expression of alpha-synuclein in adenoviral vector containing human pleiotrophin Parkinson’s disease: Multiple-level evidence cDNA S. Papapetropoulos, N. Adi, L. Shehadeh, J. Ffrench- I.R. Taravini, M. Chertoff, E. Cafferata, G.M. Murer, Mullen, N. Bishopric, D.C. Mash (Miami, Florida, USA) F. Pitossi, O.S. Gershanik (Capital Federal, Buenos 63 Mutant forms of parkin cause protein aggregation, Aires, Argentina) alterations of the ubiquitin-proteasome system 73 Selective suppression of REM sleep in MPTP and neuronal death in human neuroblastoma cells non-human primates: A long term continuous E. Kyratzi, M. Pavlaki, D. Kontostavlaki, H.J. Rideout, electroencephalographic study by telemetry L. Stefanis (Athens, Attiki, Greece) V. Lambrecq, C. Forni, F. Tison, E. Balzamo, B. Bioulac, I. Ghorayeb (Bordeaux, France) 58 74 Neuronal a-synuclein overexpression affects lymphocytic gene networks in a transgenic mouse Poster numbers 84-107 model of Parkinson’s disease 84 Botulinum toxin treatment in perioral dyskinesia B.A. Chase, G. Lu, K. Markopoulou (Omaha, M.-W. Seo (Chonju, Jeonbuk, Korea) Nebraska, USA) 85 Huntington’s disease-like 2: The first case report 75 Endogenous dopamine causes neurodegeneration in Latin America in a patient without African ethnic in mice origin L. Chen, Y. Ding, B. Cagniard, W. Chi, A.D. Van Laar, H.A.G. Teive, N. Becker, R.P. Munhoz, S. Raskin, L.C. A. Mortimer, T.G. Hastings, U.J. Kang, X. Zhuang Werneck, C. Cazeneuve, A. Durr, O. Russaouen, A. (Chicago, Illinois, USA) Brice (Curitiba, PR, Brazil) 76 Role of phosphorylation at serine 129 in cellular 86 Disordered post-movement excitation in surround toxicity of -synuclein muscles in paroxysmal kinesigenic dyskinesia N. Sugeno, A. Takeda, T. Hasegawa, M. Kobayashi, A. Y.H. Sohn, J.-S. Kim, H.-W. Shin, S.Y. Kang (Seoul, Kikuchi, Y. Itoyama (Sendai-City, Miyagi, Japan) Korea) 77 Neuroprotective effect of human mesenchymal 87 Hemichorea secondary to striatal hemorrhage in stem cell on dopaminergic neurons by anti- hyperglycemic hyperosmolar coma inflammatory action S. Ozkan, G. Tekgol, S. Dagli, D. Ozbabalik (Eskisehir, P.H. Lee, Y.-J. Kim, H.-J. Park, S.W. Yong (Suwon, Turkey) Gyeonggi, Republic of Korea) 88 Levels of the light subunit of neurofilament triplet 78 Prolonged microglial activation in the substantia protein in cerebrospinal fluid in Huntington’s nigra of zitter rat disease T. Kadowaki, A. Nakamura, K. Hashimoto, K. R. Constantinescu, M. Romer, L. Rosengren, D. Nakadate, S.-I. Sakakibara, K. Hirata, S. Ueda (Mibu, Oakes, K. Kieburtz (Goteborg, Sweden) Tochigi, Japan) 89 Atypical onset movement disorders in Brazilian 79 Ubiquitylation of synphilin-1A modulates its Huntington’s disease patients aggregation and neurotoxicity in Parkinson’s H.A.G. Teive, N. Becker, R.P. Munhoz, S. Raskin, L.C. disease Werneck (Curitiba, PR, Brazil) R. Szargel, A. Eyal, J. Haskin, E. Avraham, E. Liani, R. 90 Aripiprazole in Huntington’s disease: A first case Rott, S. Engelender (Haifa, Israel) report 80 Relationship of -synuclein to chaperone mediated A. Ciammola, J. Sassone, F. Squitieri, B. Poletti, N. autophagy Mencacci, A. Ciarmiello, V. Silani (Milano, Italy) T. Vogiatzi, K. Vekrellis, L. Stefanis (Athens, Attiki, 91 Chorea following acute sensory deprivation Greece) D. França, A.V. Giannetti, F. Cardoso (Belo Horizonte, 81 Comparative analysis of progenitor cell MG, Brazil) populations in the adult midbrain of wild-type and 92 Clinical findings in Titf-1 and SGCE-mutation Parkinsonian mice models carriers: Towards a clinical differentiation of A. Hermann, C. Suess, F. Pan-Montojo Puga, benign hereditary chorea and myoclonus-dystonia M. Jungnitsch, S. Gehre, J. Schwarz, A. Storch F. Asmus, A. Zimprich, M. Munz, T. Gasser, P.F. (Dresden, Germany) Chinnery (Tuebingen, Germany) 82 Apoptotic mechanisms in mutant LRRK2-mediated 93 Chorea isolated on the both lower limbs cell death associated with C. Vitale, C. Iaccarino, C. Crosio, G. Sanna, M.T. Carri, Y.-H. Sung, H.-T. Kim, D.-J. Shin (Incheon, Korea) P. Barone (Naples, Italy) 94 Late-onset Huntington’s disease in our movement 83 The nociceptin/orphanin FQ receptor antagonist disorder unit J-113397 enhances the effects of L-DOPA in the A. De la Cerda, E. Muñoz, E. Tolosa (Barcelona, MPTP-lesioned non-human primate model of Spain) Parkinson’s disease 95 Bradykinesia in patients with history of N.P. Visanji, S.H. Fox, R.M.A. Debie, A.C. McCreary, sydenham’s chorea J.M. Brotchie (Toronto, Ontario, Canada) L.B. Barreto, F. Cardoso, D.P. Maia, A.L. Teixeira, Jr, R.G. Beato (Belo Horizonte, Minas Gerais, Brazil) 59 96 Chorea and compulsive behavior – an unusual Clinical Electrophysiology presentation of myasthenia gravis Poster numbers 108-126 M. Niethammer, M. Daras, S. Frucht (New York, New 108 Peripheral neuropathy and plasma homocysteine York, USA) level in Parkinson’s disease patients: A pilot study 97 A case of CHAP syndrome M. Nevrly, H. Vranova, Z. Chovancova, I. Nestrasil, M.-W. Seo, S.-Y. Jeong (Chunju, Jeonbuk, Korea) P. Otruba, J. Dufek, P. Kanovsky (Olomouc, Czech 98 Choreoathetosis precipitated by subclinical Republic) hypothyroidism in an Asian patient 109 Differential modulation of cranial and limb muscle W.S.S. Hameed, T.E. King (Singapore, Singapore) function by levodopa in Parkinson’s disease 99 Encephalitis with hyperkinesias P.B. Tawadros, J.A. Burne (Sydney, NSW, Australia) A.E. Collins, S. Honarmand, C.A. Glaser (New York, 110 Elecrically and auditory evoked brain stem New York, USA) reflexes in cervical dystonia 100 Oxidative stress parameters in plasma of M.E. Kiziltan, A. Gunduz, O. Uyanik, R. Sahin Huntington’s disease patients, asymptomatic (Istanbul, Turkey) Huntington’s disease gene carriers and healthy 111 Reflex inhibition of muscle by electrical subjects: A cross-sectional study stimulation of muscle tendons N. Klepac, M. Relja (Zagreb, Croatia) S.I. Khan, B.A. John (Sydney, NSW, Australia) 101 Early onset Huntington disease presenting with 112 Hyperexcitable motor responses to flash choreiform movements in the abdominal muscles stimulation in Parkinson’s disease: A TMS study A.A. Ege, B. Koçer, S. Bilen, N.S. Oztekin, F. Ak S. Tamburin, A. Fiaschi, P. Manganotti, F. Milanese, A. (Ankara, Turkey) Polo, G. Zanette (Peschiera del Garda, VR, Italy) 102 Therapeutics for Huntington’s disease: A 113 Evidence of negative myoclonus in clozapine systematic review induced folding legs phenomena and drop attacks T. Mestre, J. Ferreira, M. Coelho, M.M. Rosa, C. D. Murgia, L. Fabiano, N.J. Toms, C. Cordivari Sampaio (Lisbon, Portugal) (London, United Kingdom) 103 Serum brain-derived neurotrophic factor (BDNF) 114 Executive functions processed in the frontal and changes in Huntington’s disease subjects lateral temporal cortices. An intracerebral event- J. Sassone, A. Ciammola, M. Cannella, B. Poletti, L. related de/synchronization study with writing of Frati, F. Squitieri, V. Silani (Cusano Milanino, Milano, single letters Italy) M. Bockova, J. Chladek, P. Jurak, J. Halamek, I. 104 Sydenham’s chorea may be associated with Rektor (Brno, Czech Republic) sustained monocyte activation 115 ParkinSense comparison to the unified K.C. Torres, W.O. Dutra, D.P. Maia, F. Cardoso, K.J. Parkinson’s disease rating scale: Preliminary Gollob, A.L. Teixeira (Belo Horizonte, Brazil) tremor and bradykinesia results 105 Chorea in adults after pulmonary J. Giuffrida, L.C. Trout, L. Mather, B. Maddux, D. Riley thromboendarterectomy with deep hypothermia (Cleveland, Ohio, USA) and circulatory arrest 116 Extracellular microrecordings during stereotactic R.M.A. De Bie, H.M.M. Smeding, M.A.J. Tijssen neurosurgery for Parkinson’s disease: Spike (Amsterdam, Netherlands) descriptors in the human subthalamus and 106 Motor neuron disease and chorea substantia nigra J. Klempir, O. Klempirova, Z. Lebedova, J. Roth S. Mrakic-Sposta, S. Marceglia, F. Cogiamanian, (Prague, Czech Republic) M. Egidi, P. Rampini, M. Locatelli, G. Carrabba, M. 107 Inefficient deep brain stimulation in a young Vergari, A. Priori (Milan, Italy) patient suffering from choreoathetosis 117 Long-term effect of locally administered K. Schumm, K. Kiening, M.C. Kraus, M. Krause, M. botulinum toxin a on neuromuscular transmission: Kloss (Heidelberg, Germany) Longitudinal single-fiber EMG study S. Vohanka, B. Micankova, J. Bednarik (Brno, Czech Republic)

60 118 Delayed blink reflex in Lewy bodies dementia Dystonia L. Bonanni, F. Anzellotti, S. Varanese, A. Thomas, L. Poster numbers 127-168 Manzoli, M. Onofrj (Pescara, Italy) 127 Blepharospasm associated with Sjogren’s 119 The role of ipsilateral motor cortex in complex syndrome finger movements: A rTMS study J.-S. Liu, M.-Y. Lan, C.-S. Su, S.-L. Lai, H.-S. Wu, L. Avanzino, A. Tacchino, C. Ogliastro, M. Bove, C. Y.-Y. Chang (Kaohsiung, Taiwan) Trompetto, G. Abbruzzese (Genova, Italy) 128 Impaired disinhibition of the motor cortex during 120 Use of a geste antagoniste device in a case of development of LTP-like plasticity in dystonia cervical dystonia S. Meunier, H. Russmann, M. Hallett (Paris, France) N.J. Toms, C. Cordivari (London, United Kingdom) 129 Diffusion tensor imaging in patients with primary 121 Validation of spiral analysis for quantification of adult onset focal dystonias motor improvement in Parkinson’s patients after G. Fabbrini, P. Totaro, V. Calistri, C. Colosimo, P. deep brain stimulation Pantano, A. Berardelli (Rome, Italy) M.M. Kurtis, Q. Yu, A.G. Floyd, R.R. Goodman, G.M. 130 Clinical outcome predictors of pallidal stimulation McKhann, L. Winfield, B. Ford, L. Côté, S.L. Pullman in patients with primary dystonia (New York, New York, USA) I.U. Isaias, R.L. Alterman, J. Miravite, D. Weisz, J.L. 122 Putative central effects of botulinum toxin, Shils, M. Tagliati (Monza, Italy) possibly mediated by changes in Renshaw cell 131 Muscle hypertrophy in cervical dystonia: A activity, following intramuscular injection in magnetic resonance imaging (MRI) based analysis humans R. Cakmur, S. Men, E. Karakas, E. Yaka, F. Uzunel R. Mazzocchio, R. Spidalieri, F. Dominici, T. Popa, M. (Izmir, Turkey) Hallett, A. Rossi (Siena, Italy) 132 Exercise as an environmental trigger for focal 123 The tonic stretch reflex studied in Parkinsonism dystonia over a wide range of stretch frequencies and E.L. Peckham, P.T. Lin, E.A. Shamim, M. Hallett contraction levels (Bethesda, Maryland, USA) V. Stanislaus, J.A. Burne (Sydney, NSW, Australia) 133 Is fluoxetine innocent as thought 124 Abnormal excitability of inhibitory mechanisms at S. Bilen, F. Ak (Ankara, Turkey) central nervous system level in idiopathic primary 134 Sensorimotor organisation of the hand area is vaginismus and vulvar vestibulitis syndrome differently modulated by proprioceptive training in E. Frasson, A. Graziottin, G. Didonè, E. Garbin, S. musician’s dystonia and writer’s cramp Vicentini, E. Dall’Ora, L. Bertolasi (Cittadella, Padua, K. Rosenkranz, K. Butler, A. Williamon, C. Cordivari, Italy) A.J. Lees, J.C. Rothwell (London, United Kingdom) 125 The syndrome of dystonia and cerebellar ataxia: 135 Efficiency of botulinum toxin in treatment of Cortical excitability and pathophysiological writer’s cramp: Long-term follow-up results implications Z. Matur, H. Hanagasi, Y. Parman (Istanbul, Turkey) P. Talelli, B.P.C. van de Warrenburg, S.A. Schneider, 136 Pediatric writer’s cramp in myoclonus-dystonia. P. Giunti, N.P. Quinn, N.W. Wood, J.C. Rothwell, K.P. Maternal imprinting hides positive family history Bhatia (London, United Kingdom) M.C.F. Gerrits, E.M.J. Foncke, J.H.T.M. Koelman, 126 Voluntary and reflex blinking in Parkinson’s M.A.J. Tijssen (Amsterdam, Netherlands) disease 137 Long-term motor learning in focal hand dystonia R. Agostino, B. Gregori, L. Dinapoli, M. Bologna, D. (FHD) Belvisi, G. Fabbrini, A. Berardelli (Roma, Italy) E.A. Shamim, S.Y. Kang, M. Hallett (Bethesda, Maryland, USA) 138 A patient with Meige-like psychogenic Movement Disorder S. Turan, D. Uluduz, S. Ozekmekci (Istanbul, Turkey)

61 139 Influence of coffee drinking and cigarette smoking 151 New onset or worsening in patients on the risk of primary late-onset blepharospasm: with Wilson’s disease on treatment Evidence from a multicentre case-control study A. Aggarwal, A. Nagral, M. Bhatt (Mumbai, A. Berardelli, G. Abbruzzese, P. Girlanda, D. Martino, Maharashtra, India) M. Tinazzi, G. Defazio (Rome, Italy) 152 Defective inhibition and functional connectivity 140 Focal limb dystonia with ipsilateral cerebellar in pianists with musician’s dystonia (MD): An EEG hemiatrophy study J.S. Baik, J.H. Park, J.Y. Kim, S.W. Han, J.H. Kim M. Herrojo Ruiz, P. Senghaas, M. Grossbach, H.- (Seoul, Korea) C. Jabusch, M. Bangert, F. Hummel, C. Gerloff, E. 141 Sepiapterin reductase deficiency masquerading as Altenmüller (Hanover, Germany) hypotonic cerebral palsy 153 Retrocollis: Classification, clinical phenotype, G.M. Wali, B. Thony, N. Blau (Belgaum, Karnataka treatment outcomes and risk factors State, India) S. Papapetropoulos, S. Baez, J. Zitser, C. Sengun, C. 142 Associative plasticity in psychogenic dystonia Singer (Miami, Florida, USA) A. Quartarone, V. Rizzo, C. Terranova, S.A. Schneider, 154 The thorburn posture: See it again for the second F. Morgante, P. Girlanda, K.P. Bhatia, J.C. Rothwell time (Messina, Italy) P.J. Sweeney (Cleveland, Ohio, USA) 143 Autosomal dominant myoclonus dystonia: Unusual 155 Secondary nonkinesigenic paroxysmal dystonia phenotype with prominent hypotonia/motor after thalamic infarcts impersistence and positive celiac serology L.C. Shih, M. Sobeih, D. Tarsy (Boston, V.S.C. Fung, N. Mahant, C.M. Sue, A. Grünewald, C. Massachusetts, USA) Klein (Sydney, NSW, Australia) 156 Treatment of post-traumatic segmental axial 144 Brainstem reflexes in essential blepharospasm dystonia with zolpidem G. Benbir, M.E. Kiziltan (Istanbul, Turkey) M.-W. Seo, S.-Y. Jeong (Chunju, Jeonbuk, Korea) 145 A case of paroxysmal dyskinesia: Atypical or 157 Quantitative characteristics of limb tremor in psychogenic? cervical dystonia J.S. Baik, J.H. Park, J.Y. Kim, S.W. Han, J.H. Kim A.G. Shaikh, H.A. Jinnah, R.M. Tripp, S. Ramat, D.S. (Seoul, Korea) Zee (Baltimore, Maryland, USA) 146 Long-term therapy of blepharospasm and facial 158 Disturbed topographic specific plasticity in hemispasm with botulinum toxin type A cervical dystonia and blepharospasm H. Streitova, M. Bares, I. Rektor (Brno, Czech A. Schramm, D. Weise, M. Beck, K. Reiners, J. Republic) Classen (Wuerzburg, Germany) 147 Bilateral cortical grey matter changes support 159 Natural course of idiopathic torsion dystonia: Is the sensory endophenotype hypothesis in familial focal dystonia actually focal? adult onset primary torsion dystonia: A VBM study M.V. Svetel, T. Pekemzovic, N. Ivanovic, J. Jovic, N. R. Walsh, R. Wheelan, J.P. O’Dwyer, S. O’Riordan, Dragasevic, V.S. Kostic (Belgrade, Serbia) S. Hutchinson, R. Reilly, R. O’Laoide, K. Malone, M. 160 Transcranial magnetic stimulation in myoclonus- Hutchinson (Dublin, Ireland) dystonia 148 Tactile training with or without 1Hz rTMS to S.M.A. van der Salm, A.-F. van Rootselaar, E.M.J. : A case study in two patients Foncke, J.T.H.M. Koelman, L.J. Bour, K.P. Bhatia, J.C. with focal hand dystonia Rothwell, M.A.J. Thijssen (Amsterdam, Netherlands) A.J. Nelson, W. Chau, B. Ross, G. Carolyn, R. Chen 161 A new locus for adult-onset Focal Idiopathic (Toronto, Ontario, Canada) Torsion Dystonia 149 Nuclear envelope phenotype in Dyt1 mutant mice M.Y. Frederic, C.-M. Dhaenens, C. Davin, R. Y. Li, F. Yokoi, M. Dang (Birmingham, Alabama, USA) Mazzoleni, A. Kreisler, I. Vuillaume, M. Marinez, 150 Neuroanatomy of dystonia: A motor network M. Claustres, S. Tuffery-Giraud, G. Collod-Beroud concept (Montpellier, France) V.K. Neychev, E.J. Hess, V.I. Mitev, H.A. Jinnah (Baltimore, Maryland, USA)

62 162 Pallidal deep brain stimulation for primary 171 Cognitive and motor effects of globus pallidus segmental dystonia externus stimulation in patients with Huntington’s S. Biguzzi, M. Sensi, M.A. Cavallo, C. Lettieri, R. disease Quatrale, E. Sette, V. Tugnoli, E. Fainardi, M.R. Tola, E. P. Krystkowiak, D. Devos, K. Dujardin, C. Delmaire, Granieri, R. Eleopra (Ferrara, Italy) E. Bardinet, A. Delval, M. Delliaux, O. Cottencin, 163 Abstract withdrawn Huntington French Speaking Group (Lille, France) 164 A case of cerebello pontine angle tumor 172 Social cognition and emotional recognition in early presenting as cervical dystonia and late stages of Parkinson’s disease S. Chandran, Y.R. Godge, P.J. Oak, S.H. Ravat J. Peron, I. Biseul, S. Fournier, S. Drapier, D. Drapier, (Mumbai, Maharashtra, India) V. Thomas-Ollivier, R. Cohen, M. Verin (Rennes, 165 Botulinum toxin for treatment of task-specific France) orofacial dystonia 173 Gait disturbances induced by stimulation of the C.-H. Pek, R.C.S. Seet, J.-H. Yik, E.C.H. Lim subthalamic region in Parkinson’s patients (Singapore) G. Tommasi, M. Lanotte, E. Fincati, M. Zibetti, G. 166 Survey of families presenting with late-onset focal Moretto, L. Lopiano (Verona, Italy) idiopathic torsion dystonia in France 174 Response of subthalamic nucleus neurons to M.Y. Frederic, C.-M. Dhaenens, B. Sablonniere, R. vocalization Mazzoleni, A. Kreisler, I. Vuillaume, M. Claustres, M.D. Richardson, S.G. Ojemann, O.S. Klepitskaya S. Tuffery-Giraud, G. Collod-Beroud, the INSERM (Denver, Colorado, USA) National Dystonia Network and GIS Maladies Rares 175 Complication avoidance with multitrack (Montpellier, France) microelectrode recording in STN-DBS for 167 Spasmodic dysphonia and writer’s cramp in the Parkinson’s disease Korean patient with novel missense mutations in H. Toda, H. Saiki, S. Matsumoto (Osaka, Japan) the PANK2 gene 176 Influence of subthalamic deep brain stimulation J.Y. Kim, W.Y. Lee, C.S. Ki, H.-Y. Shin, W.T. Yoon, E.J. and levodopa on motor perseveration in Chung (Seoul, Republic of Korea) Parkinson’s disease 168 Assessment of TOR1A mutation carriers identified J. Herzog, B. Möller, K. Witt, G. Deuschl, J. Volkmann through the network of TOR1A diagnostic (Kiel, Germany) laboratories in France 177 Experiences from microrecording during DBS M.Y. Frederic, F. Clot, A. Durr, A. Brice, G. Lesca, I. neurosurgery of the basal ganglia Vuillaume, A. Calender, B. Sablonniere, T. Besnard, L.J. Bour, E.M.J. Foncke, M.-F. Contarino, H.D. D. Thorel, C. Saquet, L. Ozelius, L. Hjermind, A. Speelman, R. Schuurman (Amsterdam, Netherlands) Roubertie, L. Cif, M. Claustres, S. Tuffery-Giraud, G. 178 Where is the optimal target for STN-DBS? A Collod-Beroud (Montpellier, France) retrospective analysis of our 56 cases T. Agari, T. Matsui, S. Kuramoto, A. Kondou, I. Date Surgical Therapy (Okayama, Japan) Poster numbers 169-223 179 Deep brain stimulation of subthalamic nucleus for 169 Apraxia of eyelid opening after subthalamic deep Parkinson’s disease: Anatomical localization of brain stimulation may be caused by reduction of effective contacts levodopa P.-P. Derost, M. Ulla, B. Stephanie, B. Debilly, L. A. Umemura, T. Toyoda, M. Mizuguchi, F. Ishii, K. Ouchchane, J.-J. Lemaire, F. Durif (Clermont- Yamada (Nagoya, Japan) Ferrand, France, Metropolitan) 170 Determining factors for the reduction of dose of 180 PET cerebral glucose metabolism in PD patients dopaminergic drugs after bilateral subthalamic after STN-DBS nucleus stimulation M.A. Volonté, V. Garibotto, S. Lalli, D. Ceppi, F. S.J. Chung, S.R. Kim, T.Y. Lee, M.J. Kim, S.K. Lee, Spagnolo, P. Picozzi, A. Franzin, A. Panzacchi, F. C.S. Lee, M.C. Lee (Seoul, Republic of Korea) Fazio, G. Comi, D. Perani (Milan, Italy) 181 The atypical subthalamic nucleus J. Herzog, M.O. Pinsker, F. Wodarg, A. Morsnowski, G. Deuschl, J. Volkmann (Kiel, Germany) 63 182 Effect of contact site and voltage amplitude of 191 Treatment of sporadic dystonia-parkinsonism STNDBS on speech and movement in Parkinson’s by bifocal pallidal and subthalamic deep brain disease stimulation E. Tripoliti, L. Zinzro, E. Borrell, E. Frost, S. Tisch, J.C. Woehrle, C. Blahak, H.-H. Capelle, W. Fogel, H. I. Martinez, M. Hariz, P. Limousin (London, United Baezner, J.K. Krauss (Hannover, Germany) Kingdom) 192 Bilateral pallidal chronic deep brain stimulation 183 Weight gain after DBS STN in Parkinson’s disease improves quality of life in segmental dystonia is related to electrode placement rather than to H.-H. Capelle, C. Blahak, H. Baezner, K. Kekelia, the stimulation R. Weigel, J.C. Woehrle, J.K. Krauss (Hannover, L. Novakova, R. Jech, J. Roth, D. Urgosik, F. Ruzicka, Germany) E. Ruzicka (Prague, Czech Republic) 193 GPi-DBS in Huntington’s disease: Results on motor 184 Bilateral pallidotomy failed to improve generalized function and cognition in a 72-year-old case dystonia in Wilson’s disease A. Fasano, P. Mazzone, C. Piano, G. Loria, D. R. Bhidayasiri, T. Srikijvilaikul, N. Kanjanasut, L. Quaranta, A.R. Bentivoglio (Rome, Italy) Tuchinda, S. Lerdlum, S. Kaoroptham (Bangkok, 194 Neuropsychiatric therapy in the follow-up of PD Thailand) patients after STN-DBS 185 Parkinson’s disease in developing countries M. Zibetti, M. Pesare, A. Cinquepalmi, M. Rosso, – transfer from exclusively conservative treatment L. Castelli, B. Bergamasco, M. Lanotte, L. Lopiano to deep brain stimulation. Successes, difficulties, (Torino, Italy) preliminary experience 195 Single unit and local field potential recordings M. Ivanov, C. Ivanov, L. Cucos (Iasi, Romania) from human STN during reach-to-grasp 186 Long term superiority of bilateral STN stimulation movements over unilateral pallidotomy, four years follow-up of M. Poetter, F. Steigerwald, J. Herzog, R. a RCT Wenzelburger, M. Pinsker, G. Deuschl, J. Volkmann R.A. Esselink, R.M. Bie, R.J. Haan, R.P. Schuurman, (Kiel, Germany) A.D. Bosch, J.D. Speelman (Nijmegen, Netherlands) 196 Holmes’ tremor caused by midbrain cavernomas 187 Objective monitoring of tremor and bradykinesia J. Zhong, S.-T. Li (Shanghai, China) during deep brain stimulation of STN for 197 Bilateral STN DBS in PD patients with history of Parkinson’s disease: A pilot study benign visual hallucinations S. Papapetropoulos, J. Jagid, C. Sengun, C. Singer, C.E. Martin, C. Chau, R. Alterman, M. Tagliati (New B.V. Gallo (Miami, Florida, USA) York, New York, USA) 188 Correction of esthetic complications of facial 198 Movement Disorder surgery: Experience of single nerve pathology with the use of Botulinum toxin surgeon Type A (DYSPORT) S. Peker, Y. Akgun, D. Kaya, U. Isik (Istanbul, Turkey) O.R. Orlova, A.I. Nerobeev, S.V. Surovykh, M.O. 199 Effect on the quality of life of patients with Sokolova (Moscow, Russian Federation) Parkinson’s disease by subthalamic stimulation, 189 Orthostatic tremor improvement after using subjective evaluation of Japanese PDQ-39 ventrointermedial deep brain stimulation T. Matsui, S. Kojima, A. Kondo, S. Kuramoto, T. Agari, implantation: Clinical and electrophysiologic I. Date, T. Hayashi, K. Abe (Takasago, Hyogo, Japan) observations at 3 months 200 Predictors of neuropsychological and psychosocial A.J. Espay, A.P. Duker, E.T. Barrett, J. Devoto, M. outcome one year after STN DBS in Parkinson’s Gartner, N. Burton, H.A. Miranda, G.T. Mandybur, F.J. disease Revilla (Cincinnati, Ohio, USA) H. Smeding, H.M. Huizenga, J.D. Speelman, P.R. 190 Bilateral benefit from unilateral deep brain Schuurman, B. Schmand (Amsterdam, Netherlands) stimulation of the subthalamic nucleus in PD at 201 Long-term lack of motor symptom progression in 1 year: A prospective analysis of 34 consecutive Parkinson’s disease patients with bilateral STN cases deep brain stimulation H.C. Walker, S. Guthrie, D. Wang, B.L. Guthrie, R.L. C.E. Martin, R. Alterman, M. Tagliati (New York, New Watts (Birmingham, Alabama, USA) York, USA)

64 202 Role of subthalamic deep brain stimulation for 211 Prospective evaluation of deep brain stimulation in levodopa-induced dyskinesia in Parkinson’s a series of 15 patients with segmental dystonia disease J.K. Krauss, C. Blahak, H.-H. Capelle, K. Kekelia, A. Umemura, T. Toyoda, K. Yamamoto, M. Mizuguchi, H. Baezner, R. Weigel, J.C. Woehrle (Hannover, F. Ishii, T. Yamanaka, K. Yamada (Nagoya, Japan) Germany) 203 Low rate of complications with unilateral STN-DBS 212 Deep brain stimulation perioperative course in in advanced Parkinson’s disease older (70 years) vs. younger Parkinson’s patients S. Papapetropoulos, J. Jagid, N. Ahmad, J. Zitser, C. B. Navi, K. Strybing, M.J. Nirenberg, L. Steinberg, T.F. Sengun, C. Singer, B.V. Gallo (Miami, Florida, USA) Burgut, B. Nikolov, M.G. Kaplitt, C. Henchcliffe (New 204 Recognition of negative emotions is impaired by York, New York, USA) subthalamic nucleus deep brain stimulation in 213 Long-term follow-up of pallidal DBS for primary Parkinson’s disease dystonia J. Peron, I. Biseul, S. Fournier, S. Drapier, D. Drapier, M. Tagliati, I.U. Isaias, D. Weisz, J. Shils, R. Alterman P. Sauleau, C. Haegelen, M. Verin (Rennes, France) (New York, New York, USA) 205 Apathetic patients after deep brain stimulation of 214 Microlesion effects and tremor outcomes in the subthalamic nucleus in Parkinson’s disease ventrointermediate deep brain stimulation (VIM- have an associated fear recognition impairment DBS) D. Drapier, J. Peron, P. Sauleau, S. Drapier, D. O. Sitburana, W.G. Ondo (Houston, Texas, USA) Travers, A. Bourguignon, B. Millet, M. Verin (Rennes, 215 Optimisation of the stimulation parameters in France) STN-DBS for Parkinson’s disease 206 Quality of life and behavioral changes after STN I. Martinez, L. Zrinzo, C.C. Chen, S. Tisch, E. Tripoliti, DBS in Parkinson’s disease E. Borrell, P. Brown, M. Hariz, P. Limousin (London, F. Tamma, E. Caputo, G. Rodolfi, S. Molteni, F. United Kingdom) Cogiamanian, M. Egidi, M. Locatelli, S. Marceglia, A. 216 Does subthalamic nucleus deep brain stimulation Priori, S. Sposta-Mrakic, P. Rampini (Milano, Italy) (STNDBS) influence personality in Parkinson’s 207 Different cerebral cortical areas influence the disease? effect of subthalamic nucleus stimulation on A. Gronchi-Perrin, S. Aybek, A. Jaques, C. Pollo, parkinsonian motor deficits and off gait freezing P.R. Burkhard, F. Vingerhoets (Lausanne, Vaud, C.H. Lyoo, S. Aalto, J.O. Rinne, K.O. Lee, S.H. Oh, Switzerland) J.W. Chang, M.S. Lee (Seoul, Republic of Korea) 217 PD patient’s can perform activities of their own 208 Effect of subthalamic nucleus deep brain choice after DBS in STN stimulation on emotional experience in A.L. Törnqvist, G. Ahlström, H. Widner, S. Rehncrona Parkinson’s disease patients (Lund, Sweden) S. Fournier, I. Biseul, J. Peron, P. Philippot, S. 218 Hemichorea/hemiballism after craniopharyngeoma Drapier, D. Drapier, P. Sauleau, C. Haegelen, M. Verin resection: Treatment with bifocal brain stimulation (Rennes, France) J.K. Krauss, T. Kinfe, H.-H. Capelle (Hannover, 209 Thalamic deep brain stimulation in patients with Germany) tremor due to multiple sclerosis: A series of 11 219 Bilateral GPi stimulation with 4 leads in primary patients generalized dystonia H.-H. Capelle, C. Schrader, R. Dengler, J.K. Krauss B. Biolsi, L. Cif, S. Gil Robles, X. Vasques, S. Gavarini, (Hannover, Germany) S. Plagnol, P. Coubes (Montpellier, France) 210 Radiological and clinical predictive factors of long- 220 Effective treatment of myoclonus-dystonia term outcome of bilateral subthalamic stimulation syndrome (MDS) by bilateral internal pallidal in advanced Parkinson’s disease stimulation T. Rouaud, S. Drapier, J. Peron, E. Leray, P. Sauleau, L. Cif, B. Biolsi, A. Saux, S. Gavarini, S. Gil Robles, X. Y. Rolland, M. Verin (Rennes, France) Vasques, P. Coubes (Montpellier, France)

65 221 Bilateral subthalamic nucleus stimulation in 230 Parkinson’s disease mimicking multiple system advanced Parkinson’s disease: Five years follow- atrophy, with involvement of Onuf’s nucleus up S.S. O’Sullivan, J.L. Holton, L.A. Massey, L. Silveira- H. Gervais-Bernard, J. Xie-Brustolin, P. Mertens, Moriyama, D.R. Williams, T. Revesz, A.J. Lees G. Polo, H. Klinger, I. Benatru, E. Broussolle (Lyon, (London, United Kingdom) France) 231 Pulmunary dysfunction in fluctuating Parkinson’s 222 Do neuropsychological changes after deep brain disease stimulation of the subthalamic nucleus relate to M. Peraino, A. Zarzana, L. Ferri, G. Marsili, P. Rigon, F. alterations of cerebral glucose metabolism in Stocchi (Roma, Italy) Parkinson patients? 232 Quantification of subtle movement changes in M. Haarer, E. Kalbe, T. Weber, G.R. Fink, R. Hilker healthy subjects with increased echogenicity of (Koln, Germany) the substantia nigra 223 Psychosis induced by subthalamic nucleus W. Ilg, I. Liepelt, C. Urban, M.A. Giese, D. Berg stimulation in a patient with Parkinson’s disease (Tuebingen, Germany) M. Pilleri, A. Caria, G. Nordera (Arcugnano, Vicenza, 233 Tripchlorolide protects against 1-methyl-4- Italy) phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice Parkinson’s disease S. Chen, Z. Hong (Shanghai, China) Poster numbers 224-345 234 Correlation of patient quality of life and a clinical 224 Rotigotine transdermal patch for the treatment of rating scale in advanced Parkinson’s disease (PD) early morning and night time motor symptoms in – results from the PD SURG trial patients with idiopathic Parkinson’s disease S. Mistry, C.E. Rick, N.J. Ives, A. Williams, N. Giladi, B. Boroojerdi (Tel Aviv, Israel) C. Jenkinson, S. Gill, T. Varma, K. Wheatley 225 Improved motivation and initiative with levodopa, (Birmingham, United Kingdom) DDCI and entacapone compared with traditional 235 How to deal with controversies about iron levodopa and DDCI: Pooled analysis of UPDRS I in concentration in parkinsonian and control SN four Phase III double-blind studies in Parkinson’s J. Galazka-Friedman, A. Friedman, K. Szlachta disease patients with wearing-off (Warsaw, Poland) H. Nissinen, M. Kuoppamäki, M. Leinonen (Espoo, 236 Electroconvulsive therapy for olfactory Finland) hallucination in a patient with Parkinson’s disease 226 Validation of PDQ-8 as an independent instrument E. Hoshiyama, T. Kadowaki, K. Suzuki, M. Tatsumoto, in English and Chinese T. Miyamoto, K. Hirata (Mibu, Tochigi, Japan) P.N. Lau, N. Luo, W.L. Au, L.C.S. Tan (Singapore, 237 Intracellular presentation of LRRK2- examined by Singapore) our anti-LRRK2-antibodies 227 Parkinson’s disease (PD) patients retain the K. Hasegawa, H. Ichinose, I. Toyoshima, S. Yaghisita capacity for postural recovery following imposed (Sagamihara, Kanagawa, Japan) sensory incongruence 238 Use of rehabilitation services in Parkinson’s L.A. Brown, S.A. Cooper, J.B. Doan, C. Dickin, I.Q. disease (PD): A preliminary survey Whishaw, O. Suchowersky (Lethbridge, Alberta, V. Dahan, S. Chouinard, M. Panisset (Montreal, Canada) Quebec, Canada) 228 Blinding strategies in a clinical trial involving cell 239 Knowledge and awareness of Parkinson’s disease: transplantation – the STEPS trial A comparison among various religions and J.E. Jimenez, T. McClain, B. McMurray, M.-L. ethnicities in the state of Florida Musante, D. Turpin, L. Wilson, H. Steiner (Houston, M.P. Silverstein, V. Gosein, C.E. Jacobson IV, M.S. Texas, USA) Okun, R.L. Rodriguez, H.H. Fernandez (Gainesville, 229 Behind the masked face: Emotion self-perception Florida, USA) and apathy in PD 240 Swallowing efficiency in Parkinson’s disease A.E. Mikos, B. Skoblar, U. Springer, I.L. Kellison, L. Leow, M.-L. Huckabee, T. Anderson (Christchurch, A. Nisenzon, H. Fernandez, M.S. Okun, D. Bowers New Zealand) (Gainesville, Florida, USA) 66 241 Neural networks underlying pathological gambling 252 Reward processing associated with novelty in Parkinson’s disease measured by resting-state seeking in Parkinson’s disease perfusion SPECT J. Koerts, M. Keitz, M. Van Beilen, K.L. Leenders R. Cilia, C. Siri, G. Marotta, D. De Gaspari, M. Canesi, (Groningen, Netherlands) I.U. Isaias, G. Pezzoli, A. Antonini (Milan, Italy) 253 Fundamental frequency variation in parkinsonian 242 What aspects of quality of life show the greatest speech improvement after DBS among Parkinson W. Visser, U. Schlegel, S.K. Skodda (Bochum, patients? Germany) I.U. Haq, M.S. Okun, R. Rodriguez, K. Foote, C. 254 A new measure for quantifying the bilateral Jacobson, C. Garvan, H. Fernandez (Gainesville, coordination of human gait: Effects of aging and Florida, USA) Parkinson’s disease 243 The role of telephone counseling in patients with M. Plotnik, N. Giladi, J.M. Hausdorff (Tel Aviv, Israel) Parkinson’s disease 255 Ambulatory monitoring of freezing of gait in M.S. Kim, S.J. Chung, S.R. Kim, T.Y. Lee, C.S. Lee, Parkinson’s disease M.C. Lee (Seoul, Republic of Korea) S.T. Moore, H.G. MacDougall, W.G. Ondo (New York, 244 Speech rate in Parkinson’s disease New York, USA) S.K. Skodda, W. Visser, U. Schlegel (Bochum, 256 Cerebrospinal phosphotau levels in Parkinson’s Germany) disease with and without dementia 245 Restoration of gait for the Parkinson’s disease and Y. Compta, M.J. Marti, M. Ezquerra, E. Tolosa vascular parkinsonism patients using the tempo- (Barcelona, Catalonia, Spain) rhythmic correction method 257 Pure Parkinsonian tremor: Clinical follow up study D.V. Pokhabov, V.G. Abramov (Krasnoyarsk, Siberia, of 23 cases Russian Federation) A. Leventoglu, A.I. Baysal (Ankara, Turkey) 246 Hallucinations in Parkinson’s disease treated by 258 The CISI-PD: Data from a multi-centre study subthalamic deep brain stimulation (STNDBS) P. Martinez-Martin, C. Rodriguez-Blazquez, S. Arroyo, S. Aybek, A. Gronchi-Perrin, P. Burkhard, C. Pollo, M.J. Forjaz, The ELEP Group (Madrid, Spain) F.J.G. Vingerhoets (Lausanne, Vaud, Switzerland) 259 Effects of B-vitamins on plasma homocysteine 247 Association of catechol – O-methyltransferase concentrations in L-dopa treated Parkinson’s gene Val158Met polymorphism with Parkinson’s disease patients disease S. Zoccolella, R. Mastronardi, G. Iliceto, C. dell’ A. Sazci, G. Akpinar, E. Ergul, H.A. Idrisoglu, I. Kara, Aquila, A. Fraddosio, P. Livrea, P. Lamberti (Bari, Italy) K. Bayulkem (Kocaeli, Turkey) 260 The effects of Tai Chi training on general 248 Perception of Parkinson’s disease: How do various wellbeing and motor performance in patients with religions and ethnicities compare? Parkinson’s disease (PD): A pilot study M.P. Silverstein, V. Gosein, C.E. Jacobson IV, M.S. M.A. Purchas, D.G. MacMahon (Truro, Cornwall, Okun, R.L. Rodriguez, H.H. Fernandez (Gainesville, United Kingdom) Florida, USA) 261 Features on development of dopamine 249 Weight loss in Parkinson’s disease (PD) dysregulation syndrome in patients with E.L. Wooff, B. Wood (Wigan, Lancashire, United Parkinson’s disease Kingdom) G. Kenangil, M. Sohtaoglu, S. Ozekmekci, E. Erginoz 250 Sensorimotor integration is abnormal in (Istanbul, Turkey) asymptomatic parkin mutation carriers – a TMS 262 Behavior and hippocampal pathology in parkin null study mice over-expressing human mutated tau T. Bäumer, P.P. Pramstaller, S. Schippling, H.R. J.A. Rodriguez-Navarro, R.M. Solano, M.J. Casarejos, Siebner, C. Gerloff, C. Klein, A. Münchau (Hamburg, I. Rodal, A. Gomez, J. García de Yebenes, M.A. Mena Germany) (Madrid, Spain) 251 Sharing medical communication with Parkinson’s 263 Hipersialorrhea: “Treatment with botulinum toxin” disease patients F. Vivancos-Matellano, F.J. Rodriguez-Ribera, F.J. S. O’Hanlon, L. Robinson, B. Wood, A. Hand, R. Arpa, E. Diez-Tejedor (Madrid, Spain) Walker (North Shields, United Kingdom) 67 264 Dopaminergic cells do not show particular 274 Clinical experience with continuous levodopa susceptibility to proteasomal inhibition infusion therapy in Parkinson’s disease H.-Y. Zhou, Y.-Y. Tan, Z.-Q. Wang, G. Wang, G.-Q. Lu, V. Puente, O. De Fabregues, C. Oliveras, G. Ribera, S.-D. Chen (Shanghai, China) C. Pont, G. Cucurella, E. Cuadrado, T. Delgado, J. 265 Patient quality of life impacts on carer quality of Espinosa, R. Campo, A. Seoane (Barcelona, Spain) life in advanced Parkinson’s disease – results 275 Hypersexuality in Parkinson’s disease from the PD SURG trial D.A. Gallagher, S.S. O’Sullivan, A. Schrag, A.J. Lees C.E. Rick, S. Mistry, N.J. Ives, A. Williams, (London, United Kingdom) C. Jenkinson, S. Gill, T. Varma, K. Wheatley 276 Effect of UCH-L1 protein on the dopaminergic (Birmingham, United Kingdom) neurotoxicity of accumulated -synuclein in vivo 266 Detecting fluctuations in Parkinson’s disease with T. Yasuda, K. Wada, H. Mochizuki, Y. Mizuno (Tokyo, the Wearing Off Questionnaire (WOFF) Japan) M. Panisset, H. Turcotte, S. Chouinard (Montreal, 277 Interleukin-10 gene transfection of C17.2 cells Quebec, Canada) improves behavior in rat model of Parkinson’s 267 Cardiac failure secondary to rasagiline treatment disease through inhibition of microglia activation in two patients with Parkinson’s disease X.-J. Wang, W.-G. Liu, Y.-H. Zhang, G.-Q. Lu, S.-D. M. Blazquez-Estrada (Oviedo, Asturias, Spain) Chen (Shanghai, China) 268 , chronic diseases and trauma as risk 278 Assessment of different “Best Medical Treatment” factors for Parkinson’s disease: A case-control strategies as potential alternatives to early study surgical intervention in Parkinson’s disease J.M. Maksimovic, H.D. Vlajinac, S.B. Sipetic, J.M. E. Pourcher (Quebec, Quebec, Canada) Marinkovic, E.D. Dzoljic, V.S. Kostic (Belgrade, 279 Health-related quality of life in Parkinson’s Serbia) disease patients undergoing deep brain 269 Angiotensin I-converting enzyme gene I/D stimulation polymorphism and Parkinson’s disease C. Kenney, A. Diamond, A. Davidson, L. Shinawi, J. G. Akpinar, E. Ergul, A. Sazci, I. Kara, H.A. Idrisoglu, K. Jankovic (Houston, Texas, USA) Bayulkem (Kocaeli, Turkey) 280 Fluctuations in Parkinson’s disease despite deep 270 Prevalence of LRRK2 mutations in Australians with brain stimulation: Resurrection of the beast Parkinson’s disease M.H. Strothjohann, N. Kuehnl, G.A. Fuchs, D. Y. Huang, G.M. Halliday, H. Vandebona, G.D. Mellick, Dschunja (Wolfach, Germany) F.L. Mastaglia, J. Stevens, J. Kwok, M. Garlepp, P.A. 281 Presenting symptoms in patients with Parkinson’s Silburn, M.K. Horne, K.E. Kotschet, A. Venn, D.B. disease: A prospective, cross-sectional, Rowe, J.P. Rubio, C.M. Sue (St. Leonards, NSW, observational study Australia) P. Stathis, V. Tsagaraki, The Early Symptoms Study 271 The treatment of sialorrhea with botulinum toxin Group (Athens, Greece) (BTXA) in Parkinson’s disease 282 Abnormalities of tau processing in aged parkin M. Panisset, L. Spevack, M. Wiseman (Montreal, null mice Quebec, Canada) J.A. Rodríguez-Navarro, M.J. Casarejos, R.M. Solano, 272 Apathy is severe in right-side dominant A. Gomez, I. Rodal, J. García de Yébenes, M.A. Mena Parkinson’s disease patients (Madrid, Spain) K. Kannari, A. Arai, M. Tomiyama, M. Baba, M. Shoji 283 Frequent doses of levodopa/carbidopa/entacapone (Fujisaki-machi, Japan) (Stalevo®) are associated with an improved 273 Emotional experience in early and late stages of levodopa plasma profile compared with traditional Parkinson’s disease levodopa/carbidopa in healthy volunteers S. Fournier, J. Peron, I. Biseul, P. Philippot, S. Drapier, J. Hänninen, K. Korpela, M. Kailajärvi, P. Ruokoniemi, D. Drapier, M. Verin (Rennes, France) M. Kuoppamäki, J. Ellmén (Turku, Finland)

68 284 Restoration of normal motor control in Parkinson’s 294 Regulation of alpha-synuclein phosphorylation in disease during REM sleep mammalian cells V. Cochen De Cock, M. Vidailhet, S. Leu, A. Texeira, D.W. Miller, N.R. Patel, J. Clarimon, M. van der Brug, A. Emmanuelle, A. Elbaz, E. Roze, J.C. Willer, J.P. M.R. Cookson (Bethesda, Maryland, USA) Derenne, Y. Agid, I. Arnulf (Toulouse, France) 295 Ropinirole 24-hour prolonged release as adjunct 285 Qualitative changes in ultrasonic vocalization to L-dopa in patients with advanced Parkinson’s in rats after unilateral dopamine depletion or disease – efficacy according to baseline haloperidol depression score M.R. Ciucci, T.-S. Ma, C.M. Fox, J.R. Kane, L.O. F. Stocchi, N.P. Stover, L. Giorgi (Roma, Italy) Ramig, T. Schallert (Austin, Texas, USA) 296 A case report of a deliberate overdose of ropinirole 286 Early impairment of verbal learning and recall I. Ahmed (London, United Kingdom) memory in Parkinson’s disease with dorsolateral 297 Ability to arise from the floor in persons with prefrontal and mesio-frontal dysfunction Parkinson’s disease S. Bohlhalter, D. Weniger, B. Weder (Tschugg, J.A. Kraakevik, R.G. Blehm, S. O’Connor, C. Tepper, Switzerland) J.G. Nutt (Portland, Oregon, USA) 287 PARK2 screening reveals high frequency of 298 The primary olfactory cortex in Parkinson’s unique hotspots and non smokers among Indian disease (PD) and incidental Lewy body disease PD population significantly altering the parkin (ILBD) expression in blood L. Silveira-Moriyama, J.L. Holton, A. Kingsbury, H. S. Prabhakar, M. Bhatia, M. Khullar, A. Anand Ayling, W. Sterlacci, W. Poewe, H. Maier, A.J. Lees, T. (Chandigarh, Utah, India) Revesz (London, United Kingdom) 288 Patient factors associated with caregiver strain in 299 Cortical atrophy patterns in PSP and MSA patients Parkinson’s disease detected via 3D cortical morphometry on MRI H. Munger-Clary, D. Breslow, L. Vainio, T. Simuni D. Tosun, S. Duchesne, A.W. Toga, C. Barillot, Y. (Chicago, Illinois, USA) Rolland, M. Vérin (Los Angeles, California, USA) 289 Olfactory dysfunction and environmental exposure 300 Effect of adjunct rasagiline on dopaminergic and in Parkinson’s disease patients non-dopaminergic motor features of Parkinson’s M. Canesi, I.U. Isaias, G. Pezzoli (Milano, Italy) disease 290 Food vs levodopa: What worsens hypotension in J.M. Rabey, C.J. Fitzer-Attas (Zerifin, Israel) Parkinson’s disease? 301 Ropinirole 24-hour prolonged release in advanced M. Ragothaman, N. Sarangmath, S. Koshy, C.J. Parkinson’s disease: Relationship between Mathias, U. Muthane (Bangalore, India) treatment response and disease severity 291 Do Israeli patients with Parkinson’s disease who K.D. Sethi, F. Stocchi, L. Giorgi (Augusta, Georgia, carry the LRRK2 G2019S mutation have different USA) professional preferences and occupational 302 Does pregnancy affect the progression of background than non-carrier? Parkinson’s disease? C. Shifrin, A. Orr-Urtreger, I. Alroy, A. Hillel, N. Giladi B. Robottom, J. Mullins, L.M. Shulman (Baltimore, (Tel Aviv, Israel) Maryland, USA) 292 The Mini Mental Parkinson brief cognitive test: 303 Mild cognitive impairment in Parkinson’s disease Comparison with the Mattis dementia rating scale E. Stefanova, M. Petrovic, M. Svetel, N. Dragasevic, in 289 patients with Parkinson’s disease V. Kostic (Belgrade, Serbia) G. Di Virgilio, A. Leroy, P. Cunin, F. Mahieux, A.-C. 304 Tolcapone as an alternative to entacapone for Bachoud-Levi, G. Fénelon (Creteil, France) adjunctive therapy in Parkinson’s disease: An 293 Does learning curve of subthalamic nucleus evidence-based efficacy comparison deep brain stimulation for advanced Parkinson’s A.J. Lees, H. Achenbach (London, United Kingdom) disease exist in a developing center? 5 years 305 Health-related quality of life in Parkinson’s experience disease: Development and predictors during long- S.-T. Tsai, S.-H. Lin, S.-Z. Lin, S.-Y. Chen (Hualien, term disease progression Taiwan) E.B. Forsaa, K. Herlofson, T. Wentzel-Larsen, J.P. Larsen, G. Alves (Stavanger, Norway) 69 306 Neurocircuitries associated with tremor and 316 Postural impairment in Parkinson’s disease: dyskinesia: Insights from an fMRI case study Diagnostic utility of the “first trial effect” S. Sen, M. Lewis, X. Huang (Chapel Hill, North J.E. Visser, L. Janssen, C.M. Bastiaanse, G.F. Borm, Carolina, USA) J.E.J. Duysens, B.R. Bloem (Nijmegen, Netherlands) 307 Ropinirole 24-hour prolonged release delays the 317 Evaluation of cognitive impairment in Parkinson’s onset of dyskinesia compared with carbidopa/ disease by computerized neuropsychological tests levodopa in patients with Parkinson’s disease H. Shabtay, A.D. Korczyn (Tel Aviv, Israel) treated with levodopa 318 Weight gain post deep brain stimulation of the R.L. Watts, K.D. Sethi, R. Pahwa, B.E. Adams, N.L. subthalamic nucleus in Parkinson’s disease: Earl (Birmingham, Alabama, USA) Exploring possible causes 308 Growth hormone stimulation test (CGHST) detects H.U. Jorgensen, L. Simonsen, L.M. Werdelin, S. autonomic failure earlier than clinical autonomic Rusborg, A. Lokkegaard (Copenhagen, Denmark) testing in Parkinson’s disease 319 Clinical findings with Austrian LRRK2 mutation- M. Ragothaman, S. Koshy, D.K. Subbakrishna, C.J. subtype PD patient Mathias, U. Muthane (Bangalore, India) G. Daniel, T. Bruecke, Z. Alexander (Vienna, Austria) 309 Pathological hypersexuality in Parkinson’s 320 An integrated speech and physical therapy disease: A clinician-rated survey and a working approach for Parkinson’s disease: Training big and definition loud T. Thomsen, J.M. Miyasaki, M. Zurowski, M. De C.M. Fox, B.G. Farley, L.O. Ramig, D.F. McFarland Sousa, R.M.A. De Bie, P. Wadia, G. Adeli, A.E. Lang, V. (Denver, Colorado, USA) Voon (Toronto, Ontario, Canada) 321 Clinical factors associated with freezing of gait in 310 FP0011 extends the duration of the anti- Parkinson’s disease: A multidisciplinary approach parkinsonian actions of L-DOPA and reduces A.A. Zylstra, A.F. Griffith, M.L. Glisky (Kirkland, L-DOPA-induced dyskinesia in the MPTP-lesioned Washington, USA) macaque model of Parkinson’s disease 322 Toll-free helpline reveals diverse needs of J.M. Brotchie, T.H. Johnston, S.H. Fox, P. Zerr, F. Parkinson’s disease community Tiberghien, L. Bossi (Toronto, Ontario, Canada) R.A. Elliott, J. Rosner, L. Pituch, P. Wiener, C.M. Evers 311 Reflexive eye and arm movement in Parkinson’s (New York, New York, USA) disease and the gap effect 323 Overlap of cognitive deficits in Parkinson’s (PD) Y. Shirakura, M.M. MacAskill, D. Myall, T.J. Anderson and Alzheimer’s (AD) diseases: Potential use of (Christchurch, New Zealand) safinamide 312 Non-motor symptoms in patients with incident T. Sharma, R. Anand, R. Hartman, S. Rossetti and untreated Parkinson’s disease – the (Newark, Delaware, USA) Norwegian ParkWest study 324 Rasagiline is effective in treating patients with B. Mueller, G. Alves, K. Herlofson, I. Hoegen-Esch, W. early Parkinson’s disease, regardless of disease Telstad, O.B. Tysnes, J.P. Larsen (Stavanger, Norway) duration at treatment initiation (<1 year; 1 year) 313 A pilot data and analysis validity study on a NPF J.M. Bertoni, R. Pahwa (Omaha, Nebraska, USA) center of excellence database 325 Evaluation of c-Abl tyrosine kinase mediated C.W. Garvan, C.E. Jacobson, R. Stephen, K.D. White, regulation of parkin as therapeutic target for R.L. Rodriguez, K.D. Foote, H.H. Fernandez, M.S. Parkinson’s disease Okun (Gainesville, Florida, USA) S.Z. Imam, S. Sriram, H.S. Ko, D.W. Pearson, A.J. 314 Can we modify the factors influencing selection of Valente, J.M. Savitt, E. Andres-Mateos, D.B. Trinkaus, drug therapy in Parkinson’s disease (PD)? O. Pletnikova, J.C. Troncoso, A. Yamamoto, P.J. Kahle, A. Nasar, P. Dyer, C. Short, J. Cowling, W. Lynda, K. S.F. Ali, V.L. Dawson, S. Li, J.L. Roberts, T.M. Dawson, Turner, L. Wheelhouse, E. Howard (Bridlington, East R.A. Clark (San Antonio, Texas, USA) Yorkshire, United Kingdom) 326 Correlation between UPDRS-III scores and [11C]di 315 Parkinson’s disease and apomorphine – an Indian hydrotetrabenazine (DTBZ) PET measures in early experience Parkinson’s disease N. Surya (Mumbai, Maharashtra, India) M. Wieler, J. Stoessl, W. Martin (Edmonton, Alberta, Canada) 70 327 The pharmacokinetic profile of levodopa 336 Adherence to antiparkinson medication in a multi- administered with and without tolcapone in centre European study patients with advanced PD D. Grosset, A. Antonini, M. Canesi, G. Pezzoli, A.J. D. De Lucrezia, F. Guadagni, N. Santucci, L. Vacca, F. Lees, K. Shaw, E. Cubo, P. Martinez-Martin, O.O. Stocchi (Rome, Italy) Rascol, L. Negres-Pages, A. Senard, J. Schwarz, 328 Development and evaluation of a community- K. Strecker, H. Reichmann, A. Storch, M. Löhle, K. based exercise programme for people with Grosset (Glasgow, United Kingdom) Parkinson’s disease 337 Safety of Zydis selegiline orally disintegrating K.J.E. Reinikka, A. MacLeod, M. Johnson, M. Bedard, tablet (ODT) with concomitant M. Jog (Thunder Bay, Ontario, Canada) therapy in Parkinson’s disease (PD) 329 The Norwegian ParkWest study – study design M.F. Lew, K.D. Sethi, G. Kricorian (Augusta, Georgia, and incidence calculations USA) G. Alves, B. Mueller, K. Herlofson, I. Hoegen-Esch, W. 338 Switch from an oral dopamine agonist to Telstad, O.B. Tysnes, J.P. Larsen (Stavanger, Norway) rotigotine transdermal patch in Parkinson’s 330 Specificity and sensitivity of transcranial disease ultrasound in the differential diagnosis of P.A. LeWitt, J.M. Patton, D.G. MacMahon, J. Jankovic Parkinson’s disease (Southfield, Michigan, USA) A. Gaenslen, B. Unmuth, I. Liepelt, A. Di Santo, K. 339 Vascular events in Parkinson’s disease with Schweitzer, J. Godau, T. Gasser, M. Reimold, D. Berg hyperhomocysteinemia (Tubingen, Germany) R. Ribacoba, M. Menendez, J.R. Virgili, G. Jimenez, 331 Improved compliance with levodopa/carbidopa/ C. Huerta, V. De la Vega (Mieres, Asturias, Spain) entacapone (L/C/E; Stalevo®) vs levodopa/ 340 Safety of concomitant therapy with rasagiline and carbidopa and entacapone (L/C + E) as separate in Parkinson’s disease tablets in Parkinson’s disease (PD) M. Panisset, S. Schwid, W. Ondo, C. Fitzer-Attas, J.J. T.E. Delea, S.K. Thomas, M. Hagiwara, L. Mancione, Chen (Montreal, Quebec, Canada) M. Stacy (Brookline, Massachusetts, USA) 341 Defining features of subsyndromal depression in 332 Effects of pramipexole on tremor and anxiety in de Parkinson’s disease novo patients with Parkinson’s disease D.A. Nation, H.L. Katzen, R.A. Rodriguez, J.A. Ledon, H. Takahashi, F. Yoshii, K. Fujimoto, H. Chiba, R. A. Capano, S. Papapetropoulos, B.V. Gallo, J.R. Jagid, Kumazawa, S. Kobori, S. Takagi (Isehara, Kanagawa, B.E. Levin (Miami, Florida, USA) Japan) 342 Quality of life influenced by presence of patients’ 333 Screening for LRRK2 mutations in UK familial with Parkinson’s disease relatives Parkinson’s disease patients S.M. Nica, I.E.-V. Davidescu, G. Mihailescu A.J. Lewthwaite, T.D. Lambert, N.W. Wood, D.J. (Bucharest, Romania) Nicholl, K.E. Morrison (Birmingham, West Midlands, 343 The effects of loudness and noise on speech United Kingdom) intelligibility in Parkinson’s disease 334 Patient report of initial symptom in Parkinson’s A. Halpern, J. Spielman, L. Ramig, J. Cable, I. Panzer, disease, ataxia, and essential tremor A. Sharpley (Denver, Colorado, USA) D.A. Hall, M.A. Leehey, K. Howard, P. Hagerman, G. 344 What looks like a duck and sounds like a duck, Zerbe, T. Byers (Denver, Colorado, USA) may not really be a duck: Acute 3 335 Neurophysiological correlates of Parkinsonian weeks after DBS dyskinesias in subthalamic oscillatory activity Q.A. Shamim-Uzzaman, E.A. Shamim, C.G. Kalhorn, S. Marceglia, A. Leone, G. Foffani, F. Cogiamanian, S. A.S. Mandir, F.L. Pagan (Washington, District of Mrakic-Sposta, F. Tamma, E. Caputo, S. Barbieri, A. Columbia, USA) Priori (Milan, Italy) 345 Complications of spinal surgery in Parkinson’s disease: Case reports of 3 patients E. Wolf, K. Mair, A. Muigg, K. Twerdy, W. Poewe (Innsbruck, Tirol, Austria)

71 Poster Session 2 356 Effects of repetitive transcranial magnetic stimulation on levodopa induced dyskinesias and Wednesday, June 6, 2007 - 12:30 PM - 2:30 PM motor performance in Parkinson’s disease Rumeli Hall, Lower Level S. Sayin, R. Cakmur, E. Yaka, G. Yener, F. Uzunel Poster Viewing 9:00 a.m. to 4:00 p.m. (Izmir, Turkey) Authors Present 12:30 p.m. to 2:30 p.m. 357 Sleep and periodic leg movements in Poster numbers 346-662, and Poster 788 schizophrenic patients with neuroleptic-induced Drug-induced Movement Disorders parkinsonism Poster numbers 346-361 T.C. Wetter, S. Fulda (Munich, Germany) 346 Veralipride: A case report of irreversible dystonia 358 Movement disorder caused by injections of M.T. Rivas, J. Pascual, A. Sesar (Santiago de manganese containing compounds Compostela, Spain) I. Khatiashvili, K. Akhvlediani, M. Megrelishvili, M. 347 Evidence that lithium protects against tardive Janelidze, N. Lobjanidze (Tbilisi, Georgia) dyskinesia: The Curacao Extrapyramidal 359 Deep brain stimulation for tardive dyskinesia and Syndromes Study VI akathisia P.N. van Harten, H.W. Hoek, G.E. Matroos, J. van Os C. Kenney, R.L. Barbano, J.K. Sheffield, J. Jankovic (Amersfoort, Netherlands) (Houston, Texas, USA) 348 Ephedrone-induced Parkinsonism: Clinico- 360 Acute dystonia induced by adding midodrine to neuroimaging study Perphenazine Y. Sanotsky, M. Selikhova, L. Fedoryshyn, Y. A. Castrioto, L. Pierguidi, N. Tambasco, A. Rossi, P. Matviyenko, I. Komnatska, M. Kyrylchuk, A. Calabresi (Perugia, Italy) Friedman, L. Krolicki, A.J. Lees (Moscow, Russian 361 Capecitabine-induced oromandibular dystonia Federation) P.K. Manharlal, C.S. Pin, L.Y. Long, T.Y. Albert, S.S. Ju, 349 Reversible parkinsonism induced by short-term P. Ratnagopal (Singapore, Singapore) treatment with valproate in Alexander’s disease Dystonia G. Sechi, K.S. Paulus, G.A. Cocco, G.M. Pes, G. Sau, Poster numbers 362-403 V. Agnetti (Sassari, Italy) 362 Extreme task specificity in writer’s 350 Parkinsonism induced by mefloquine E.A. Shamim, J.M. Savitt, H.A. Jinnah, M. Hallett M.G. Senol, M. Saracoglu (Istanbul, Turkey) (Bethesda, Maryland, USA) 351 Tardive eating dystonia: A case report 363 Chronic low back pain related to idiopathic Y. Kutukcu, S. Bek, F. Ozgen, Z. Odabasi (Ankara, extensor truncal dystonia Turkey) G. Sau, V. Agnetti, E. Coco, B. Nieddu, I. Magnano, I. 352 Oromandibulary dyskinesia and dystonia with khat Aiello (Sassari, SS, Italy) chewers 364 Mental rotation of body parts in DYT1 carriers L. Harms, F. Sporkert, H. Alwarith, F. Pragst, L. M. Fiorio, M. Gambarin, C. Stanzani, E.M. Valente, G. Dögnitz (, Germany) Defazio, G. Moretto, M. Loi, P. Soliveri, N. Nardocci, A. 353 The course of tardive dystonia: A population based Albanese, A. Fiaschi, M. Tinazzi (Verona, Italy) study – the Curacao Extrapyramidal Study VIII 365 A slow flow arterio-venous malformation as P.N. van Harten, G.E. Matroos, J. van Os (Amersfoort, a cause of a neuro-psychiatric syndorme Netherlands) comprising hemi-dystonia and behavioral changes 354 Clinical features of motor disturbances at toxic M.A. Sierra-Beltrán, U. Rodrìguez-Ortiz, M.S. encephalopathy provoked by using of substitute Rodrìguez (Mexico City, DF, Mexico) psychoactive substances 366 Improvement of treatment effect with a higher N.V. Fedorova, N. Amosova, T. Ismailova (Moscow, dilution of botulinum toxin type A: Results of a Russian Federation) controlled blepharospasm study 355 Tardive antidepressant drug-induced dyskinesia: S. Grafe, G. Comes, P. Roggenkaemper (Frankfurt, Report on 5 cases and search for MRI predictors Germany) P.J. Blanchet, N. Ouatik, Y. Kuznetsov, A. Khiat, Y. Boulanger (Montreal, Quebec, Canada) 72 367 Tonic versus phasic cervical dystonia: Persistence 378 Low-frequency rTMS of the premotor and influence of botulinum toxin treatment on cortex in pantothenate kinase-associated dystonic type neurodegenerative disease D.D. Duane, K.B. Zebatto, J.M. Johnson, R.L. Owen, V. Mylius, A. Gerstner, A. Leonhardt, D. Hellwig, F. J.H. Flutie, K.A. Shunk (Scottsdale, Arizona, USA) Rosenow, W.H. Oertel (Marburg, Germany) 368 Changes of perfusion pattern using ECD-SPECT 379 Autosomal dominant myoclonus-dystonia and in patients with primary focal or generalized Tourette syndrome in a family without linkage to dystonia the SGCE gene N. Kawashima, E. Horiuchi, K. Hasegawa, Y. Ujihara, M. Orth, A. Djarmati, T. Bäumer, S. Winkler, A. Y. Hasegawa (Fujisawa, Japan) Grünewald, K. Lohmann-Hedrich, K. Kabakci, J. 369 Neuropathology in idiopathic cervical dystonia Hagenah, C. Klein, A. Münchau (Hamburg, Germany) M.C. Zerrate, C.A. Pardo, H.A. Jinnah (Baltimore, 380 Deep brain stimulation of the globus pallidus Maryland, USA) internus (Gpi-DBS) in a patient with generalized 370 Neuropathology of primary dystonia unrelated to dystonia due to tyrosine hydroxylase deficiency DYT1 mutations A. Kaelin-Lang, J. Abu-Isa, M. Schuepbach, A. Stibal J.L. Holton, S.A. Schneider, S. Gandhi, T. (Bern, Switzerland) Ganesharajah, C. Strand, P. Shashidharan, J. Barreto, 381 The entitity of jaw tremor and dystonia N.W. Wood, A.J. Lees, K.P. Bhatia, T. Revesz (London, S.A. Schneider, K.P. Bhatia (London, United Kingdom) United Kingdom) 382 Early dystonia in probable Creutzfeldt-Jakob 371 Repetitive TMS of the somatosensory cortex disease with diffusion weighted MR images improves writer’s cramp S.-H. Lee, S.-B. Koh, K.-W. Park, D.-H. Lee (Seoul, R. Jech, P. Havrankova, N.D. Walker, J. Vymazal, E. Korea) Ruzicka (Prague, Czech Republic) 383 Long-term treatment of cervical dystonia with 372 Longitudinal effects of pallidal stimulation on botulinum toxin A – retrospective assessment of motor cortex function in dystonia the clinical and quality of life impact in patients S. Tisch, D. Ruge, P. Limousin, J. Hariz, K.P. Bhatia, treated for 10 years N.P. Quinn, L. Zrinzo, M. Jahanshahi, J.C. Rothwell M. Bares, I. Rektorova, M. Balaz, H. Streitova, E. (London, United Kingdom) Minks, P. Kanovsky, I. Rektor (Brno, Czech Republic) 373 Clinical characteristics of dystonia in a Movement 384 Can blepharospasm herald multiple sclerosis? Disorder Centre in Venezuela G. Loria, F. Soleti, S. Servidei, A. Evoli, A.P. Batocchi, M. Gallardo, A. Soto, G. Orozco, M. Camacaro, G. A.R. Bentivoglio (Rome, Italy) Ramirez, R. Weiser, L. Vink (Caracas, Miranda, 385 Deep brain stimulation in dystono-dyskinetic Venezuela) syndromes secondary to mitochondrial diseases: 374 Homocystinuria and dystonia – case presentation Predictive value of 18F-FDG PET O. Akan, S. Ozbakir, S. Ozturk, S. Ozturk, A. Findik L. Cif, F. Comte, B. Biolsi, H. Elfertit, S. Gavarini, A. (Ankara, Turkey) Saux, X. Vasques, P. Coubes (Montpellier, France) 375 A novel mutation (64-65DelGGInsAACC(G21fsX 386 Case reports: Blepharospasmus in Hashimoto 66)) in the GTP cyclohydrolase 1 gene causing disease Segawa’s disease (DYT5 dystonia) M. Arnaoutoglou, E. Koutsouraki, V. Costa, E. M. von Mering, H. Gabriel, G.F. Hoffmann, A. Storch Avdelidou, S.A. Kapsali, E. Kalliolia, C. Karamanidis, (Dresden, Germany) N. Arnaoutoglou, G. Spanos, G. Xiromerisiou, S.I. 376 Quality of life in patients with different types of Baloyannis (Thessaloniki, Greece) focal dystonias in Serbia 387 The characteristics of adult onset Segawa disease T.D. Pekmezovic, M. Svetel, N. Ivanovic, N. M. Segawa, Y. Nomura, K. Kimura, R. Hanajima Dragasevic, I. Petrovic, V.S. Kostic (Belgrade, Serbia) (Tokyo, Japan) 377 Clinical genetics of musician’s dystonia 388 No difference in efficacy between Xeomin® and A. Schmidt, H.-C. Jabusch, J. Hagenah, L. Enders, Botox® in the treatment of cervical dystonia – a N. Brüggemann, K. Lohmann, R. Saunders-Pullman, detailed subgroup analysis S.B. Bressman, P.L. Kramer, A. Münchau, E. H. Hefter, R. Benecke, G. Comes, S. Grafe Altenmüller, C. Klein (Hannover, Germany) (Duesseldorf, Germany) 73 389 A retrospective study of Botox versus Dysport in 400 Short intracortical inhibition (SICI) during different patients with movement disorders phases of movement in patients with focal hand A.L.Z. Rosso, D.H. Nicaretta, J.P. Mattos, S.A.P. Novis dystonia (Rio de Janeiro, RJ, Brazil) S. Beck, S. Pirio Richardson, M. Hallett (Bethesda, 390 Post-traumatic adult-onset focal dystonia: A Maryland, USA) retrospective study of six consecutive cases 401 A Multi-centre, open-label, multiple-dose, R. Riemer, Y.-L. Zheng, H. Luo, C. Lindsey, V. dose-escalation, safety and tolerability study of Wheelock, L. Zhang (Sacramento, California, USA) Botulinum Toxin Type B in patients with cervical 391 Secondary dystonia related to celiac disease dystonia A.L. Diamond, P. Agarwal, V. Segro (Englewood, E.J. Pappert (San Antonio, Texas, USA) Colorado, USA) 402 Experience of treatment focal dystonic 392 Behavioural abnormalities in DRD hyperkinesis with botulinic toxin in center I. Trender-Gerhard, P. Mir, M. Edwards, M. Sweeney, neurology and neurorehabilitation FSE “Siberian L. Majahi, A. Gerhard, N. Wood, K. Bhatia (London, Regional Medical Center” United Kingdom) D.V. Pokhabov, V.G. Abramov (Krasnoyarsk, Siberia, 393 Atypical phenotype in DYT1 dystonia with Russian Federation) paroxysmal dystonia 403 Wilson’s disease facies – a distinctive clinical sign B. Biolsi, L. Cif, S. Gil Robles, S. Gavarini, X. Vasques, A. Aggarwal, A. Nagral, M. Bhatt (Mumbai, S. Plagnol, P. Coubes (Montpellier, France) Maharashtra, India) 394 Immobilization followed by motor training is an Gene and Cell-Based Therapies effective therapeutical approach in patients with Poster numbers 404-407 writer’s cramp 404 Normalization of 6-hydroxydopamine-induced K.E. Zeuner, M. Peller, A. Knutzen, I. Holler, M. Hallett, rotational behavior by transplantation of dermal G. Deuschl, H.R. Siebner (Kiel, Germany) fibroblasts 395 Abnormal low frequency drive in Myoclonus- J.P.M. Finberg, Y. Feld, Z. Gluzman, S. Marom, O. Dystonia patients correlates with presence of Mohsen, M. Reshef (Haifa, Israel) dystonia 405 Preliminary results of an open-label, dose- E.M.J. Foncke, L.J. Bour, J. van der Meer, J.H.T.M. escalation, safety study of AADC gene transfer Koelman, M.A.J. Tijssen (Amsterdam, Netherlands) therapy for Parkinson’s disease 396 Clinical and poly-electromyographic diagnostics M.J. Aminoff, C.W. Christine, K. Bankiewicz, P.A. of facial movement disorders and their treatment Starr, P. Larson, R. Mah, J.L. Eberling, W.J. Jagust with botulinum toxin (San Francisco, California, USA) G. Reichel, A. Stenner, W. Hermann (Zwickau, 406 Suicide-gene mediated ablation of Oct4 Germany) expressing cells for ES-cell based cell 397 Knowledge and perception of dystonia: A replacement therapy in Parkinson’s disease comparison among various religions and J. Schindehuette, P.C. Baier, T. Kuhlmann, C. ethnicities in the state of Florida Trenkwalder, W. Paulus, A. Mansouri (Goettingen, V. Gosein, M.P. Silverstein, C.E. Jacobson IV, M.S. Lower Saxony, Germany) Okun, R.L. Rodriguez, H.H. Fernandez (Gainesville, 407 Transplantation of bone marrow stromal cells Florida, USA) containing the neurturin gene in rat model of 398 Sensorimotor cortex hypoactivation during writing Parkinson’s disease in writer’s cramp: An event-related fMRI study M. Ye, X.J. Wang, Y.H. Zhang, S.D. Chen (Nanjing, P. Havrankova, R. Jech, N.D. Walker, J. Vymazal, E. China) Ruzicka (Prague, Czech Republic) 399 Is it always necessary to apply botulinum toxin into the lower facial muscles in hemifacial ? A randomized, single-blinded, crossover trial B. Donmez Colakoglu, R. Cakmur, F. Uzunel (Izmir, Turkey)

74 Genetics 416 Association of MAPT haplotype-tagging SNPs with Poster numbers 408-444 Parkinson’s disease 408 Low prevalence of PANK2 mutations in Brazilian J. Vandrovcova, A.M. Pittman, E. Malzer, N.W. Wood, cases of neurodegeneration with brain iron A.J. Lees, R. de Silva (London, United Kingdom) accumulation 417 Screening for POLG1 mutations in a Southern S. Camargos, F. Cardoso, J.G. Giannetti, A.L. Teixeira, Italian ataxia population Jr, D.P. Maia, M. Cunninham, A.J. Lees, J. Hardy, A. C. Criscuolo, P. Mancini, S. Ammendola, D. Cicale, G. Singleton (Belo Horizonte, Minas Gerais, Brazil) De Michele, A. Filla (Naples, Italy) 409 New insights into SNCA duplication in a French 418 Clinical and molecular analysis of carriers of GAG Parkinson’s disease pedigree. Relevance for deletion in DYT1 gene among Polish patients with genetic and phenotypic evaluations primary dystonia E. Le Rhun, L. Larvor, K. Dujardin, A. Emptaz, E. K. Szczaluba, J. Bal, B. Kadziolka, A. Szolna, A. Mutez, V. Mouroux, J. Andrieux, F. Lepretre, M. Friedman, T. Kmiec, T. Mazurczak (Warsaw, Poland) Steinling, L. Defebvre, A. Destee, M.-C. Chartier- 419 Clinical features of movement disorders in Harlin (Lille, France) hemochromatosis 410 Glucocerebrosidase mutations in a patients with D.A. Hall, S. Ringel, K. Howard, J. Jankovic (Denver, sporadic Parkinson’s disease from Taiwan Colorado, USA) S.G. Ziegler, U. Gutti, M.J. Eblan, K. Hruska, O. Goker- 420 Parkinsonian spectrum associated with Alpan, E. Sidransky (Bethesda, Maryland, USA) glucocerebrosidase mutations 411 High prevalence of LRRK2 mutations in familial O. Goker-Alpan, G. Lopez, M. Hallett, E. Sidransky and sporadic Parkinson’s disease in Portugal (Bethesda, Maryland, USA) J.J. Ferreira, L. Correia Guedes, M.M. Rosa, M. 421 Familial Parkinsonism with double mutations of Coehlho, M. van Doeselaar, D. Schweiger, A. Di Parkin and PINK1 Fonzo, B.A. Oostra, C. Sampaio, V. Bonifati (Lisbon, M. Funayama, L. Yuanzhe, H. Yoshino, T.-H. Tsoi, C.- Portugal) W. Lam, T. Obi, E. Uyama, Y. Imamichi, H. Takahsima, 412 Spastic paraplegia 5: Locus refinement, candidate Y. Mizuno, N. Hattori (Bunkyo, Tokyo, Japan) gene analysis and clinical description 422 Do Ashkenazi Jew patients with Parkinson’s S. Klebe, A. Durr, N. Bouslam, D. Grid, C. Paternotte, disease want to be acquainted about their G2019S C. Depienne, S. Hanein, A. Bouhouche, N. Elleuch, mutation status in the LRRK2 gene? H. Azzedine, S. Poea-Guyon, S. Forlani, E. Denis, O. Moore, C. Shifrin, S. Levin, J. Knaani, N. Giladi (Tel C. Charon, J. Hazan, A. Brice, G. Stevanin (Paris, Aviv, Israel) France) 423 LRRK2 Gly2385Arg in Parkinson’s disease patients 413 Case-control analysis of glucocerebrosidase gene of non-Chinese Asian ethnicity mutations in Parkinson’s disease and dementia E.K. Tan, Y. Zhao, L. Tan (Singapore, Singapore) with Lewy bodies 424 APOe alleles in Parkinson’s disease: Relation to I.F. Mata, S.H. Schneer, A. Sanii, J.W. Roberts, A.F. cognitive decline and hallucinations. A longitudinal Griffith, B.C. Leis, J.B. Leverenz, G.D. Schellenberg, study E. Sidransky, D.W. Tsuang, C.P. Zabetian (Seattle, M.W. Kurz, G. Dekomien, J.P. Larsen, D. Aarsland Washington, USA) (Stavanger, Norway) 414 LRRK2 mutations in patients with Parkinson’s 425 Are parkin mutation carriers better candidates for disease in southern Spain deep brain stimulation? P. Mir, L. Gao, F. Diaz, F. Carrillo, M. Carballo, A. E. Lohmann, M.L. Welter, V. Fraix, P. Krack, S. Laine, Palomino, J. Diaz-Martin, R. Mejias, P.J. Vime, E. J.-L. Hueto, V. Mesnage, P. Pollak, A. Durr, A. Brice Pintado, M. Lucas, J. Lopez-Barneo (Seville, Spain) (Paris, France) 415 DJ-1 protects against dopamine toxicity by 426 Narrowing down a dystonia gene in a family with increasing its vesicular sequestration: Implications translocation t(7;18): New locus or independent for Parkinson’s disease dystonia occurrence? N. Lev, N. Pilosof, H. Cohen, D. Offen, E. Melamed K. Szczaluba, J. Pietrzak, J. Noskowska, A. (Petah-Tikva, Israel) Friedman, E. Bocian (Warsaw, Poland)

75 427 A detailed clinical study of early-onset Parkinson 436 Parkinson’s disease in Turkish patients: Molecular patients analyses of parkin and LRRK2 genes in familial E. Lohmann, S. Thobois, S. Laine, S. Tezenas, E. and isolated cases Broussolle, P. Pollak, L. Mallet, B. Dubois, Y. Agid, A. C.S. Pirkevi, S. Lesage, A. Brice, A.N. Basak (Istanbul, Brice (Paris, France) Turkey) 428 Investigation of the molecular aetiology of South 437 Sporadic and familial Parkinson’s disease in African patients diagnosed with Parkinson’s Uruguay disease V.E. Raggio, E.M. Dieguez, R. Aljanati, O. de Medina, J.A. Carr, S. Bardien (Tygerberg, South Africa) A. Scaramelli, R. Ventura, R. Buzo (Montevideo, 429 Is the G2019S LRRK2 mutation common in all Uruguay) southern European populations? 438 The frequency of the LRRK2 G2019S mutation S. Papapetropoulos, N. Adi, L. Shehadeh, N. in Ashkenazi and non-Ashkenazi with Bishopric, C. Singer, A.A. Argyriou, E. Chroni (Miami, Parkinson’s disease in Israel Florida, USA) A. Orr-Urtreger, C. Shifrin, U. Rozovski, S. Rosner, D. 430 Analysis of glucocerebrocidase mutations in Bercovich, T. Gurevich, H. Yagev-More, A. Bar-Shira, Parkinson’s disease N. Giladi (Tel Aviv, Israel) G.R. Clark, P.F. Chinnery, D.J. Burn, C.M. Morris 439 Mutation spectrum and clinical features of SPG4 (Newcastle upon Tyne, Tyne Wear, United Kingdom) HSP 431 Obstructive sleep apnea and searching for C. Depienne, E. Fedirko, B. Bricka, E. Denis, S. a genetic cause – looking for influences by Forlani, A. Durr, A. Brice (Paris, France) polymorphisms of endothelin receptor subtype-a 440 Multiregional high-throughput gene expression D. Buck, K. Diefenbach, I. Fietze, T. Penzel, U. profiling of Braak regions in Parkinson’s disease Malzahn, I. Roots (Berlin, Germany) S. Papapetropoulos, D.M. Maraganore, N. Adi, 432 Analysis of SCA2 and SCA3 in Parkinson’s plus J. Ffrench-Mullen, D. McCorquodale, D.C. Mash syndromes (Miami, Florida, USA) P. Ratnagopal, Z. Yi, E.K. Tan (Singapore, Singapore) 441 Familial Parkinsonism and early onset 433 Worldwide prevalence of Leucine-Rich Repeat Parkinson’s disease: Phenotypic and genotypic Kinase 2 gene mutations in Parkinson’s disease: A characterization in a Brazilian Movement systematic review Disorders clinic L. Correia Guedes, J.J. Ferreira, M.M. Rosa, M. S.T. Camargos, F. Cardoso, L.O. Dormas, P. Momeni, Coelho, V. Bonifati, C. Sampaio (Lisbon, Portugal) A.L. Teixeira, Jr, D.P. Maia, M. Cunningham, A.J. 434 ATP13A2 missense mutations in juvenile Lees, J. Hardy, A. Singleton (Belo Horizonte, Minas parkinsonism and young onset Parkinson’s Gerais, Brazil) disease 442 Phenotypes and genotypes in myoclonus-dystonia: A. Di Fonzo, H. Chien, M. Socal, S. Giraudo, C. Significance of deletions of the entire SGCE gene Tassorelli, G. Iliceto, G. Fabbrini, R. Marconi, E. A. Grünewald, A. Djarmati, K. Lohmann-Hedrich, K. Fincati, G. Abruzzese, P. Marini, F. Squitieri, M.W.I.M. Farrell, C. Klein (Lubeck, Germany) Horstink, P. Montagna, A. Dalla Libera, F. Stocchi, 443 Caffeine intake and CYP1A2 variability in S. Goldwurm, J. Ferreira, G. Meco, E. Martignoni, Parkinson’s disease L. Lopiano, L. Jardim, B.A. Oostra, E. Barbosa, V. E.K. Tan, E. Chua, L. Tan, Y. Zhao (Singapore, Bonifati (Rotterdam, Netherlands) Singapore) 435 Fibroblast growth factor 20 gene and Parkinson’s 444 Focal dystonia as an important feature of X- disease in the Japanese population linked mental retardation caused by ARX gene T. Toda, W. Satake, I. Mizuta, M. Watanabe, A. Takeda, duplication K. Hasegawa, M. Yamamoto, N. Hattori, M. Murata K. Szczaluba, M. Nawara, K. Poirier, J. Pilch, (Suita, Osaka, Japan) M. Gajdulewicz, K. Spodar, J. Chelly, J. Bal, T. Mazurczak (Warsaw, Poland)

76 Myoclonus 455 Flair sequences in Wilson’s disease MRI. A case Poster numbers 445-449 report 445 Gabapentine induced myoclonus: Case report V. Sánchez, C. Coca, M. Fernández, J. Chacón, L. F. Ege, Y. Kocak, A.P. Titiz, S. Ozturk, S. Ozbakir Redondo (Seville, Spain) (Ankara, Turkey) 456 Altered brain response in PD patients with 446 Two cases of segmental myoclonus: Primary hallucinations during a face perception task. An spinal myoclonus and radicular myoclonus fMRI study induced by cervical physiotherapy stretching B. Ramirez-Ruiz, C. Junque, C. Falcon, N. Bargallo, J. Vaamonde, G. Martin-Palomeque, J.M. Flores, R. M.-J. Marti, F. Valldeoriola, T. Eduard (Barcelona, Ibanez (Ciudad Real, Spain) Spain) 447 Propriospinal myoclonus: Report of seven new 457 Amyloid deposition and glucose metabolism in cases and literature review Parkinson’s disease dementia (PDD): An [11C]PIB P. Bounolleau, E. Apartis, D. Ducreux, Y. Beaugendre, and [18 F]FDG PET study M.-C. Lavallard-rousseau, F. Bourdain, P. Dupont, I. Ahmed, P. Edison, N.P. Quinn, Z. Walker, D.J. L. Carluer, L. Verdure, M. Vidailhet, E. Roze (Paris, Brooks (London, United Kingdom) France) 458 In vivo qualitative and semi-quantitative analysis 448 Steroid responsive propriospinal myoclonus in basal ganglia disorders: A [(123)I]-FP-CIT associated with antithyroid antibodies (Ioflupane) study E. Roze, E. Apartis, M. Vidailhet, V. Cochen, Y. L. Pierguidi, N. Tambasco, F. Fabiani, C. Menichetti, Beaugendre, J.-M. Trocello, P. Lasjaunias, D. M. Sebastianelli, P. Calabresi, A. Rossi (Perugia, Italy) Ducreux (Paris, France) 459 Substantia nigra evaluation in atypical 449 Psychogenic propriospinal myoclonus parkinsonian syndromes and Parkinson’s disease M. Cowey, K. Tuck, B. Day, D. Williams (Melbourne, P. Bartova, D. Skoloudik, T. Fadrna, P. Ressner, P. VIC, Australia) Kanovsky, R. Herzig (Ostrava, Czech Republic) 460 White matter damage is more severe in PSP than Neuroimaging MSA or PD, a diffusion tensor MRI study Poster numbers 450-489 C.R.V. Blain, G.J. Barker, X.A. Chitnis, R.G. Brown, 450 Diffusion tensor imaging finding in a Chinese J.M. Jarosz, D.K. Jones, S.C.R. Williams, N. Leigh family with aceruloplasminemia (London, United Kingdom) Q. Chen, X.-P. Chen, Q.-Y. Gong, J.-M. Burgunder, D. 461 Functional 3 Tesla MRI for target identification Zhou, H.-F. Shang (Chengdu, China) before deep brain stimulation (DBS) 451 Diffusion tensor imaging of two unrelated Chinese T.M.-L. Loennfors-Weitzel, C. Kiefer, C. Ozdoba, men with hereditary spastic paraplegia associated A. Kaelin-Lang, A. Stibal (Bern, Kanton Bern, with thin Switzerland) H.-F. Shang, Q. Chen, J.-G. Wang, Q.-Y. Gong, D. 462 Diffusion tensor MR imaging for evaluation of Zhou, J.-M. Burgunder (Chengdu, China) fronto-subcortical neural pathway changes in 452 fMRI correlates of foot movement relative to gait Parkinson’s disease with dementia dysfunction in PD M.Y. Park, H.U. Kang, G.Y. Jung (Daegu, Kyungbuk, P. Schwingenschuh, P. Katschnig, S. Ropele, F. Korea) Gorani, F. Ebner, E. Ott, F. Fazekas, C. Enzinger (Graz, 463 Unexpected MRI changes in younger carriers of Austria) premutation in the FMR1 gene 453 fMRI in gene-positive myoclonus-dystonia L.D. Litewka, D.Z. Loesch, M. Cook, E. Storey, F. R.J. Beukers, E.M. Foncke, J.N. van der Meer, A.J. Tassone (Fitzroy, VIC, Australia) Nederveen, M.B. de Ruiter, L.J. Bour, D.J. Veltman, 464 Gray matter abnormalities in dementia with M.A. Tijssen (Amsterdam, Netherlands) Lewy bodies (DLB) and Parkinson’s disease with 454 Major depression and brain perfusion images in dementia (PDD) Parkinson’s disease C. Sanchez-Castaneda, B. Ramirez-Ruiz, R. Rene, J. I.U. Isaias, G. Marotta, D. De Gaspari, C. Siri, R. Benti, Gascon, M. Calopa, J. Campdelacreu, M. Juncadella, R. Cilia, M. Canesi, G. Pezzoli, A. Antonini (Monza, C. Junque (Barcelona, Spain) Italy) 77 465 InSPECT: Investigating the effect of short-term 476 Substantia nigra T2 measurements in PD patients treatment with pramipexole or levodopa on [123I] and healthy controls -CIT and SPECT imaging K.J. Schweitzer, A. DiSanto, T. Brussel, J. Godau, D. D.L. Jennings, R. Tabamo, J.P. Seibyl, K. Marek (New Berg, U. Klose (Tuebingen, Germany) Haven, Connecticut, USA) 477 The occurrence of “typical” MRI findings in 466 Cerebral activation patterns in psychogenic progressive supranuclear palsy and multiple system atrophy: A retrospective study M. Van Beilen, B.M. de Jong, E.W. Gieteling, K.L. Z. Chovancova, P. Hlustik, P. Kanovsky (Olomouc, Leenders (Groningen, Netherlands) Czech Republic) 467 Camptocormia in Parkinson’s disease: Magnetic 478 Modulation of cerebral functional interactions resonance image and near-infrared spectroscopy by cortical dopamine in health and Parkinson’s (NIRS) study of paraspinal muscles disease K.-Y. Murata, K. Hama, T. Kihira, H. Miwa, T. Kondo G. Garraux, L. Talagala, R. Carson, M. Hallett (Liege, (Wakayama, Japan) Belgium) 468 Phenotype and genotype driven changes of basal 479 Involuntary psychogenic movement increases ganglia structure in primary dystonia limbic activity and decreases voluntary B. Draganski, S.A. Schneider, K. Stefan, K.P. Bhatia, movement-related activity in an fMRI study of R.S.J. Frackowiak (London, United Kingdom) psychogenic movement disorder 469 Magnetic resonance imaging in Wilson’s disease V. Voon, N. Hattori, C. Gallea, M. Bruno, M. Hallett M. Behari, J. Garg, G. Shukla, S. Singh, V. Goyal (New (Bethesda, Maryland, USA) Delhi, India) 480 Unexpected extra-striatal 123 I-FP-CIT uptake in a 470 Myocardial 123I-MIBG scintigraphy is a sensitive case of Parkinsonism tool with which to differentiate Lewy body J. Hernandez-Vara, M. Boronat-De Ferrater, C. disorders from the other neurodegenerative Lorenzo-Bosquet, F. Miquel-Rodriguez, J. Castell- disorders Conesa, J. Alvarez-Sabin (Barcelona, Spain) K. Kashihara, M. Nakashima, M. Ohno, S. Kawada, T. 481 Susceptibility-weighted imaging of the substantia Imamura (Okayama, Japan) nigra in patients with Parkinson’s disease 471 Brain perfusion SPECT analysis using NEUROSTAT T. Maeda, H. Toyoshima, K. Nagata (Akita, Japan) in multiple system atrophy — a comparison 482 Cerebral and cerebellar activation during postural between MSA-C and MSA-P and kinetic self-paced task in essential tremor: A Y. Osaki, Y. Morita, N. Akagi, M. Fukumoto, T. f-MRI study Kuwahara, C. Mori, Y. Doi (Nankoku, Kochi, Japan) C. Menichetti, O. Presciutti, L. Pierguidi, W. Di Iorio, V. 472 Test re-test reliability of ALTROPANE® SPECT in Rossi, A. Rossi, P. Calabresi, N. Tambasco (Perugia, Parkinson’s disease patients Italy) K. Marek, D. Jennings, G. Zubal, J. Seibyl (New 483 Diagnolstic usefulness of 3T magnetic resonance Haven, Connecticut, USA) imaging in multiple system atrophy 473 Midbrain transcranial sonography in Korean J.-Y. Lee, J.-Y. Kim, D.G. Na, B.S. Jeon, J.-W. Cho patients with Parkinson’s disease (Seoul, Republic of Korea) J.Y. Kim, W.Y. Lee, S.T. Kim, S.H. Jeon, E.J. Chung, 484 Demonstration of the neuroanatomy of the W.T. Yoon (Seoul, Republic of Korea) midbrain using high field MRI 474 Dopa responsive sub-acute parkinsonism with L.A. Massey, M. Miranda, H. Parkes, S.-W. Po, T. pallidal T1 hyperintensity on MRI of brain Revesz, J.L. Holton, A.J. Lees, T. Yousry (London, M. Molaie, N. Molaie (San Pedro, California, USA) United Kingdom) 475 Assessment of the feasibility of midbrain 485 Patterns of cerebral blood flow reduction in sonography in a population-based study patients with vascular parkinsonism: Perfusion H. Stockner, K. Seppi, S. Kiechl, C. Schmidauer, MRI study J. Schwaiger, M. Sawires, J. Willeit, W. Poewe S.H. Kim, S.H. Lee (Chuncheon, Kangwon-do, (Innsbruck, Austria) Republic of Korea)

78 486 [123]-FP-CIT SPECT imaging of dopamine 496 Does an infusion of apomorphine at low transporters in patients with recurrent sudden concentrations inhibit motor function in falls Parkinson’s disease? R. Djaldetti, M. Lorberboym, S. Yust-Katz, I. Ziv, E. S.A. Gunzler, M. Pavel, C. Koudelka, N.E. Carlson, Melamed (Petah Tiqva, Israel) S. Crocker, P. Kirchhoff, J.G. Nutt (Portland, Oregon, 487 A comparison of white matter changes in patients USA) with Parkinson’s disease and Alzheimer’s disease 497 Reversible posterior leukoencephalopathy relative to cognitively-healthy elderly controls syndrome in a patient with multiple system using diffusion tensor imaging atrophy: A possible association with oral M.A. Trivedi, C.M. Murphy, J.M. Pagonabarrago, midodrine treatment J.G. Goldman, L. DeToledo-Morrell, G.T. Stebbins J.-S. Kim, K.-S. Lee, I.-U. Song, H.-T. Kim (Seoul, (Chicago, Illinois, USA) Korea) 488 Cardiac sympathetic denervation in Parkinson’s 498 Naturalistic long term follow-up of psychotic disease is correlated with age at onset and Parkinson’s disease patients treated with either severity of specific motor symptoms clozapine or quetiapine J.-S. Kim, K.-S. Lee, I.-U. Song, H.-T. Kim (Seoul, C. Klein, T. Prokhorov, E. Dobronevsky, A. Miniovich, Korea) J.M. Rabey (Zerifin, Israel) 489 Nociceptive brain activation in painful patients 499 Pramipexole treatment reverses motor deficits with Parkinson’s disease with low risk of dyskinesia in MPTP-treated C. Brefel-Courbon, P. Payoux, F. Ory, C. Thalamas, common marmosets O.O. Rascol (Toulouse, France) P. Jenner, M.J. Jackson, K. Tayarani-Binazir, S. Rose, C.W. Olanow (London, United Kingdom) Neuropharmacology 500 Quality of post-marketing drug surveillance Poster numbers 490-502 – EMEA regulatory restraints and reality of drug 490 Levodopa as a first-line treatment for the safety monitoring exemplified with tolcapone neuroleptic malignant syndrome prescription in Parkinson’s disease in Germany G. Mihailescu, C. Mihailescu, S. Nica (Bucharest, M.M. Unger, W.H. Oertel, K.M. Eggert (Marburg, Romania) Germany) 491 Analgesic effect of botulinum toxin type A in 501 The new neuroprotective agent; BN83026 reduces experimental models of pain L-DOPA-induced dyskinesia in hemiparkinsonian C. Favre, M. Auguet, P.-E. Chabrier (Les Ulis, France) rats 492 Effect of some naturally occuring antioxidants B. Spinnewyn, C. Charnet, S. Cornet, M. Auguet, P.-E. (vitamins) in the treatment of chronic lead Chabrier (Les Ulis, France) intoxication-interaction Parkinson’s disease in rats 502 In vitro pharmacological profile of the A2A N. Djebli (Mostaganem, Algeria) receptor antagonist istradefylline on adenosine 493 Topiramate as a monotherapy in essential receptors tremor. Comparison of a new drug to prior golden M. Saki, K. Sasaki, M. Ichimura, T. Kanda (Shizuoka, standard medication Japan) M. Arnaoutoglou, V. Costa, G. Spanos, A. Tychalas, S.A. Kapsali, E. Avdelidou, E. Kalliolia, N. Non-motor Aspects of Movement Disorders Arnaoutoglou, S.J. Baloyannis (Thessaloniki, Greece) Poster numbers 503-543 494 Effects of pramipexole on the motor response 503 Rest-activity rhythm and sleep-wake cycle are to levodopa infusion in Parkinson’s disease: A altered in PD patients with hallucinations double-blind, placebo controlled crossover study D.L. Whitehead, A.D.M. Davies, J.R. Playfer, C.J. M.A. Brodsky, M.C. Barnard, B.S. Park, J.G. Nutt Turnbull (London, United Kingdom) (Portland, Oregon, USA) 504 Anxiety in Parkinson’s disease relates to limbic 495 Effect of early use of amantadine on the and brainstem alpha-synuclein pathology development of motor fluctuations and M.E. Kalaitzakis, R.K.B. Pearce, M.B. Graeber, S.M. dyskinesias during levodopa treatment in Gentleman (London, United Kingdom) Parkinson’s disease A. Kishore, S. Gopinathan (Trivandrum, Kerala, India) 79 505 Neuropsychological early detection and the 514 The effect of nighttime levodopa and entacapone characteristics of Parkinson’s disease associated on subjective and objective sleep measures in with mild dementia Parkinson’s disease K.-S. Lee, I.-U. Song, J.-S. Kim, J.-Y. An (Seoul, I. Itin, C.L. Comella, J.A. Jaglin, M. Park, L. Benson, Republic of Korea) W. Fan, S. Lergans (Cleveland, Ohio, USA) 506 Reduced nocturnal heart rate variability in 515 A guided interview to assess behavior in Parkinson’s disease: A polysomnographic case- Parkinson’s disease control study C. Ardouin, I. Chereau, P.M. Llorca, F. Durif, A. M. Vaillant, N.J. Diederich, J. Tiete, J.P. Lobreau Pelissolo, M. Schupbach, A. Funkiewiez, K. Dujardin, (Luxembourg-City, Luxembourg) P. Krystkowiak, C. Arbus, F. Tison, J.L. Houeto, P. 507 Striatal amyloid plaques relate to dementia in Auquier, P. Pollak, P. Krack (Grenoble, France) Parkinson’s disease 516 Features of gastric motility at rest in Parkinson’s M.E. Kalaitzakis, M.B. Graeber, S.M. Gentleman, disease R.K.B. Pearce (London, United Kingdom) G. Albani, N. El Assawy, S. Cattaldo, A. Mauro 508 Depressive disorders in early-onset Parkinson’s (Piancavallo, Verbania, Italy) disease 517 Neuroanatomical loci of subjective panic-like A. Kummer, S.T. Camargos, M.C. Cunningham, D.P. phenomena in OCD DBS subjects Maia, F. Cardoso, A.L. Teixeira (Belo Horizonte, Brazil) I.U. Haq, W.K. Goodman, K. Foote, C. Jacobson, M.S. 509 Effects of motor and cognitive tasks on Okun (Gainesville, Florida, USA) hemodynamic parameters in orthostatic 518 Sleep and circadian changes in early stage hypotension Huntington’s disease B. Shihman, L. Grundlinger, J.M. Hausdorff, N. Giladi, A.O.G. Goodman, J. Morton, M. King, J. Shneerson, T. Gurevich (Tel Aviv, Israel) R.A. Barker (Cambridge, United Kingdom) 510 The predictors of fatigue in Parkinson’s disease: 519 Trajectory control and motor learning in pre- Results from a UK-German study of 135 cases symptomatic Huntington’s disease (pHD) Y. Naidu, P. Martinez-Martin, R. Brown, P. Odin, F. Ghilardi, A. Feigin, C. Moisello, F. Battaglia, A. Di A. Russemann, K. Ray Chaudhuri, International Rocco, D. Eidelberg (New York, New York, USA) Parkinson’s Disease Non Motor Group (London, 520 Disturbance of automatic auditory change England, United Kingdom) detection in dementia associated with Parkinson’s 511 Prevalence of behavioural symptoms in PSP and disease: A mismatch negativity study MSA: Evidence from NNIPPS (Neuroprotection and K. Bronnick, H. Nordby, J.P. Larsen, D. Aarsland Natural History in Parkinson’s Plus Syndromes) (Stavanger, Norway) B.R. Stanton, P.N. Leigh, G. Bensimon, Y. Agid, 521 A novel paradigm to assess mental fatigue in A.C. Ludolph, J.R. Hodges, T.H. Bak, J. Noth, L. Parkinson’s disease Lacomblez, B. Dubois, I. Uttner, R.G. Brown, The F. Battaglia, D. Crupi, A. Di Rocco, A. Quartarone, F. NNIPPS Consortium (London, United Kingdom) Ghilardi (New York, New York, USA) 512 Correlation of psychomotor dysfunction in patients 522 Major depression and cognitive dysfunctions in with Parkinson’s disease, multisystem atrophy and non demented parkinsonian patients progressive supranuclear palsy S. Gabriella, C. Vitale, M.E. De Martino, T. Luigi, G. N. Amosova, O.S. Levin (Moscow, Russian Dario, P. Barone (Neaples, Italy) Federation) 523 Diagnosis of dementia in Parkinson’s disease with 513 A prospective study of mood in Parkinson’s FDG PET disease: The PROMS-PD study I. Liepelt, M. Reimold, W. Maetzler, G. Reischel, K. R.G. Brown, D. Burn, J. Hindle, C.S. Hurt, S. Landau, Schweitzer, A. Gaenslen, J. Godau, T. Gasser, H.-J. J. Playfer, M. Samuel, K. Wilson (London, United Machulla, R. Bares, D. Berg (Tuebingen, Germany) Kingdom) 524 Assessment of odor identification and discrimination in Dutch Parkinson’s disease patients S. Boesveldt, D. Verbaan, D.L. Knol, J.J. van Hilten, H.W. Berendse (Amsterdam, Netherlands) 80 525 Towards a better understanding of the relationship 535 The behavioural changes in progressive between the Mariana dementia and the supranuclear palsy (PSP) are not just a mild form Parkinsonism/dementia complex of Guam (Lytico- of frontotemporal dementia (FTD) bodig): Evidence from a longitudinal study T.H. Bak, J.R. Hodges (Edinburgh, Scotland, United T.H. Bak, J.R. Hodges, J.C. Steele (Edinburgh, Kingdom) Scotland, United Kingdom) 536 Pain in Parkinson’s disease – 526 An acceleration of rhythmic finger tapping in pharmacoepidemiological research into the patients with Parkinson’s disease consumption of analgesic drugs I.S. Smolenteva, L.A. Batukaeva, O.S. Levin C. Brefel-Courbon, S. Grolleau, J. Micaleff, C. (Moscow, Russian Federation) Thalamas, O.O. Rascol, J.L. Montastruc, M. Lapeyre- 527 Knowledge of disease among patients with Mestre (Toulouse, France) hemifacial spasm 537 Searching for subtle sleep abnormalities by W.S. Shahul Hameed, T.E. King (Singapore, polysomnography in early Parkinson’s disease: A Singapore) prospective case-control study 528 Symptomatic REM sleep behavior disorder in N.J. Diederich, M. Vaillant, O. Rufra, S. Blyth, V. Pieri patients with Parkinson’s disease over eight years (Luxembourg-City, Luxembourg) M.D. Gjerstad, B.B. Boeve, T. Wentzel-Larsen, D. 538 Neuropsychological predictors of hallucinations Aarsland, J.P. Larsen (Stavanger, Norway) in Parkinson’s disease: Cognitive and perceptual 529 Psychiatric comorbidities in a Brazilian sample of biases early-onset Parkinson’s disease D.L. Whitehead, A.D.M. Davies, J.J. Downes, C.J. A. Kummer, S.T. Camargos, M.C. Cunningham, D.P. Turnbull, J.R. Playfer (London, United Kingdom) Maia, F. Cardoso, A.L. Teixeira (Belo Horizonte, Brazil) 539 Prevalence of non-motor symptoms in idiopathic 530 Cognitive and motor mediators of the changes in Parkinson’s disease. The PRIAMO study gait stability during dual tasking in healthy older C. Colosimo, PRIAMO Study Group, Italy (Rome, Italy) adults 540 Improvement of hyperdopaminergic behaviors by J.M. Hausdorff, T. Herman, N. Inbar-Borovsky, M. subthalamic nucleus (STN) stimulation Brozgol, G. Yogev, N. Giladi (Tel-Aviv, Israel) E. Lhommee, C. Ardouin, H. Klinger, J. Xie, A. Kistner, 531 Constipation in Parkinson’s disease: A literature S. Thobois, P. Pollak, P. Krack (Grenoble, France) review 541 Validation of the CAMCOG neuropsychological K.M. Mahawish (Prescot, Merseyside, United assessment in Parkinson’s disease Kingdom) P.J. Hobson, J.R. Meara (Rhyl, Denbighshire, United 532 Safe and efficacious treatment of sialorrhea Kingdom) related to Parkinson’s disease, parkinsonism and 542 Altered pain and pain tolerance thresholds in other neurological diseases with blind single Parkinson’s disease – a result of multifocal transdermical botulinum toxin injections into degeneration? the parotid glands: Clinical experience with 58 D. Samal, D. Haubenberger, T. Sycha, E. Auff (Vienna, patients Austria) O. De Fabregues, G. Ribera, D. Coll, J. Martinez, D. 543 Executive functioning in early-onset Parkinson’s Canovas, M. Viguera, M. Marco, F. Miquel, J. Gamez disease (Sabadell, Barcelona, Spain) A. Kummer, S.T. Camargos, M.C. Cunningham, D.P. 533 Intimate partner abuse in movement disorders and Maia, F. Cardoso, A.L. Teixeira (Belo Horizonte, Brazil) the role of health care professionals Parkinson’s disease J. Posen, N. Giladi (Tel Aviv, Israel) Poster numbers 544-662 534 Dopamine dysregulation syndrome, impulse 544 Continuous levodopa duodenal infusion in control disorders and subthalamic nucleus deep advanced Parkinson’s disease: Long-term follow- brain stimulation: A case series and literature up review M. Canesi, I.U. Isaias, M. Zibetti, F. Mancini, L. S.S. O’Sullivan, D.A. Gallagher, A.H. Evans, S. Tisch, Manfredi, M. Del Fante, L. Lopiano, G. Pezzoli, A. P. Limousin, A.D. Lawrence, A. Schrag, A.J. Lees Antonini (Milano, Italy) (London, United Kingdom) 81 545 Correlations of initial ‘mentation’ rating in UPDRS 556 Parkinson’s disease: Atypical improve of gait and progression of motor and cognitive functions disturbances. Case report in Parkinson’s disease E.M. Dieguez, R.M. Buzo, A. Scaramelli, R. Aljanati, J.-G.G. Hou, E.C. Lai (Houston, Texas, USA) O. de Medina, R. Ventura, V. Raggio, M. Pebet 546 Risk factors of falls related to balance and gait (Montevideo, Uruguay) disorders in Parkinson’s disease – prospective 557 Statin use and the risk of Parkinson’s disease study A.D. Wahner, J.M. Bronstein, Y.M. Bordelon, B. Ritz M. Rudzinska, J. Stozek, W. Chwala, S. Bukowczan, (Los Angeles, California, USA) K. Banaszkiewicz, A. Szczudlik (Krakow, Poland) 558 Biceps brachii myoelectric manifestations in 547 Elevated prevalence of malignant melanoma in medicated Parkinson’s disease patients Israeli patients with Parkinson’s disease M. Kankaanpaa, S.M. Rissanen, M.P. Tarvainen, J. R. Inzelberg, J.M. Rabey, R. Djaldetti, A. Reches, S. Nuutinen, I. Tarkka, P.A. Karjalainen, A. Meigal, O. Badarny, S. Hassin-Baer, H. Trau, J. Aharon-Peretz, Airaksinen (Kuopio, Finland) M. Huberman, L. Gilead, N. Giladi (Kfar Saba, Israel) 559 Clinical evaluation of asymptomatic G2019S 548 The effect of mechanical vibration in Parkinson’s LRRK2 mutation carriers and assessment of disease (PD): A randomized blind controlled trial factors influencing LRRK2 related Parkinson’s A.R. Bayes, M.V. Cosculluela (Barcelona, Catalunya, disease expression (the ASAP LRRK2 study) Spain) C. Gaig, E. Tolosa, M. Ezquerra, A. Rojo, M. Aguilar, 549 The neuropathological substrate of the dementia J. Hernandez, F. Miquel, M. Calopa, P. Pastor of Parkinson’s disease (Barcelona, Spain) T. Voss, M.S. Forman, J. Duda, H. Hurtig 560 Parkinson’s disease in boxers: A link or a myth? (Philadelphia, Pennsylvania, USA) P. Lolekha, K. Phanthumchinda, R. Bhidayasiri 550 Outcome of acute ischemic in hospitalized (Bangkok, Thailand) Parkinson’s disease patients 561 The mutant C-allele of the variant MTHFR M. Niethammer, H.C. Schumacher, B.T. Bateman, C. c.1298A>C (E429A) is associated with later age of Henchcliffe (New York, New York, USA) onset in Parkinson’s disease and multiple system 551 Side and symptom of disease onset is related to atrophy and provides resistance against oxidative lifespan in Parkinson’s disease stress in vitro B.K. Scanlon, H.L. Katzen, D.A. Nation, R.A. M. Linnebank, U. Wüllner (Bonn, Germany) Rodriguez, S. Papapetropoulos, J.A. Ledon, A. 562 Is there a correlation between clinical presentation Capano, D. Wilensky, J. Zitser, C. Singer, B.V. Gallo, and body mass index in Parkinson’s disease? J.A. Jagid, B.E. Levin (Miami, Florida, USA) R.P. Munhoz, H.A. Teive, C.B. Ribas (Curitiba, PR, 552 Weight loss and disease progression in Brazil) Parkinson’s disease 563 Enhanced lymphocyte apoptosis in treated and Y. Tsuboi, Y. Baba, H. Inoue, T. Kobayashi, T. Yamada untreated Parkinson patients (Fukuoka, Japan) J. Bas, M. Calopa, M. Mestre (Barcelona, Spain) 553 Sleep disturbances in Parkinson’s disease patients 564 Diagnostic accuracy of SPECT in parkinsonian D. Dobi, M. Kapisyzi, B. Kokona, J. Kruja (Tirana, syndromes: A meta-analysis Albania) A.M.M. Vlaar, M.J.P.G. Kroonenburgh Van, A.G.H. 554 Training and placebo effects outweigh effects of Kessels, S.C. Tromp, W.E.J. Weber (Maastricht, single session conventional rTMS and theta burst Netherlands) stimulation in PD patients 565 Treadmill training improves functional ability and H. Rothkegel, M. Sommer, T. Rammsayer, C. cardiopulmonary capacity in stable Parkinson’s Trenkwalder, W. Paulus (Goettingen, Germany) disease 555 Diversity in Parkinson’s disease prevalence among E. Pelosin, E. Faelli, F. Lofrano, L. Marinelli, M. Bove, elder South Carolinians P. Ruggeri, G. Abbruzzese (Genova, Italy) K.J. Bergmann, J.K. Rodgers, V.L. Salak, V.K. Hinson (Charleston, South Carolina, USA)

82 566 Clinical predictors of on-road driving performance 577 Levodopa therapy is associated with reduced body in patients with Parkinson’s disease weight in advanced Parkinson’s disease patients D.P. McCarthy, C. Garvin, D.N. Lanford, M.S. Okun, C.G. Bachmann, A. Zapf, E. Brunner, C. Trenkwalder R.L. Rodriguez, J. Romrell, W.C. Mann, S. Bridges, (Goettingen, Germany) H.H. Fernandez (Gainesville, Florida, USA) 578 The relationship between antiparkinsonian therapy 567 Is there a morphological substrate of parkinsonian and sleep disturbances in patients with moderate rest tremor a voxel-based morphometry study stage of Parkinson’s disease D. Benninger, S. Thees, C.L. Bassetti, S.S. Kollias, D. M. Boczarska-Jedynak, B. Jasinska-Myga, G.A. Waldvogel (Zurich, Switzerland) Klodowska-Duda, M. Arkuszewski, G. Opala 568 Non motor symptoms in untreated patients with (Katowice, Poland) Parkinson’s disease in Tanzania 579 The pesticide of rotenone selectively enhances C.L. Dotchin, R.W. Walker (North Shields, Tyne and voltage-gated potassium channels and Wear, United Kingdom) endogenous PACAP mRNA expression in neuronal 569 Use of clozapine in Brazilian patients with differentiated PC12 cells Parkinson’s disease G. Wang, H.-Y. Zhou, S.-D. Chen (Shanghai, China) L. Gomide, A. Kummer, S.T. Camargos, M.C. 580 Genetic polymorphism of thymidylate synthase Cunningham, D.P. Maia, F. Cardoso, A.L. Teixeira enhancer region (TSER) in patients with idiopathic (Belo Horizonte, Brazil) Parkinson’s disease 570 Therapeutic effect of neuropeptide PACAP27 on W.-C. Kim, K.-K. Kim, H.-S. Kim, Y.-H. Koo, O.-J. Kim, MPTP-induced parkinsonism in mice M.-S. Lee (Seong-Nam City, Gyeong-Gi Do, Korea) G. Wang, Y.-Y. Tan, X.-K. Sun, R.-J. Ren, H.-Y. Zhou, 581 The PARS study: Reaching for pre-motor S.-D. Chen (Shanghai, China) Parkinson’s disease 571 Sleep disturbances in patients with Parkinson’s D.L. Jennings, A. Siderowf, M.B. Stern, K. Marek disease (New Haven, Connecticut, USA) T. Smiljkovic, S. Kostic, V. Dedic, J. Potic, V. Nikolic 582 Early-onset Parkinson’s disease and depression (Belgrade, Serbia) D.C. Bertucci Filho, H.A.G. Teive, R.P. Munhoz, N. 572 Rotigotine transdermal patch as adjunct to Becker, L.C. Werneck (Curitiba, PR, Brazil) levodopa in the treatment of advanced-stage 583 Is there an increased risk of young onset Parkinson’s patients Parkinson’s disease in patients with a history of P.A. LeWitt, K.E. Lyons, R. Pahwa (Southfield, poliomyelitis? Michigan, USA) P. Agarwal, A.L. Diamond, V.R. Segro (Englewood, 573 Quantitative motor tests for early detection of Colorado, USA) motor dysfunction in Parkinson’s disease 584 A study of clinical effect of STN-DBS for C.A. Haaxma, B.R. Bloem, G.F. Borm, M.W.I.M. Parkinson’s disease in younger and elder patients Horstink (Nijmegen, Netherlands) H. Saiki, H. Toda, M. Nishida, S. Kaneko, S. Kosaka, 574 Detection of increased echogenicity in the M. Ishikawa, H. Itoh, S. Matsumoto (Osaka, Japan) substantia nigra in a large family with homo- and 585 Worsening of motor symptoms and gynecomastia heterozygous PINK1 mutations during spironolactone treatment in a patient with J.M. Hagenah, G. Seidel, N. Brüggemann, A. Parkinson’s disease and congestive heart failure Djarmati, K. Lohmann, A. Sprenger, C. Klein H.A. Teive, R.P. Munhoz (Curitiba, Brazil) (Luebeck, Germany) 586 Studying emergence of behavioral changes during 575 Metric attributes of a quantitative motor test one month of intensive voice treatment (LSVT) in a battery for practical and scientific use in person with Parkinson’s disease Parkinson’s disease J. Spielman, A. Halpern, L. Ramig, C. Fox (Denver, C.A. Haaxma, B.R. Bloem, G.F. Borm, M.W.I.M. Colorado, USA) Horstink (Nijmegen, Netherlands) 587 Dopamine dysregulation syndrome: Impact of 576 The evaluation of tau-protein in the CSF in subthalamic chronic stimulation patients suffering from Parkinson’s disease T. Witjas, J. Régis, M. Delphini, J.C. Péragut, J.P. H. Vranova, P. Kanovsky, M. Nevrly, J. Mares, P. Azulay (Marseille, France) Hlustik (Olomouc, Czech Republic) 83 588 Does somatization have a role in the manifestation 598 Adult human stem cells differentiated into of the non-motor symptoms of Parkinson’s astrocytes: Therapeutic potential for Parkinson’s disease? disease H. Murck, M. Stacy, K. Kroenke (Hanover, New M.B. Stroomza, Y. Barhom, Y. Levy, O. Karpov, S. Jersey, USA) Bulvik, E. Melamed, D. Offen (Petah-Tikva, Israel) 589 Parkinson’s disease; relationship between 599 The influence of walking speed on lower extremity neuroinflammation and cognition JOINT TORQUE asymmetry in persons with early A. Bora Tokcaer (Ankara, Turkey) Parkinson’s disease 590 Diplopia in Parkinson’s disease: A clinical and J. Song, G.M. Petzinger, B. Fisher, J. Gordon, G.J. optometric study Salem (Los Angeles, California, USA) L. Bye, K. Ray Chaudhuri (London, United Kingdom) 600 Molecular mechanism of levo-dopa induced 591 End-of-dose blepharospasm and its relationship to dyskinesia in Parkinson’s disease the dose of levodopa: Observation in a patient with F.U.H. Subhani (Quetta, Balochistan, Pakistan) Parkinson’s disease 601 Clinical impact of fatigue in Parkinson’s disease P.Kr. Pal, A. De Souza, P.S. Bindu (Bangalore, V.K. Metta, A. Matouskova, R. Mitchell-Hay, A. Karnataka, India) Deshraj, J. Roomi, K. Ray Chaudhuri (London, United 592 Factors that impact quality of life in patients with Kingdom) Parkinson’s disease 602 Types of driving errors committed by patients with T. Simuni, D. Breslow, L. Vainio, S. Miskevics, C. Parkinson’s disease Zadikoff, F. Weaver (Chicago, Illinois, USA) D.P. McCarthy, C. Garvin, M.D. Justiss, D.N. Lanford, 593 PRODEST study: Depressive symptoms in M.S. Okun, R.L. Rodriguez, J. Romrell, W.C. Mann, S. Parkinson’s disease Bridges, H.H. Fernandez (Gainesville, Florida, USA) P. Barone, C.G. Goetz, J. Houben, K. Juergen, A.F.G. 603 Metabolomic analysis in LRRK2 Parkinson’s Leentjens, W. Poewe, O.O. Rascol, H. Reichmann, disease A.H. Schapira, E. Tolosa (Naples, Italy) K.K. Johansen, W. Matson, F. Beal, J.O. Aasly, M. 594 Cognitive function assessment in idiopathic Bogdanov (Trondheim, Norway) Parkinson’s disease patients. Control study with 604 Effect of L-type Ca2+ channel antagonist, normal subjects Isradipine, in the abnormal involuntary movement M.R. Piovezan, H.A.G. Teive, E.J. Piovesan, M.J. rat model of dyskinesia Maeder, L.C. Werneck (Curitiba, PR, Brazil) S. Schuster, A. Berthet, E. Doudnikoff, C. Ittrich, B. 595 Hypersexuality in Parkinson’s disease: Differences Bloch, B. Hengerer, E. Bezard (Biberach, Germany) in associated factors may lead to the expression 605 Chocolate consumption is increased in Parkinson’s of different impulse control behaviors disease V. Voon, T. Thompsen, J.M. Miyasaki, M. de Souza, M. Wolz, A. Kaminski, L. Matthias, S. Alexander, H. M. Zurowski (Bethesda, Maryland, USA) Reichmann (Dresden, Germany) 596 Decreased plasma alpha synculein levels in 606 Nonmotor symptoms of Parkinson’s disease: patients with Parkinson’s disease Prevalence and awareness of patients and A. Neumayer, R. Reindl, K. Seppi, E. Wolf, S. families Boesch, H. Stockner, M. Kogler, A. Zangerl, K. Mair, S.-M. Cheon, H.M. Jeong, S.M. Jun, J.W. Kim (Busan, G.K. Wenning, M. Stampfer-Kountchev, W. Poewe Republic of Korea) (Innsbruck, Tirol, Austria) 607 Impact of young onset parkinson’s disease on 597 Evaluation of a multidisciplinary daycare unit for employment patients with Parkinson’s disease (PD) C.L. Wielinski, C. Erickson-Davis, S.A. Parashos M.A. van der Marck, B.R. Bloem, M.L. van (Golden Valley, Minnesota, USA) Nimwegen, M.A.M. Schmidt, M. Munneke (Nijmegen, 608 Striatal dopamine transporter function and apathy Netherlands) in Parkinson’s disease Z. Katsarou, S. Bostantjopoulou, G. Gerasimou, G. Kourtesi, V. Tsipropoulou, A. Kafantari, E. Peitsidou (Thessaloniki, Greece)

84 609 Dementia and hyperhomocysteinemia in 619 Accuracy of patient versus spousal reports of Parkinson’s disease disability in Parkinson’s disease M. Menendez, R. Ribacoba, G. Jimenez, J.R. Virgili, H. Tanji, A.L. Gruber-Baldini, K.E. Anderson, S.G. C. Huerta, V. De la Vega (Mieres, Asturias, Spain) Reich, P.S. Fishman, W.J. Weiner, L.M. Shulman 610 Does gait analysis quantify the efficacy of PPN- (Baltimore, Maryland, USA) DBS in Parkinson’s disease patients? 620 A comparison of MMSE to MoCA in identifying A. Peppe, A. Stefani, P. Mazzone, A. Gasbarra, M. cognitive deficits in Parkinson’s disease Pierantozzi, D. Crovato, C. Caltagirone, P. Stanzione C. Zadikoff, S.H. Fox, D.F. Tang-Wai, T. Thomsen, (Rome, Italy) R.M.A. De Bie, S. Duff-Canning, P. Wadia, T. Steeves, 611 The effectiveness of cabergoline vs levodopa in A.E. Lang, C. Marras (Toronto, Ontario, Canada) early Parkinson’s disease: Results of a three year 621 No sleep-dependent consolidation of an implicit follow up learning task in patients with Parkinson’s disease N.S. Oztekin, M.F. Oztekin (Ankara, Turkey) S. Wailke, M. Fehlau, G. Deuschl, J. Volkmann (Kiel, 612 Neuropsychological assessment of mild to Germany) moderate stage Parkinson’s disease without 622 The short- and long-term effects of a single dementia: Comparison with mild stage of dose of apomorphine on micturition function in Alzheimer’s disease (AD) – a preliminary study conscious and free moving rats Y.D. Kim, J.E. Kim, J.H. Kim (Daejeon, Republic of T. Uchiyama, R. Sakakibara, Z. Liu, T. Yamamoto, T. Korea) Ito, T. Hattori (Chiba, Japan) 613 Evolution of patients with Parkinson’s disease 623 Weight change in Parkinson’s and Alzheimer’s chronically treated with continuous subcutaneous disease patients taking atypical antipsychotic apomorphine infusion. A multicenter study drugs P.J. Garcia Ruiz, M. Alvarez, J.A. Burguera, M. O. Sitburana, S. Rountree, K. Dat Vuong, W.G. Ondo Calopa, M. Carballo, A. Castro, J.R. Chacon, J. (Houston, Texas, USA) Hernandez Vara, E. Lezcano, F. Miquel, P. Mir, J. 624 Molecular screening of the LRRK2 and parkin Obeso, M.C. Rodriguez Oroz, A. Sesar, J. Vaamonde, genes in a large cohort of Russian patients with J.M. Arbelo (Madrid, Spain) Parkinson’s disease 614 Anti-apoptotic mechanisms by D2/D3 receptor S.N. Illarioshkin, S.A. Klyushnikov, P.A. Slominsky, agonist ropinirole against rotenone-induced cell M.I. Shadrina, G.K. Bagyeva, E.V. Bespalova, T.B. death in dopaminergic cell line Zagorovskaya, E.D. Markova, S.A. Limborska, I.A. S. Chen, X.-J. Zhang, W. Le (Shanghai, China) Ivanova-Smolenskaya (Moscow, Russian Federation) 615 Influence of red and green laser lights on freezing 625 The SCOPA motor scale in Latin-America: Metric of gait (FOG) in persons with Parkinson’s disease properties (PD) M.J. Forjaz, F.J. Carod, J. Virues, G. Galeano, G. M. Suteerawattananon, D.H. Rintala, E.C. Lai, J.-G.G. Meza-Rojaz, C. Velazquez, F. Micheli, G. Reina, Hou, E.J. Protas (Houston, Texas, USA) M. Serrano-Duenas, B. Calero, P. Martinez-Martin 616 Vascular parkinsonism: A case of lacunar (Madrid, Spain) infarction localized to mesencephalic substantia 626 Medication review in patients on anti-parkinson nigra medication in the community A. Akyol, U.O. Akyildiz (Aydin, Turkey) E.J. Newman, K. Grosset, E. Thomson, M. Liddle, D. 617 The contribution of Jules Froment to the study of Grosset (Glasgow, United Kingdom) parkinsonian rigidity 627 Transcranial sonography (TCS) of the substantia E. Broussolle, P. Krack, S. Thobois, J. Xie-Brustolin, P. nigra (SN) – biological and clinical significance in Pollak, C.G. Goetz (Lyon, France) patients with Parkinsonian syndromes (PS) 618 Steady state administration of istradefylline does D. Weise, R. Lorenz, M. Schliesser, K. Reiners, J. not affect the pharmacokinetics of levodopa/ Classen (Wuerzburg, Germany) carbidopa 628 Impaired information processing as a key N. Rao, K. Allenby, T. Uchimura, A. Mori, P. Chaikin determinant of akinesia in Parkinson’s disease (Princeton, New Jersey, USA) B. Christe, C.-A. Hauert, A.J. Pegna, P.R. Burkhard (Geneva, Switzerland) 85 629 Efficiency of physiotherapy in Parkinson’s disease: 639 Rotigotine transdermal patch as a treatment of The ParkNet trial nocturnal symptoms in patients with idiopathic M. Munneke, M.J. Nijkrake, S.H.J. Keus, I.I.K. Lim, Parkinson’s disease G.F. Borm, G.J. van der Wilt, R.A.C. Roos, G. Kwakkel, K.R. Chaudhuri, J. Jankovic, C. Trenkwalder, B. H.W. Berendse, B.R. Bloem (Nijmegen, Netherlands) Boroojerdi (London, United Kingdom) 630 Frequency and phenomenology of motor and 640 Plasma ceruloplasmin ferroxidase activity non-motor features of wearing-off phenomenon in correlates with substantia nigra sonographic area Brazilian Parkinson’s disease patients in Parkinson’s disease patients F. Cardoso, B.P. Cesar, A.L. Teixeira, Jr, S.T. R. Martinez-Hernandez, S. Montes, J. Higuera- Camargos, D.P. Maia, M.C. Cunningham (Belo Calleja, C. Rios (Mexico City, DF, Mexico) Horizonte, MG, Brazil) 641 Effects of subthalamic nucleus stimulation and 631 Postural instability in persons with Parkinson’s levodopa on freezing of gait in Parkinson’s disease disease: Comparison among disability scales of M. Ferraye, B. Debu, V. Fraix, J. Xie-Brustolin, S. the Hoehn and Yahr Chabardes, A.-L. Benabid, P. Pollak (Grenoble, M. Suteerawattananon, S. Kamolsawat, V. France) Hiengkaew, C. Akamanon, N. Poungvarin (Houston, 642 Tremor related neuronal activity correlated with Texas, USA) segregated somatotopy in the human subthalamic 632 Biopsychosocial needs of people living with PD nucleus and their caregivers P. Zhuang, M. Hallett, J. Li, Y. Zhang, Y. Li (Beijing, S. Giles, L. Johnston, C. Marras (Toronto, Ontario, China) Canada) 643 Taste threshold is abnormal in Parkinson’s disease 633 Socio-demographic characteristics of the and suggests cortical spread caregivers of patients with Parkinson’s disease M. Shah, J. Deeb, M. Fernando, E. Visentin, A. Noyce, P. Martinez-Martin, S. Arroyo, B. Frades, J. de Pedro, L.J. Findley, C.H. Hawkes (Romford, Essex, United The ELEP Group (Madrid, Spain) Kingdom) 634 Handwriting in Parkinson’s disease: The effects of 644 Levodopa, DDCI and entacapone has minor long- disease severity and acute levodopa dosing term effects on dyskinesia while significantly M. Contin, P. Martinelli, R. Shrairman, C. Scaglione, decreasing OFF-time in Parkinson’s disease (PD) A. Landau, F. Albani, R. Riva, A. Baruzzi (Bologna, patients with wearing off Italy) M. Kuoppamäki, M. Vahteristo, H. Nissinen, J. Ellmen 635 Continuous and low-dose infusion of (Turku, Finland) erythropoietin into the brain shows 645 Patient-reported autonomic symptoms in neuroprotective effect and induces neurogenesis Parkinson’s disease without hematogenesis in the parkinsonian rat D. Verbaan, J. Marinus, M. Visser, S.M. van model Rooden, A.M. Stiggelbout, J.J. van Hilten (Leiden, A. Kondo, T. Shingo, T. Kadota, T. Yasuhara, Y. Netherlands) Miyoshi, T. Matsui, I. Date (Okayama, Japan) 646 SOS Parkinson: An emergency call service report 636 Correlation between depressive symptoms and on five years of experience nocturnal disturbances in Japanese patients with A.L. Zecchinelli, A. Antonini, M. Barichella, A. Parkinson’s disease Marczewska, G. Pezzoli (Milano, Italy) K. Suzuki, Y. Okuma, N. Hattori, S. Kamei, F. Yoshii, 647 Glucose-6-Phosphate dehydrogenase in the H. Utsumi, Y. Iwasaki, M. Iijima, T. Miyamoto, M. peripheral blood of patients with Parkinson’s Miyamoto, K. Hirata (Mibu, Tochigi, Japan) disease 637 A simple model of dopamine-related neurotoxicity P. Mir, L. Gao, F. Diaz, R. Mejias, F. Carrillo, P.J. Vime, — Parkinson’s? J. Diaz-Martin, A. Palomino, M. Carballo, E. Pintado, L.R. Baxter, H.H. Fernandez, M.S. Okun, S. Janssen, M. Lucas, J. Lopez-Barneo (Seville, Spain) K. Williams, S. Constance, J. Riley, Y. Liang, M. Boules, E. Richelson (Gainesville, Florida, USA) 638 Abstract Withdrawn

86 648 Establishing a model of “Standards of Care” 657 What is dorso-lateral in the STN? An anatomical for patients with Parkinson’s disease using a consideration on the ambiguous nomenclature of comprehensive database — Interdisciplinary today’s principle target for DBS surgery Florida Registry and Movement Disorders V.A. Coenen, A. Prescher, T. Schmidt, F.I.H. Gielen Database (INFORM) (Aachen, Germany) R.L. Rodriguez, C. Jacobson, C. Garvan, R. Stephen, 658 Discharge properties of human subthalamic K.D. Foote, C. Nugent, J. Romrell, P. Zeilman, M.S. nucleus neurons in the parkinsonian and non- Okun, S. Vaidyanathan, H.H. Fernandez (Gainesville, parkinsonian state Florida, USA) F. Steigerwald, P. Stangenberg, M. Pötter, J. Herzog, 649 Inter-individual variations of plasma M. Pinsker, H.M. Mehdorn, G. Deuschl, J. Volkmann concentrations of amantadine hydrochloride in (Kiel, Germany) patients with Parkinson’s disease 659 Rotigotine transdermal patch in early stage M. Nagai, M. Kubo, N. Nishikawa, H. Yabe, M. Parkinson’s disease: Results of a placebo- and Nomoto (Toon, Ehime, Japan) ropinirole-controlled trial 650 Environmental and genetic factors in Parkinson’s N. Giladi, A. Korczyn, B. Boroojerdi (Monheim, disease. The FRAGAMPP case-control study Germany) A. Nicoletti, P. Pugliese, G. Nicoletti, G. Arabia, G. 660 Two novel missense mutations were found Torchia, M. De Mari, P. Lamberti, L. Grasso, R. in a Parkin2 gene and may be related to the Marconi, A. Epifanio, L. Morgante, L. Cozzolino, P. development of the early onset parkinsonism Barone, A. Quattrone, M. Zappia (Catania, Italy) M. Kasap, G. Akpinar, E. Ergul, H.A. Idrisoglu, A. Sazci 651 Investigation on the prevalence of dyskinesia (Kocaeli, Turkey) following the switch from continuous rotigotine to 661 Impaired attention: A risk factor for falls in L-DOPA treatment and vice versa Parkinson’s disease? K. Stockwell, D.K.A. Scheller, S. Rose, M. Jackson, P. L.M. Allcock, E.N. Rowan, K. Wesnes, R.A. Kenny, Jenner (Monheim, Germany) D.J. Burn (Newcastle upon Tyne, Tyne and Wear, 652 Proteome analysis of human substantia nigra in United Kingdom) Parkinson’s disease 662 Age-dependent changes in glial cells from parkin C.J. Werner, R. Heyny-von Haussen, G. Mall, S. Wolf null mice (Aachen, NRW, Germany) R.M. Solano, M.J. Casarejos, J. Menéndez-Cuervo, 653 Elevated C-reactive protein in Parkinson’s disease: J.A. Rodríguez-Navarro, J. García de Yébenes, M.A. Are they associated with neuropsychiatric Mena (Madrid, Spain) complications? S. Hassin-Baer, O.S. Cohen, B.-A. Sela, Z. Nitzan, E. Vakil, R. Schwartz, J. Chapman, T. David (Ramat- Gan, Israel) 654 Brain permeable iron chelators M-30 and AK-28 rescue degenerated nigral dopamine neurons in animal model of PD W. Zhu, T. Pan, W. Xie, J. Jankovic, H. Zheng, M. Youdim, W. Le (Houston, Texas, USA) 655 Dynamic foot pressure measurement in Parkinson’s disease with foot scan system C.-N. Lee, D.-H. Lee, K.-W. Park, B.-J. Kim, K.-M. Oh (Seoul, Korea) 656 Risk factors for heavy burden among family caregivers of Parkinson’s disease patient O. Benavides, P. Chana, D. Alburquerque, T. Parrao, C. Juri, C. Kunstmann (Santiago, Chile)

87 Poster Session 3 672 Mirror movements in different neurological diseases Thursday, June 7, 2007 - 12:30 PM - 2:30 PM S. Sahin, S. Ayalp, S. Karsidag (Istanbul, Turkey) Rumeli Hall, Lower Level 673 3 cases of bilateral striatopallidodental calcinosis Poster Viewing 9:00 a.m. to 4:00 p.m. E. Lobsien, A. Bick-Sander, S. Eibach, K.-T. Authors Present 12:30 p.m. to 2: 30 p.m. Hoffmann, T. Trottenberg, A. Kupsch (Berlin, Poster numbers 663-973 Germany) Other Clinical 674 Posterior alien limb phenomenon as presenting Poster numbers 663-708 symptom of bacterial endocarditis 663 High-level gait disturbance is a manifestation A. Glik, R. Inzelberg (Kfar Saba, Israel) of the pyramidal, cortico-pontine and thalamic- 675 Methylphenidate improves cognition and reduces demyelination in elderly people. MRI pilot study fall risk in older adults with cognitive decline: Y. Balash, M. Kafri, E. Sasson, O. Eizenstein, Y. Assaf, Single dose, placebo controlled, double-blind J.M. Hausdorff, N. Giladi (Tel Aviv, Israel) study 664 Substantia nigra and olfactory function in R. Ben-Itzhak, J.M. Hausdorff, E.S. Simon, N. Giladi idiopathic REM sleep behaviour disorder: A pilot (Tel-Aviv, Israel) study 676 Two cases of primary progressive freezing gait V. Gschliesser, H. Stockner, B. Hogl, B. Frauscher, C. with different chronologic progression and Schmidauer, W. Poewe (Innsbruck, Austria) different imaging 665 Ipsilateral upper limb and contralateral M. Kim, E. Son, S. Choi, K. Lee, S. Lee, M. Park, K. parkinsonism related to putaminal hemorrhage Cho (Gwangju, Korea) M.J. Kim, J.K. Kim, B.G. Yoo, K.S. Kim (Busan, Korea) 677 The Dynamic Gait Index provides insight into stair 666 Botulinum toxin treatment is effective for epilepsia climbing and fear of falling in healthy elderly men partialis continua and women J.-S. Kang, K. Krakow, H. Steinmetz, R. Hilker T. Herman, M. Brozgol, N. Ibar-Borovsky, N. Giladi, G. (Frankfurt/Main, Germany) Yogev, L. Grundlinger, J.M. Hausdorff (Tel Aviv, Israel) 667 Appearance of Kleine-Levin Syndrome (KLS) after 678 Associated conditions and clinical significance of acute awake bruxism K. Dimitrios, K. Konstantinos, B. Aggeliki (Athens, Y.T. Kwak, S.-H. Suk, W.-J. Kim (Yongin-shi, Greece) Kyeongki-do, Republic of Korea) 668 A system for syncronized recording and automatic 679 Nordic walking improves mobility in Parkinson’s processing of video- and biodata files in disease movement disorder evaluation F. Vereijkeren, R. Reijmers, A. Minten, J.P. ter E. Nordh, M. Larsson, M. Johansson (Umea, Sweden) Bruggen (‘sHertogenbosch, NB, Netherlands) 669 High Prevalence of tremor, parkinsonism and 680 A progressive, fatal dystonia-parkinsonism neuropsychological impairment induced by syndrome in a patient with primary mercury in handmade miners. Andacollo, IV immunodeficiency receiving chronic IVIG therapy region, Chile S. Papapetropoulos, J. Friedman, C. Blackstone, G.I. F. Pancetti, G. Lam, P. Lillo, D. Saez, D. Moraga, S. Kleiner, C. Sengun, C. Singer (Miami, Florida, USA) Corral (Coquimbo, Chile) 681 New assessment concerning movement signs/ 670 An acquired neuromyotonia case non-associated symptoms in atypical movements diseases to thymoma with significant clinical improvement consulted in units-setting. Treatment rationalizing after thymectomy S.G. Echebarria (Spain) M.A. Sierra-Beltrán, U. Rodríguez-Ortiz, J.A. Nader- 682 EEG comparison in early AD, LBD, PDD patients Kawachi, M.S. Rodrìguez (Mexico City, DF, Mexico) with a 2-year follow-up 671 Movement Disorders at university hospital L. Bonanni, A. Thomas, L. Manzoli, M. Onofrj emergency room; an analysis of clinical pattern (Pescara, Italy) and etiology P.H. Lee, J.H. Yoon, H.Y. Park, T.S. Lim, J.Y. Choi (Suwon, Gyeonggi, Republic of Korea) 88 683 Atypical PKAN, a broadening clinical spectrum: 695 Clinical trial participation in Movement Disorders: Case report and video Why do patients accept or reject? N. Lubarr, S. Frucht, S.K. Westaway, A. Gregory, S.J. M.P. Silverstein, C.E. Jacobson IV, M.S. Okun, R.L. Hayflick (New York, New York, USA) Rodriguez, H.H. Fernandez (Gainesville, Florida, USA) 684 Normal interhemispheric inhibition in persistent 696 Analysis of survival in patients with Huntington’s developmental stuttering disease in Serbia M. Sommer, K. Knappmeyer, E.J. Hunter, A. Wolff von I.N. Petrovic, M. Svetel, T. Pekmezovic, N. Gudenberg, W. Paulus (Goettingen, Germany) Dragasevic, V.S. Kostic (Belgrade, Serbia) 685 Patients with hyperhidrosis treated with botulinum 697 Motor neuron disease associated with copper toxin have changed grip force, coefficient of deficiency in a case of Wilson’s disease friction and safety margin A. Foubert, A. Kasadi, M. Rouanet, A. Lagueny, F. T. Zackrisson, B. Eriksson, N. Hosseini, B. Johnels, Tison (Pessac, France) A.L. Krogstad (Gothenburg, Sweden) 698 Beneficial effect of Piracetam on obstructive sleep 686 Long-term follow-up of deep brain stimulation: apnea syndrome in patients with multiple system Timing of generator replacement atrophy M. Takanashi (Sapporo, Hokkaido, Japan) Y. Nakamura, I. Yamada, H. Sakamoto (Sakai, Osaka, 687 The other babinski sign in hemifacial spasm Japan) W.P. Stamey, J. Jankovic (Houston, Texas, USA) 699 Electroconvulsive therapy for a patient with lethal 688 Electroconvulsive therapy for depression in a catatonia-neuroleptic malignant syndrome patient with right-sided VIM DBS V.C. Chang, D. Hardesty, M. Pietro (New York, New V.C. Chang, D. Hardesty, B. Ford, P. Greene (New York, USA) York, New York, USA) 700 A rare combination of Klippel-Feil syndrome and 689 Clinical and electrophysiological features of 12 pheochromocytoma: Case report patients with painful legs and moving toes S. Telarovic, T. Bajica, S. Juren, M. Relja (Zagreb, M.V. Alvarez, V.G. Evidente, E.D. Driver-Dunckley, J.N. Croatia) Caviness, C.H. Adler (Scottsdale, Arizona, USA) 701 Safety and efficacy of Hengli® and Dysport® 690 A study on the effects of botulinum toxin A, for primary hemifacial spasm: A randomized Botox® and Dysport®, in patients with hemifacial controlled trial spasm Y.W. Wu, L.L. Zeng, S.D. Chen (Shanghai, China) N. Wan Yahya, N. Mohamad Ibrahim, R. Sahathevan, 702 Paroxysmal kinesogenic dyskinesia following H. Basri, R. Azman Ali (Kuala Lumpur, Malaysia) ischemic insult 691 New and associated motor signs in movement S.R. Daniels, K. Nakamura, G.A. Kang (San disorders units case sampling Francisco, California, USA) S.G. Echebarria (Spain) 703 Frontotemporal dementia due to VCP mutations: 692 Prevalence of movement disorders in Orhangazi Clinical and functional neuroimaging findings district of Bursa, Turkey (a population-based door D. Haubenberger, G. Pusswald, M. Hoffmann, A. to door study) (Bursa, Turkey) Zimprich, E. Auff (Vienna, Austria) M. Zarifoglu, S. Erer, N. Karli, A. Ozcakir, A. Semra, N. 704 Wilson’s disease: A study of 21 cases from Indian Caliskan, D. Aslan (Bursa, Turkey) subcontinent 693 Miraxion treatment for Huntington’s disease – a 2 B. Sharma, R.K. Sureka, A. Panagariya, N. Agarwal, V. year follow-up Agarwal, A. Dev (Jaipur, Rajasthan, India) A. Clarke, B.R. Leavitt, M. Manku, A. Rosenblatt 705 L-Dopa responsive movement disorder in a young (Oxford, Oxfordshire, United Kingdom) patient with mixed connective tissue disease 694 A new test to measure upper limb apraxia (sharp syndrome) (TULIAS): A reliability study S. Haegele-Link, A. Burrow, T. Hundsberger, B. B. Van Hemelrijk, T. Vanbellingen, A. Van de Winckel, Tettenborn (St. Gallen, Switzerland) W. De Weerdt, S. Bohlhalter (Tschugg, Switzerland) 706 Handtapping as a clinical marker for evaluating disease progression in Huntington’s disease S.L. Mason, A.O.G. Goodman, A. Michell, R.A. Barker (Cambridge, Cambridgeshire, United Kingdom) 89 707 The role of proportion of cerebrospinal fluid total 716 Roles of DJ-1, a causative gene product for tau-protein levels to phosphorylated tau-protein familial Parkinson’s disease, in dopamine levels in differential diagnosis of Creutzfeltd- biosynthesis Jacob disease S. Ishikawa, T. Taira, H. Maita, C. Maita, H. Ariga, M. Valis, J. Hort, R. Talab (Hradec Kralove, Czech S.M.M. Iguchi-Ariga (Sapporo, Japan) Republic) 717 Level of movement, cognitive and emotional 708 Alien hand syndrome and dystonia in a pediatric disturbances and their correlation in patients with patient Parkinson’s disease T. Soman, T. Steeves, A.E. Lang (Toronto, Ontario, D.R. Hristova, I.S. Grozdev (Plovdiv, Bulgaria) Canada) 718 The QUICK questionnaire identifies wearing-off in Parkinson’s disease patients Parkinson’s disease P. Martinez-Martin, E. Tolosa, B. Hernandez, X. Badia Poster numbers 709-829 (Madrid, Spain) 709 Effects of subthalamic stimulation on brain 719 Dopamine dysregulation syndrome in Parkinson’s electrical activity during a motor task in disease patients: Preliminary results of a clinical Parkinson’s disease study L. Colloca, F. Benedetti, M. Lanotte, M. Sigaudo, A. Gunduz, F. Beskardes, S. Ertan, S. Ozekmekci, G. M. Zibetti, A. Cinquepalmi, S. Vighetti, A. Ducati, L. Kiziltan (Istanbul, Turkey) Lopiano (Turin, Italy) 720 Pathological gambling in Parkinson’s disease: An 710 Salsolinol decreases expression of the antral but analysis of published case series not duodenal and colonic interstitial cells of Cajal D.A. Gallagher, S.S. O’Sullivan, A.H. Evans, A.J. Lees, T.A. Banach, A.T. Krygowska-Wajs, K.M. Gil, D. A. Schrag (London, United Kingdom) Zurowski, P.J. Thor (Cracow, Poland) 721 Driver safety errors in Parkinson’s disease 711 The differential diagnoses of Parkinsonism in E.Y. Uc, M. Rizzo, J. Sparks, S.W. Anderson, R.L. outpatient clinics of PD Northumbria Rodnitzky, J.D. Dawson (Iowa City, Iowa, USA) E. Stone, R. Walker, B. Wood (North Shields, United 722 Mitochondrial DNA polymorphisms and the risk of Kingdom) Parkinson’s disease in Taiwan 712 Continuous duodenal levodopa infusion C.-M. Chen, C.-C. Kuan, G.-J. Lee-Chen, Y.-R. Wu (DUODOPA) in advanced Parkinson’s disease: First (Taipei, Taiwan) French experience 723 Social impact on Parkinson’s disease caregivers M. Hery, F. Lallement, P. Sauleau, S. Drapier, I. Rivier, and the impact of disease duration M. Verin (Rennes, France) J. Loekk (Stockholm, Sweden) 713 Good treatment compliance in patients with 724 Antibiotics and Parkinson’s disease: Overview on Parkinson’s disease on ropinirole: The Ropi-Park literature and case reports study K.S. Paulus, V. Agnetti, P. Galistu, G.A. Cocco, G. F. Valldeoriola, S. Cobaleda, Ropipark Study Sechi (Sassari, Sardegna, Italy) Research Group (Barcelona, Spain) 725 Reversible Retrocollis in a case of Parkinson’s 714 Valvular heart disease in Parkinson’s disease disease with hyponatremia induced malignant patients treated with bromocriptine syndrome L.C.S. Tan, K.K.C. Ng, N.C.K. Tan, W.L. Au, R.K.K. Lee S. Chandran (Trivandrum, Kerala, India) (Singapore, Singapore) 726 Comparison of pharmacokinetics and 715 The diagnostic value of transcranial duplex pharmacodynamics of combined immediate- and scanning and SPECT imaging versus clinical extended-release (IR+ER)/carbidopa/levodopa diagnosis (clinical prospective study) formulations (VADOVA IR+ER) with IR carbidopa/ S.C. Tromp, A.M.M. Vlaar, M.J.P.G. Kroonenburgh levodopa and controlled-release (CR) carbidopa/ Van, W.H. Mess, T. de Nijs, A. Winogrodzka, A.G.H. levodopa in Parkinson’s disease (PD) Kessels, W.E.J. Weber (Maastricht, Netherlands) J. Nutt, P.A. LeWitt, A. Ellenbogen, S. Wang, T. Nguyen, S. Khor, A. Hsu (Portland, Oregon, USA)

90 727 Rapid efficacy of a noradrenergic reuptake 738 Prevelance of dyskinesia switching from pulsatile inhibitor in depression in advanced Parkinson’s to continuous rotigotine administration in MPTP- disease: A double-blind, randomized, placebo- treated marmosets controlled study K. Stockwell, D.K.A. Scheller, S. Rose, M. Jackson, P. D. Devos, I. Poirot, K. Dujardin, S. Duhem, B. Lucas, Jenner (Monheim, Germany) N. Waucquier, C. Moreau, P. Bocquillon, P. Devos, K. 739 The effectiveness of pramipexole, cabergoline Ajebbar, B. Thielemans, O. Cottencin, P. Thomas, A. and pergolide in early and advanced Parkinson’s Destée, R. Bordet, L. Defebvre (Lille, France) disease and comparision of the results with each 728 Botulinum toxin treatment for anterocollis in other Parkinson’s disease O. Yilmaz, B. Yucel-Altan, S. Oruc, S. Gok, N.S. H. Ito, Y. Takanashi (Akishima, Tokyo, Japan) Oztekin (Afyonkarahisar, Turkey) 729 Novel LRRK2 mutation in the Roc domain in 740 Striatal dopamine transporter imaging correlates an Western Australian family with autosomal with depressive symptoms and Tower of London dominant late-onset Parkinson’s disease (LOPD) task performance in Parkinson’s disease F.L. Mastaglia, Y. Huang, G.M. Halliday, D.B. Rowe, I. Rektorova, H. Srovnalova, R. Kubikova, J. Prasek C.M. Sue (Nedlands, WA, Australia) (Brno, Czech Republic) 730 Psychiatric features of caregivers of Parkinson’s 741 Nociceptin/orphanin FQ receptor antagonists disease patients with dopamine dysregulation reverse parkinsonism in MPTP-treated mice and syndrome: Preliminary results of a clinical study non-human primates F. Beskardes, A. Gunduz, G. Kiziltan, S. Ertan, S. M. Morari, R. Viaro, M. Marti, R. Sanchez-Pernaute, Ozekmekci (Istanbul, Turkey) O. Isacson (Ferrara, Italy) 731 Can dual-forceplate posturography support the 742 Clinical characteristics of Parkinson’s disease diagnosis Parkinson’s disease? among Jewish ethnic groups in Israel A.C. Geurts, N. Voermans, M.G. Diender, V. R. Djaldetti, S. Hassin-Baer, M.J. Farrer, T.A. Treves, Weerdesteyn, B.R. Bloem (Nijmegen, Netherlands) Y. Barhum, M.M. Hulihan, S. Yust-Katz, E. Melamed 732 Quality of life improvement in Parkinson’s patients (Petah Tiqva, Israel) after DBS: Identifying the super-responders 743 Falls in Parkinson’s disease: Analysis of the I.U. Haq, M.S. Okun, R. Rodriguez, K. Foote, C. DoPaMiP study, a cross-sectional survey in South- Jacobson, C. Garvan, H. Fernandez (Gainesville, West of France Florida, USA) O.O. Rascol, L.L. Negre-Pages, DoPaMiP D. Study 733 Increased Synphilin-1 expression in elderly and Group (Toulouse, France) parkinsonian brains 744 L-Dopa induced dyskinesia in Parkinson’s disease: A.T. Krygowska-Wajs, T. Lenda, K.I. Ossowska, D. Analysis of the DoPaMiP study, a cross-sectional Adamek, E.A. Gryz-Kurek, J. Kunz (Cracow, Poland) survey in South-West of France 734 Exercise-induced alterations in striatal glutamate L.L. Negre-Pages, O.O. Rascol, DOPAMIP D. Study in an animal model of Parkinson’s disease Group (Toulouse, France) C.K. Meshul, J.K. Wiedemann, C. Moore, R.J. Koch, 745 The natural history of treated Parkinson’s disease R.H. Walker (Bronx, New York, USA) J.J. Duarte, L.M. García Olmos, L.E. Clavería 735 A computerized survey of pain in Parkinson’s (Segovia, Spain) disease patients: A pilot feasibility study 746 Full-length expression of Park2 gene in human D.B. Page, F. Weaver, D.J. Wilkie, T. Simuni (Chicago, leukocytes Illinois, USA) M. Kasap, G. Akpinar, E. Ergul, H.A. Idrisoglu, A. Sazci 736 Clinical correlates of camptocormia in Parkinson’s (Kocaeli, Turkey) disease 747 Results of the PRAMI study: Description of D. Ottaviani, D. Tiple, C. Colosimo, G. Fabbrini, G. the therapeutic management of patients with Defazio, A. Berardelli (Rome, Italy) idiopathic Parkinson’s disease (PD) 737 Reaching out to first degree relatives M. Dujardin, P.L. Lleu (Paris, France, Metropolitan) J. Posen, Z. Heiblum, N. Giladi (Tel Aviv, Israel)

91 748 Chronic Captopril treatment accelerates injury in 758 Comparison of proton-MR-spectroscopy of the an early stage rat model of Parkinson’s disease substantia nigra in patients with Parkinson’s E. Thornton, R. Vink (Adelaide, SA, Australia) disease, relatives and controls 749 Prevalence of non-motor symptoms in Parkinson’s A. Di Santo, U. Klose, K. Schweitzer, J. Godau, D. disease patients Berg (Tuebingen, Baden-Wurttembe, Germany) L. Vela, K.F. Lyons, J.A. Pareja, J.L. Dobato, F.J. 759 Additional value of SPECT imaging in comparison Barriga, C. Sanchez, M. Baron, A.P. Polo, L. Borrega with clinical diagnosis in 248 patients with (Alcorcon, Madrid, Spain) parkinsonism 750 Identifying predictors of somnolence and edema A.M.M. Vlaar, M.J.P.G. Kroonenburgh Van, T. Nijs in patients with early Parkinson’s disease treated De, W.H. Mess, S.C. Tromp, A. Winogrodzka, W.E.J. with pramipexole: A secondary analysis of the Weber (Maastricht, Netherlands) CALM-PD study 760 Anti-psychotic treatment discontinuation and K.M. Biglan, A. Brocht, M.P. McDermott, K. Kieburtz, drug-induced psychosis in Parkinson’s disease Parkinson Study Group CALM-PD Investigators F. Morgante, A. Epifanio, M. Zappia, R. Marconi, G. (Rochester, New York, USA) Paolo, A. Quartarone, A. Quattrone, L. Morgante 751 Non-motor dysfunction contributes to swallowing (Messina, Italy) dysfunction in PD and could be a target for future 761 PD patients with STN-DNS gain weight in relation therapy to motor improvement: A prospective study N. Sengupta, H.N. Jones, J.C. Rosenbek, M.S. Okun, A. Foubert, E. Krim, C. Perlemoine, P. Burbaud, R.L. Rodriguez, F.M. Skidmore, C. Swartz, H.H. E. Cuny, S. Maurice-Tison, V. Rigalleau, F. Tison Fernandez (Gainesville, Florida, USA) (Pessac, France) 752 The impact of the use of Access Therapy Controller 762 Towards adaptive deep brain stimulation: on the postoperative outcome Recording local field potentials during stimulation N. Kovacs, I. Balas, L. Kellenyi, E. Pal, F. Nagy (Pecs, L. Rossi, G. Foffani, S. Marceglia, A. Priori (Milan, Hungary) Italy) 753 Identifying predictors of response to pramipexole 763 A comparison of cerebral glucose metabolism treatment in early Parkinson’s disease: A in Parkinson’s disease, Parkinson’s disease secondary analysis of the CALM-PD study dementia, and dementia with Lewy bodies K.M. Biglan, A. Brocht, M.P. McDermott, K. Kieburtz, S.W. Yong, P.H. Lee, Y.J. Kim (Suwon, Kyunggi-do, Parkinson Study Group CALM-PD Investigators Korea) (Rochester, New York, USA) 764 Extraction of typical features from surface EMG 754 Prevalence and characteristics of punding among signals in Parkinson’s disease Parkinson patients in North-Central Florida S.M. Rissanen, M. Kankaanpää, M.P. Tarvainen, J. F.N. Nguyen, Y.-L. Chang, M.A. Shapiro, C.E. Nuutinen, I.M. Tarkka, A. Meigal, O. Airaksinen, P.A. Jacobson, C.L. Swartz, M.S. Okun, H.H. Fernandez Karjalainen (Kuopio, Finland) (Gainesville, Florida, USA) 765 Low dose methylphenidate improves freezing in 755 The scores of UPDRS correlate with objectively advanced Parkinson’s disease during off-state measured motor performance characteristics in L. Pollak, E. Dobronevsky, T. Prokhorov, S. Bahunker, Parkinson’s disease J.M. Rabey (Zerifin, Israel) K. Noorvee, D. Uueni, M. Paasuke, P. Taba (Tartu, 766 Cerebrovascular risk factors and procedural Estonia) learning in idiopathic Parkinson’s disease 756 Task-specific limb dystonia with slow onset: Initial E. Pourcher, H. Cohen (Quebec, Quebec, Canada) symptom of Parkinson’s disease or association of 767 Starting therapy in Parkinson’s disease with two diseases? L-dopa or agonists and the occurrence of late L- I. Nestrasil, P. Kanovsky (Olomouc, Czech Republic) dopa motor problems in daily practice 757 Retention rate and tolerability of rotigotine M.W.I.M. Horstink, C.A. Haaxma, G.F. Borm, B.R. transdermal skin patch for a “real life” population of Bloem (Nijmegen, Netherlands) Parkinson’s disease patients in the UK P. Reddy, S. Muzerengi, A. Forbes, R. Weeks, K. Ray Chaudhuri (London, United Kingdom) 92 768 Correlation between postural changes and 778 Clinical characteristics and prevalence of cognitive impairment in Parkinson’s disease Parkinson’s disease in orhangazi district of Bursa, G. Marco, P. Lucia, P. Susy, F. Sandro, S. Maura Turkey (a population-based door to door study) (Ancona, Italy) (Bursa, Turkey) 769 Parkinson’s disease, malignant melanoma and M. Zarifoglu, S. Erer, N. Karli, M. Boz, A. Bican (Bursa, body mass index Turkey) E.C. Lai, S. Moore (Houston, Texas, USA) 779 Midbrain iron measured with MRI in early 770 Cognitive effects of safinamide in early Parkinson’s disease Parkinson’s disease (PD) patients W. Martin, M. Wieler, M. Gee (Edmonton, Alberta, T. Sharma, R. Anand, F. Stocchi, R. Borgohain, S. Canada) Rossetti, 015 Study Group (Newark, Delaware, USA) 780 COMT val158met genotype influences attentional 771 The effectiveness of pramipexole and levodopa as control in Parkinson’s disease an initial treatment for Parkinson’s disease C.H. Williams-Gray, A. Hampshire, A.M. Owen, R.A. N.S. Öztekin, M.F. Öztekin, R.S. Polat, B. Renkliyildiz Barker (Cambridge, United Kingdom) (Ankara, Turkey) 781 Long-term efficacy and safety of zonisamide in 772 The data base of “Quality Development in advanced Parkinson’s disease Neurology and Psychiatry (QUANUP)”-group M. Murata, K. Hasegawa, I. Kanazawa (Tokyo, Japan) – results of the Parkinson’s disease pilot project 782 An overview of specialist multidisciplinary M. Muengersdorf, P. Scherer, A. Simonow, P. Reuther, services for Parkinson’s disease patients at R. Ehret (Berlin, Germany) Llandough Day Hospital 773 Levetiracetam administration for the management M.M. Oliver, P.C. Sewter, E. Morgan, J. Pinkerton, B. of levodopa-induced dyskinesias in Parkinson’s Clarke (Penarth, Vale of Glamorgan, United Kingdom) disease: An ongoing, multicenter, double-blind, 783 Neuropsychological effects of bilateral STN DBS in placebo-controlled, parallel, crossover trial (the advanced Parkinson’s disease VALID-PD study) study design and baseline patient R. Borgohain, R. Reddy, M.K. Panigrahi, S. characteristics Shanmukhi, T. Suryaprabha, A. Jabeen (Hyderabad, P. Stathis, S. Konitsiotis, G. Tagaris, V. Kyriakakis, G. Andhra Pradesh, India) Hadjigeorgiou, The VALID-PD Study Group (Athens, 784 Postural verticality problems in parkinson patients Greece) B.R. Bloem, K.A.B. Ravenshorst, I. Benatru, A.S. 774 Factors that influenced in quality of life in Gissot, D. Pérennou (Nijmegen, Netherlands) parkinsonian patient according SF-36 (short form 785 Pathological gambling in Parkinson’s disease – 36) M. Yamamoto, Y. Kageyama (Takamatsu, Japan) A. Machin, M. Hamdan, Y. Saelan (Surabaya, East 786 Dopamine dysregulation syndrome is similarly Java, Indonesia) common among Parkinson’s disease patients 775 Freezing of gait severity and executive dysfunction treated with rotigotine transdermal patch as with in patients with Parkinson’s disease ropinirole M. Amboni, A. Cozzolino, K. Longo, M. Picillo, P. N. Giladi, H. Shabtai, A. Levi, T. Gurevich, Y. Balash, I. Barone (Naples, Italy) Girshovich, C. Peretz (Tel Aviv, Israel) 776 Comparative scintigraphic analysis of the parotid 787 Myocardial [(123)I] metaiodobenzylguanidine glands in healthy volunteers and in patients with is preserved uptake in hereditary Parkinson’s sialorrhea and Parkinson’s disease (PD) disease with LRRK2 I2020T mutation (HPD D.H. Nicaretta, A.L.Z. Rosso, C. Maliska, J.P. de Sagamihara family) Mattos, S.A.P. Novis, M.M.B. Costa (Rio de Janeiro, Y. Ogino, M. Ogino, S. Ujiie, F. Sakai (Sagamihara, RJ, Brazil) Kanagawa, Japan) 777 Dementia and depression in Parkinson’s disease 788 Nighttime sleep problems and daytime sleepiness A. Akyol, A. Ozkul, E. Turgut, E. Yilmaz, U. Akyildiz, S. in Parkinson’s disease Memis (Aydin, Turkey) D. Verbaan, S.M. van Rooden, M. Visser, J. Marinus, J.J. van Hilten (Leiden, Netherlands)

93 789 Comparison of sympathetic skin response and 799 Dementia in Parkinson’s disease (PD): A 20-year urodynamic study in Parkinson’s disease prospective Sydney Multicentre study M. Tavsan, O. Mertoglu, U. Sener, Y. Zorlu, F. Zorlu W.G.J. Reid, M.M.A. Hely, J.G.J.L. Morris, C.T. Loy, (Izmir, Turkey) G.M. Halliday (Sydney, NSW, Australia) 790 Influence of intestinal levodopa on non-motor 800 Treatment of levodopa induced dyskinesias with symptoms of Parkinson’s disease – a case report Levetiracetam M. Koegl-Wallner, R. Saurugg, P. Schwingenschuh, P. D. Richardson, M. Eisa, A. Toenjes, R. Bajwa, D. Katschnig, K. Wenzel, M. Maric, T. Hinterleitner, E. Ott Miller, B. Jabbari (New Haven, Connecticut, USA) (Graz, Styria, Austria) 801 Anxiety, depression and swallowing disorders in 791 Use of Parkinson’s disease sleep scale (PDSS) and patients with Parkinson’s disease polysomnography in “sleepy” Parkinson’s disease Y. Manor, B. Meirav, N. Giladi, R. Mootanah, J.T. (PD) patients Cohen (Tel-Aviv, Israel) S. Muzerengi, A. Williams, V. Dhawan, D. Whitehead, 802 Healthcare educational needs and experiences P. Martinez-Martin, K. Ray Chaudhuri (London, of people living with Parkinson’s disease (PD): An United Kingdom) exploratory study 792 Results of the PRAMI study: Prevalence of S. Giles, J.M. Miyasaki (Toronto, Ontario, Canada) neuropsychiatric symptoms in patients with 803 Unilateral haemorrhage in Gpe (globus pallidum idiopathic Parkinson’s disease (PD) externum) improving the Parkinsonian and M. Dujardin, P.L. Lleu (Paris, France) psychotic symptomatology. A case report 793 Community based prevalence study of Parkinson’s M. Baláž, I. Rektorová, I. Rektor (Brno, Czech disease describing age at onset distribution in Republic) Cardiff, UK 804 Increased periodontal disease and tooth loss in M.M. Wickremaratchi, E. Morgan, C. O’Loghlen, D. Parkinson’s disease Sastry, N.P. Robertson, Y. Ben-Shlomo, H.R. Morris A. Hanaoka, K. Kashihara (Okayama, Japan) (Cardiff, United Kingdom) 805 Punding in Parkinson’s disease 794 Placebo influences on dyskinesia in Parkinson’s A. Bora Tokcaer, O. Kapucu, N. Erdogmus Ince, U.O. disease Akdemir (Ankara, Turkey) C.G. Goetz, E. Laska, C. Hicking, P. Damier, T. Müller, 806 Long-term pre-administration of dopamine J. Nutt, C.W. Olanow, O.O. Rascol, H. Russ (Chicago, agonists alters L-dopa induced circling behavior in Illinois, USA) the 6-OHDA lesioned rat 795 New formulation of carbidopa/levodopa (IPX054 E.L. Lane, S.B. Dunnett (Cardiff, Wales, United (VADOVA IR+ER) vs. standard carbidopa/levodopa Kingdom) in stable PD patients 807 Increased resting-state functional connectivity in C.G. Goetz, S. Leurgans, V.K. Hinson, A. Hsu, W. Fan, de novo, untreated Parkinson’s disease S. Wang, T. Nguyen (Chicago, Illinois, USA) D. Stoffers, J.L.W. Bosboom, J.-B. Deijen, E.C. 796 Tolcapone (TASMAR®) in the treatment of Wolters, C.J. Stam, H.W. Berendse (Amsterdam, advanced Parkinson’s disease: Results of a Noord-Holland, Netherlands) postmarketing surveillance study 808 Interleukin-10 gene transfection of C17.2 cells G. Ebersbach (Paracelsusring, Germany) improves behavior in rat model of Parkinson’s 797 Safinamide potentiates the effects of DA-agonists disease through inhibition of microglia activation in early stage Parkinson’s disease (PD) patients X.-J. Wang*, W.-G. Liu*, Y.-H. Zhang, G.-Q. Lu, S.-D. R. Anand, M. Onofrj, A.H. Schapira, S.M. Rossetti Chen (China) (Pescara, Italy) 809 Shoulder pain in Parkinson’s disease 798 Automated gait detection algorithm from three W.P. Stamey, J. Jankovic (Houston, Texas, USA) dimensional acceleration signals of ankles in 810 Apolipoprotein E polymorphism and Parkinson’s patients with Parkinson’s disease disease J.-Y. Kim, J.-Y. Lee, K.S. Park, B.S. Jeon (Seoul, G. Akpinar, E. Ergul, I. Kara, H.A. Idrisoglu, K. Jongno-Gu, Korea) Bayulkem, A. Sazci (Kocaeli, Turkey)

94 811 Prevalence of sporadic Parkinson’s disease in 823 Dietary factors in Korean patients with Parkinson’s Arabic villages in Israel: A door-to-door study disease R. Inzelberg, M. Masarwa, R. Strugatsky, C. Baldwin, T.-B. Ahn, J.Y. Lee, B.S. Jeon, J.-W. Cho, K.H. Seo, L. Farrer, R. Friedland (Kfar Saba, Israel) M.R. Cho, R.W. Choue (Seoul, Republic of Korea) 812 Parkinson’s disease: A dual hit hypothesis 824 Alpha-synuclein-overexpressing neurosphere as C.H. Hawkes, K. Del Tredici, H. Braak (Romford, an in vitro model of alpha-synucleinopathies Essex, United Kingdom) M. Fukuda-Tani, T. Yasuda, H. Mochizuki, Y. Mizuno 813 Increase in vitamins A,C and E in Parkinson’s (Tokyo, Japan) disease following pramipexole treatment 825 Direct and indirect costs in Parkinson’s disease: A Y. Iwasaki, K. Ikeda, O. Kano (Tokyo, Japan) patient survey 814 Speech dysfunction in drug-naive patients with C. Peralta, A. Calle, S. Garcia, G. Gomez-Arevalo, G. early Parkinson’s disease and its response to Mizraji, O.S. Gershanik (Buenos Aires, Argentina) dopaminergic therapy 826 The familial Parkinsonism gene LRRK2 regulates H.-W. Shin, H. Kim, S.Y. Kang, Y.H. Sohn (Seoul, neurite process morphology Korea) D. MacLeod, K. Inoue, A. Abeliovich (New York, New 815 Hyponatremia and rhabdomyolysis induced by York, USA) pramipexole during the treatment of Parkinson’s 827 Urinary dysfunction in Parkinson’s disease disease H. Blackett, R. Walker, B. Wood (Ashington, M.F. Oztekin, N.S. Oztekin, B. Acar, S. Gencler Northumberland, United Kingdom) (Ankara, Turkey) 828 Results of rotigotine transdermal patch in 816 Pathological gambling secondary to dopaminergic advanced Parkinson’s patients with motor therapy in Parkinson’s disease fluctuations and in combination with levodopa: P. Katschnig, P. Schwingenschuh, R. Saurugg, K. Results of the CLEOPATRA-PD trial Wenzel, K. Petrovic, E. Ott (Graz, Austria) W. Poewe, W.H. Oertel, E. Martignoni, E. Tolosa, N.P. 817 Experiences using Japanese translation of Quinn, B. boroojerdi, M. Rupp (Innsbruck, Austria) wearing-off questionnaire (19 symptoms) 829 Screening for Parkinson’s disease in underserved Y. Kajimoto, I. Nakanishi, T. Kondo (Wakayama City, communities in Alachua County, Florida Japan) R.L. Stephen, M.S. Okun, C.W. Garvan, C.E. 818 N-acetyltransferase 2 polymorphism and risk Jacobson, R.L. Rodriguez, H.H. Fernandez factors in early onset Parkinson’s disease (Ganesville, Florida, USA) G.A. Klodowska-Duda, J. Samelska, B. Jasinska- Parkinsonism-Other Myga, M. Bialecka, K. Safranow, U. Mazurek, G. Poster numbers 830-877 Opala (Katowice, Poland) 830 In vivo magnetic resonance imaging, sensorimotor 819 Better sexual function in women with Parkinson’s behavioral and pathological phenotyping of aged disease: A case control study PLP-SYN transgenic mouse model of multiple C. Akbostanci, B.S. Arica, N. Eryigit, Z. Ayturk system atrophy (Ankara, Turkey) P.-O. Fernagut, M. Biran, A. Vital, G. Raffard, J.-M. 820 The neuronal activity of putamen in patients with Franconi, K.G. Petry, P.J. Kahle, F. Tison (Bordeaux, Parkinson’s disease before treatment France) K. Isonishi, F. Moriwaka, S. Kaneko, T. Kashiwaba 831 The “risus sardonicus”: A warning sign of multiple (Sapporo, Japan) system atrophy 821 Pain patients in Parkinson’s disease Y. Pamblanco-Bataller, E. Lopez-Valdes, S. Fanjul, C. S.O. Machnev, O.S. Levin (Moscow, Russian Cemillan, J. Domingo (Leganes, Madrid, Spain) Federation) 832 Intracranial dural arteriovenous fistula presenting 822 Smell identification in Parkinson and Alzheimer with Parkinsonism patients: Are Tabert et al’s* odours appropriate for H.J. Park, S.-K. Song, H.-W. Shin, Y.H. Sohn (Seoul, PD? Korea) H. Thagesen, L. Korbo, M. Baunsgaard, P. Moeller (Roskilde, Denmark)

95 833 “Applause Sign” secondary to infiltrative cerebral 845 Olfaction in dardarin/LRRK2 associated lymphoma Parkinsonism D.A. Gallagher, J.M. Schott, A. Childerhouse, L. Silveira Moriyama, L.C. Guedes, A. Kingsbury, J.J. T. Wilhelm, A. Gale, A. Schrag (London, United Ferreira, C. Sampaio, E.R. Barbosa, V. Bonifati, N.P. Kingdom) Quinn, A.J. Lees (London, United Kingdom) 834 The specificity and sensitivity of “applause sign” 846 Annonacin, a natural mitochondrial complex I in differentiating PSP and other parkinsonian inhibitor, causes tau pathology in cultured neurons syndromes M. Escobar Khondiker, M. Höllerhage, P.P. Michel, J. Wu, O. Sitburana, J. Jankovic (Houston, Texas, M.-P. Muriel, P. Champy, T. Yagi, A. Lannuzel, E.C. USA) Hirsch, W.H. Oertel, R. Jacob, M. Ruberg, G.U. 835 A new American kindred with hereditary diffuse Höglinger (Marburg, Germany) leukoencephalopathy with spheroids (HDLS) 847 Unusual presentation of progressive supranuclear L.A. Brown, J.A. VanGerpen, C.W. Wider, R.J. Uitti, palsy with palatal and diaphragmal myoclonus: A D.W. Dickson, Z.K. Wszolek (Jacksonville, Florida, case report USA) N.M. Browner, S. Fahn (New York, New York, USA) 836 Epidemiological data of nervous diseases in 848 Treatment of camptocormia by ultrasound-guided deep ventral injection of botulinum toxin to the Y.V. Lekomtseva (Kharkiv, Ukraine) iliopsoas muscle 837 Atypical PSP: A radiological diagnosis R. von Coelln, A. Raible, F. Asmus (Tuebingen, V.K. Gontu, D.P. Auer, N.B. Bajaj (Derby, United Germany) Kingdom) 849 Anti-beta2-glycoprotein I antibody and vascular 838 A combined case of tauopathy and Alpha- Parkinsonian synucleinopathy Y.-Y. Chang, M.-Y. Lan, Y.-L. Tseng, C.-S. Su, Y.-F. A. Marcos Gonzalez, L. Silveira Moriyama, D.R. Kao, H.-S. Wu, J.-S. Liu (Kaohsiung, Taiwan) Williams, S. O’Sullivan, L.A. Massey, R. Da Silva, J.L. 850 Comparison of brain MRI and 18F-FDG PET in the Holton, A.J. Lees (Sevilla, Spain) differential diagnosis of multiple system atrophy 839 Normal pressure hydrocephalus and vascular from Parkinson’s disease parkinsonism: Discrete or overlapping clinical S.J. Chung, K.Y. Kwon, C.G. Choi, J.S. Kim, S.K. Lee, entities? C.S. Lee, M.C. Lee (Seoul, Republic of Korea) A.J. Espay, R.K. Narayan, A.P. Duker, E.T. Barrett, G. 851 The cognitive profile versus motor severity and de Courten-Myers (Cincinnati, Ohio, USA) clinical course of patients with Parkinsonism 840 Manganese encephalopathy due to methcathinone associated to vascular disease (vascular abuse Parkinsonism) and Parkinson’s disease O.S. Levin, N.A. Amosova, N.V. Fedorova (Moscow, C. Panea, H. Nicolae, I. Codita, G. Vulpe (Bucharest, Russian Federation) Romania) 841 A focus on head drop and camptocormia 852 Severity of tau deposition in progressive N. Yardimci (Ankara, Turkey) supranuclear palsy is associated with clinical 842 Acquired hepatocerebral degeneration and phenotype dopamine transporter imaging using [123I]-FP-CIT D.R. Williams, J.L. Holton, A.J. Lees, T. Revesz SPECT (Melbourne, VIC, Australia) J.-M. Kim, Y.K. Kim, S.E. Kim, B.S. Jeon (Seongnam- 853 A patient with Gaucher’s disease successfully si, Korea) treated with pallidotomy, a 3-year follow up 843 Possibility of development of forms of pathological M.R. Sobstyl, M. Zabek, H.M. Koziara, Z.K. Wszolek, dependence on levodopa preparations and its J.E. Young (Warsaw, Poland) prevention 854 CBD – correlation of FDG PET, MRI and cognitive I.V. Bogdanova (Kharkiv, Ukraine) features 844 Possibility of development of secondary R. Borgohain, T. Suryaprabha, R.M. Kandadai, M.K. Parkinsonism caused by parasitary diseases Panigrahi, S. Shanmukhi, S.A. Jabeen (Hyderabad, I.V. Bogdanova (Kharkov, Ukraine) Andhra Pradesh, India)

96 855 Parkinson plus syndromes in a primary peripheral 866 Clinical characterization of a Chilean family with neurological center Kufor Rakeb disease and mutations in ATP13A2, a F.R. Rodolico (Giarre, Sicily - CT, Italy) lisosomal ATPase 856 High dose levodopa therapy is not toxic in multiple M.I. Behrens, P. Chana, T. Parrao, P. Venegas, M. system atrophy: Experimental evidence Miranda, C.V. Rojas, A. Ramirez (Santiago, Chile) N. Stefanova, M. Köllensperger, M. Hainzer, A. Cenci, 867 Atypical PSP: A representative case series W. Poewe, G.K. Wenning (Innsbruck, Austria) V.K. Gontu, D.P. Auer, N.B. Bajaj (Derby, United 857 PSP/CBD overlap – a case series Kingdom) S. Singhal, V.K. Gontu, D.P. Auer, N.B. Bajaj 868 Isolated gait ignition failure: Abnormalities in pre- (Nottingham, United Kingdom) and post-synaptic dopamine receptor imaging 858 Anal sphincter EMG in the diagnosis of atypical M.C. Kraus, U. Haberkorn, H.-M. Meinck (Heidelberg, Parkinsonian syndromes Germany) K. Winge, P. Jennum, A. Lokkegaard, L. Werdelin 869 Clinical phenptypes of Parkinson’s disease: (Copenhagen, Denmark) How does psychopathology cluster with motor 859 Sleep disorders in Parkinson’s disease: A symptoms? correlation with clinical characteristics A.F.G. Leentjens, J. Reijnders, U. Ehrt, R. Lousberg, S.-M. Cheon, H.Y. Cho, M.J. Park, H.W. Lee, J.W. Kim D. Aarsland (Maastricht, Netherlands) (Busan, Republic of Korea) 870 Clinical and imaging characteristics of a dominant 860 Parkinsonism as late-onset side effect of cerebral kindred with benign Parkinsonism and dopa- radiotherapy. A case report responsive dystonia F. Zanini, M. Untereiner, W. Pilloy, M. Kruger, N.J. A.J. Lewthwaite, T.D. Lambert, D.J. Nicholl, V. Diederich (Luxembourg, Luxembourg) Bonifati, K.E. Morrison (Birmingham, West Midlands, 861 Acute akinetic mutism due to subdural tension United Kingdom) pneumocephalus 871 Reversible parkinsonism in a patient with G. Luetjens, H.-H. Capelle, J.K. Krauss (Hannover, Whipple’s disease Germany) E. Gasparoli, P. Zamboni, M. Siviero, R. Manara, R. 862 Red flags for multiple system atrophy Marcolongo, N. Bonetto, C. Briani (Padova, Italy) M. Kollensperger, K. Seppi, F. Geser, M. Sawires, 872 Progressive multifocal leucoencephalopathy (PML) N.P. Quinn, V. Koukouni, P. Barone, M.T. Pellecchia, presenting as Parkinsonism in an HIV positive man W.H. Oertel, N. Schimke, E. Dupont, G. Deuschl, K.L. Poston, D.L. Raszl (New York, New York, USA) C. Daniels, N. Giladi, T. Gurevich, C. Sampaio, M. 873 Freezing of gait in older adults with high level gait Coelho, O. Lindvall, C. Nillson, A. Albanese, F. Del disorders: Association with impaired executive Sorbo, E. Tolosa, A. Cardozo, T. Klockgether, M. function Abele, R. Djaldetti, G. Meco, C. Colosimo, W. Poewe, N. Giladi, V. Huber-Mahlin, T. Herman, J.M. Hausdorff G.K. Wenning (Innsbruck, Austria) (Tel Aviv, Israel) 863 Creutzfeldt-Jacob disease mimicking progressive 874 Parkinsonism in antiphospholipid syndrome – a supranuclear palsy case report and literature review F.M. Huber, V. Sazdovitch, U. Heinemann, S. Haïk, Y.-R. Wu, Y.-C. Huang, R.-K. Lyu (Taipei, Taiwan) J.J. Hauw, F. Zanini, D.W. Droste, N.J. Diederich 875 CSF hypocretin-1 levels are normal in multiple (Luxembourg-City, Luxembourg) system atrophy 864 Neurological features of Wilson’s disease W.F. Abdo, B.R. Bloem, B. Kremer, G.-J. Lammers, precipitated by liver transplantation M.M. Verbeek, S. Overeem (Nijmegen, Netherlands) K.E. Kotschet, A.J. Hughes (Fitzroy, VIC, Australia) 876 Brain energy metabolism and effects of coenyzme 865 Pattern of cerebrospinal fluid tau forms is altered Q10 (CoQ10) in progressive supranuclear palsy in progressive supranuclear palsy (PSP) A. Padovani, B. Borroni, F. Gardoni, L. Parnetti, L. M. Stamelou, U. Pilatus, K.M. Eggert, W.H. Oertel, Magno, M. Malinverno, E. Saggese, P. Calabresi, G.U. Hoeglinger (Marburg, Germany) M.G. Spillantini, M. Di Luca (Brescia, Italy)

97 877 Levodopa response in parkinsonism with multiple 888 Pramipexole is effective treatment for RLS mitochondrial DNA deletions patients suffering from afternoon or early evening R.A. Wilcox, A. Churchyard, H. Dahl, W. Hutchinson, RLS symptoms D. Kirby, D. Thyagarajan (Brisbane, QLD, Australia) A.S. Walters, E. Lainey, J. Koester (Edison, New Jersey, USA) Restless legs syndrome 889 Burden of illness associated with Restless legs Poster numbers 878-904 syndrome: Findings from patients visiting primary 878 A patient survey assessing symptomology and care settings in the US treatment trends of Restless legs syndrome in the R.P. Allen, W.J. Kwong, M.O. Calloway, L. Palmer UK (Baltimore, Maryland, USA) S. Tluk, A. Bharkhada, E. Gill, K. Ray Chaudhuri 890 Restless legs syndrome and menopause (London, England, United Kingdom) Y. Kaplan, H. Aytan, F. Demirturk, A.C. Caliskan 879 Lack of drug drug interactions between (Tokat, Turkey) transdermal rotigotine and oral contraceptives 891 Pramipexole for Restless legs syndrome (RLS) M. Braun, J.-P. Elshoff, J.-O. Andreas, B. Strauss, R. in patients with comorbid cardiovascular (CV) Horstmann (Monheim am Rhein, Germany) disease 880 Clinical characteristics and prevalence of Restless J.W. Winkelman, E. Lainey, J. Koester (Brighton, legs syndrome in orhangazi district of Bursa, Massachusetts, USA) Turkey (a population-based door to door study) 892 Restless arms syndrome heralding MGUS-related (Bursa, Turkey) anti-MAG polyneuropathy S. Erer, M. Zarifoglu, N. Karli, S. Akgoz, C. Cavdar J. Horvath, T. Landis, P.R. Burkhard (Geneva, (Bursa, Turkey) Switzerland) 881 Restless legs syndrome in Parkinson’s disease 893 MRI determined brain iron deficiency in Restless – own experience legs syndrome (RLS) A. Budzianowska, M. Golab-Janowska, K. J. Godau, K.J. Schweitzer, A. Di Santo, T. Gasser, D. Honczarenko (Szczecin, Poland) Berg, U. Klose (Tuebingen, Germany) 882 Restless legs syndrome (RLS): A community-based 894 Prevalence of Restless legs syndrome in a study from Argentina primary-care population G. Persi, A. Ayarza, J.L. Etcheverry, V. Parisi, G. R.P. Allen, M.O. Calloway, W.J. Kwong, L. Palmer Pariso, E.M. Gatto (Buenos Aires, Argentina) (Baltimore, Maryland, USA) 883 Botulinum toxin a treatment can improve 895 Cognitive functions in patients with Restless legs symptoms of Restless legs syndrome syndrome D. Richardson, R. Bajwa, M. Eisa, D. Miller, V. S. Fulda, J. Winkelmann, T.C. Wetter (Munich, Mohsenin, B. Jabbari (New Haven, Connecticut, USA) Germany) 884 Restless legs syndrome and chiari type 1 896 Pramipexole improves daytime symptoms among malformation patients with Restless legs syndrome (RLS) with Y. Kaplan (Tokat, Turkey) impaired daytime function 885 Disruption of working life among persons with C.A. Kushida, S. Albrecht, J. Koester (Stanford, moderate to severe Restless legs syndrome California, USA) E. Lainey, S. Albrecht, J. Koester (Ridgefield, 897 Pain in the Restless legs syndrome is more Connecticut, USA) common in patients with frequent RLS 886 Clinical characterization of familial and sporadic W.A. Hening, R.P. Allen, C.J. Earley, C. Allen, C. Restless legs syndrome Hening (New York, New York, USA) L.A. Brown, S.-C. Lin, J.E. Young, R.J. Uitti, Z.K. 898 Circadian time course of laser evoked potentials Wszolek (Jacksonville, Florida, USA) (LEP) and laser induced pain thresholds in patients 887 Pregabalin in Restless legs syndrome with and with idiopathic RLS without neuropathic pain C.G. Bachmann, C. Harder, T. Tings, C. Baier, W. M. Sommer, C.G. Bachmann, K.M. Liebetanz, J. Paulus, S. Happe (Goettingen, Germany) Schindehütte, T. Tings, W. Paulus (Goettingen, Germany) 98 899 Where dopamine meets opioids: A meta-analysis 909 Quality of life following botulinum toxin (Dysport) of the placebo effect in RLS treatment studies in upper limb spasticity following stroke S. Fulda, T.C. Wetter (Munich, Germany) A. Hughes, I. Baguley, L. Davies, S. de Graaff, P. 900 Dose-response relationships for pramipexole in Katrak, P. McCrory, J. Sandanam (Melbourne, VIC, Restless legs syndrome Australia) K.D. Sethi, E. Lainey, J. Koester (Augusta, Georgia, 910 Clinical and electrophysiological evaluation of post USA) stroke spasticity – an attempt to correlate 901 Rotigotine transdermal patch provides high R.R. Garlapati, M. Umaiorubahan (Chennai, responder rates in patients with Restless legs Tamilnadu, India) syndrome – 24 month results from a multi- 911 Spasticity treatment with BTX-A improves the national, multi-centre, open-label, follow-up trial functional hand development in patients with C. Trenkwalder, K. Stiasny-Kolster, D. Garcia- cervical spinal cord injury Borreguero, B. Hoegl, J. Keffel, E. Schollmayer, W.H. E. Gasparoli, F. Piccione, A. Merico, M. Cavinato Oertel (Kassel, Germany) (Venezia Lido, VE, Italy) 902 The prevalence of Restless legs syndrome and its 912 A “N=1” randomized placebo-controlled multiple association with peripheral neuropathy in dialysis cross-over pilot study of FP0011, a novel patients antiglutamate agent, in advanced PD A. Bogucki, A. Pozdzik-Koseda, J. Wyroslak (Zgierz, O.O. Rascol, L. Lacomblez, J. Ferreira, L. Negre- Poland) Pages, J.-C. Lemarie, L. Bossi (Toulouse, France) 903 Restless legs syndrome – a clinical, etiological 913 Comprehensive spasticity treatment for and electrophysiological study institutionalized adults with mental retardation S. Vanchilingam, M. Umaiorubahan (Chennai, C.E. Gill, C.R. Blair, H.M. Taylor, C. Nixon, P.D. Charles Tamilnadu, India) (Nashville, Tennessee, USA) 904 Sleep problems in patients with RLS have a 914 Analysis of surgical intrathecal [i.t.] baclofen [ITB] negative impact on quality of life and increase the implant results emphasizing revision surgery in a RLS health burden mixed pediatric/adult population R.P. Allen, P. Stillman, A.J. Myers (Baltimore, Y.M. Awaad, N. Roosen, K. McIntosh, M. Waines Maryland, USA) (Bloomfield Hills, Michigan, USA) 915 Functional assessment following intrathecal Spasticity baclofen therapy in children with spastic cerebral Poster numbers 905-917 palsy 905 Autosomal dominant spastic paraplegia (SPG36) Y.M. Awaad (Bloomfield Hills, Michigan, USA) with sensory deficits and muscle wasting maps to 916 Retrospective cross-over evaluation of two chromosome 12q23-24 botulinum toxin type A preparations (Botox® K. Karle, M. Bonin, A. Durr, S. Forlani, J. Kassubeck, and Dysport®) in the treatment of lower limb S. Klimpe, A. Seibel, B.P.C. van de Warrenburg, P. spasticity Bauer, L. Schols (Tubingen, Germany) Y. Parman, H. Hanagasi, B. Topcular (Istanbul, Turkey) 906 SPG10 is responsible for about 3% of autosomal 917 Botulinum toxin treatment for hip flexor spasticity dominant spastic paraplegia in Germany in older children and adults – a report on 22 K. Karle, R. Schule, J. Kassubeck, S. Klimpe, T. patients Klopstock, S. Otto, L. Schols (Tubingen, Germany) A. Stenner, G. Reichel, W. Hermann (Zwickau, 907 Retrospective cross-over evaluation of two Germany) botulinum toxin type A preparations (Botox® and Dysport®) in the treatment of upper limb Tics spasticity Poster numbers 918-933 Y. Parman, H. Hanagasi, B. Topcular (Istanbul, Turkey) 918 Different perception of tourette syndrome among 908 Botulinum toxin to treat spasticity secondary to patients, relatives and physicians ipsilateral cerebellopontine oligodendroglioma E. Cubo, J. Rivera, J. Almazan (Burgos, Spain) A.M.L. Quek, R.C.S. Seet, E.C.H. Lim (Singapore)

99 919 Adult onset simple phonic tic after caudate stroke 931 Motor and behavioral outcomes after bilateral G. Meritxell, P.-S. Claustre, P. Victor, V. Rosa, O. GPi deep brain stimulation for severe Tourette Carlos, R. Jaume (Barcelona, Spain) syndrome 920 Deep brain stimulation for tourette syndrome: J. Shahed, J. Poysky, C. Kenney, R. Simpson, J. “Hope or hype?” Personal remarks Jankovic (Houston, Texas, USA) D. Servello, M. Sassi, S. Defendi, A. Brambilla, M. 932 Tic disorders associated to : 2 cases Porta (Milan, Italy) H. Alonso-Navarro, T. Adeva-Bartolomé, F.J. 921 Fragile X syndrome associated with tic disorders Jiménez-Jiménez (Salamanca, Spain) S.A. Schneider, M.M. Robertson, R. Rizzo, J. Turk, 933 Early-onset Tourette syndrome K.P. Bhatia, M. Orth (London, United Kingdom) F. Richer, P. Lesperance, S. Chouinard, G. Rouleau 922 Determinants of quality of life in Gilles de la (Montreal, Quebec, Canada) Tourette syndrome Tremor S.S. Al Faqih (Ramadi, Iraq) Poster numbers 934-973 923 Motor tics in a patient with Joubert syndrome 934 A new familial disorder: Saccadic oscillations of A.A. Contreras, J.J. Guzman de Villoria, A.A. Traba, the eyes F.F. Grandas (Madrid, Spain) A.G. Shaikh, K. Miura, L.M. Optican, S. Ramat, R.J. 924 Quality of life of patients with Gilles de la Leigh, D.S. Zee (Baltimore, Maryland, USA) Tourette’s syndrome: Results of the pilot study 935 Novel molecular mechanism of essential tremor F. Galland, L. Malet, Y. Worbe, A. Hartman, L. Mallet, – a computational approach P.-P. Derost, D. Morand, I. de Chazeron, P.-M. Llorca, Y. A.G. Shaikh, S. Ramat, L.M. Optican, K. Miura, D.S. Agid, F. Durif, I. Jalenques (Clermont-Ferrand, France) Zee (Baltimore, Maryland, USA) 925 Ziprasidone in treatment of tics in Tourette 936 Connexin gap junctions – neurophysiological syndrome correlate and therapeutic target for oculopalatal M. Blazquez-Estrada, M.T. Calatayud-Noguera, B. tremor Blazquez-Menes (Oviedo, Asturias, Spain) A.G. Shaikh, S. Hong, D. Solomon, K. Liao, L.M. 926 A case of a patient with coexistent Tourette Optican, R.J. Leigh, D.S. Zee (Baltimore, Maryland, syndrome and benign hyperbilirubinemia USA) S.G. Khachatryan, Z.D. Tavadyan, G.R. Melikyan 937 The effect of muscle loading on tremor dynamical (, ) characteristics in the essential tremor patients 927 Two cases of coexistent Tourette syndrome and S. Blesic, J. Maric, N. Dragasevic, S. Milanovic, V.S. Kostic, M.R. Ljubisavljevic (Al Ain, United Arab Z.D. Tavadyan, S.G. Khachatryan, G.R. Melikyan Emirates) (Yerevan, Armenia) 938 Effectiveness of piracetam in action tremor/ 928 Biofeedback assisted relaxation training for myoclonus of patients with Parkinson’s disease children and adolescents with tics and associated R. Neshige (Kurume City, Fukuoka, Japan) disorders 939 An open label study of pramipexole for the S. Natriashvili, U. Haller, S. Ohmann, C. Popow treatment of essential tremor (Vienna, Austria) L. Lay-Son, D. Saez, O. Trujillo (Santiago, Chile) 929 Excitability of cortico-spinal system at rest is 940 Disappearance of essential tremor after capsular associated with tic severity in Gilles de la Tourette infarction syndrome N.S. Oztekin, M.F. Oztekin (Ankara, Turkey) M. Orth, A. Münchau, J.C. Rothwell (London, United 941 Impaired motor speech and balance control in Kingdom) essential tremor 930 Behavioral deficits in rats selectively bred M. Kronenbuerger, P. Buderath, B. Frank, C. Fromm, for deficient prepulse inhibition of the startle V.A. Coenen, V.M. Tronnier, K.L. Kiening, W. Ziegler, D. response Timmann (Aachen, Germany) K. Schwabe, M. Dieckmann, J.K. Krauss, M. Koch 942 Essential tremor – easy to see, difficult to describe (Hannover, Germany) and control N. Yardimci, S. Benli (Ankara, Turkey) 100 943 Health-related quality of life in essential tremor 954 Bilateral effects of unilateral deep brain patients undergoing deep brain stimulation stimulation C. Kenney, A. Diamond, A. Davidson, L. Shinawi, J. N. Kovacs, I. Balas, L. Kellenyi, E. Pal, F. Nagy (Pecs, Jankovic (Houston, Texas, USA) Hungary) 944 The spectrum of orolingual tremor – a proposed 955 The differences of characteristics in physiologic classification system tremor between dominant and non-dominant hand M.A. Silverdale, S.A. Schneider, K.P. Bhatia, A.E. Lang in normal population (Manchester, United Kingdom) I.-U. Song, J.-S. Kim, D.-S. Jeong, K.-S. Lee (Seoul, 945 Evaluation of postoperative outcome on tremor Republic of Korea) due to posterior fossa tumors 956 Blood harmane concentration is correlated with T.M. Kinfe, H.-H. Capelle, J.K. Krauss (Hannover, cerebellar metabolism in essential tremor Germany) E.D. Louis, W. Zheng, X. Mao, D.C. Shungu (New 946 Unilateral tremor associated with autosomal York, New York, USA) dominant essential tremor 957 Does Parkinsonian tremor influence patients’ P. Hedera, F. Phibbs, J.Y. Fang, P.D. Charles, M.K. quality of life (QOL)? Cooper, T.L. Davis (Nashville, Tennessee, USA) T. Kondo, Y. Kajimoto, I. Nakanishi (Wakayama, 947 Internal Family Systems psychotherapy Japan) successfully applied in two cases of psychogenic 958 Validity of family history in essential tremor tremor P.K. Manharlal, S. Fook-Choong, Y. Yuen, T.E. King F.P. Le Doze, L. Carluer, G.L. Defer, R.C. Schwartz (Singapore, Singapore) (Caen Cedex, France) 959 Clinical characteristics and prevalence of essential 948 Dopa- responsive pseudo-orthostatic tremor in tremor in orhangazi district of Bursa, Turkey (a parkinsonism population-based door to door study) (Bursa, A. Thomas, L. Bonanni, S. Varanese, F. Anzellotti, Turkey) K. Armellino, A. D’Andreagiovanni, D. Monaco, M. S. Erer, M. Zarifoglu, N. Karli, A. Semra, Y. Demet Onofrj (Pescara, Italy) (Bursa, Turkey) 949 Lack of association between catecholamine-O- 960 Harmonic frequencies in tremor methyl transferase Val158Met polymorphism and P.H. Kraus, A. Hoffmann, G. Ellrichmann (Bochum, essential tremor Germany) E. Ergul, A. Sazci, K. Bayulkem (Kocaeli, Turkey) 961 Essential tremor characteristics during different 950 Adult-onset Alexander disease with palatal tremor arm posture positions and mechanical load and intraventricular tumor N. Dragasevic, S. Radovanovic, J. Maric, A. Tomic, Y. Okuma, T. Hirayama, J. Fukae, K. Noda, K. N. Kresojevic, I. Petrovic, M. Svetel, V.S. Kostic Fujishima, N. Hattori (Izunokuni, Shizuoka (Belgrade, Serbia) Prefecture, Japan) 962 Unique software algorithms for tremor analysis 951 Confirmation that dystonic tremor with features – comparing the novel approach and standard of parkinsonism is a cause of scans without techniques evidence of dopaminergic deficit (SWEDDs) A.G. Shaikh, T.O. Crawford, R.M. Tripp, D.S. Zee D.J. Hensman, J.W. Frank, P.G. Bain (London, United (Baltimore, Maryland, USA) Kingdom) 963 Holmes tremor due to midbrain hematoma 952 Quantitative tremor analysis in 300 consecutive F.M. Oztekin, N.S. Oztekin (Ankara, Turkey) tremor patients 964 Reduced purkinje cell number in essential tremor: M. Löhle, T. Glöckler, I. Hoffmann, K. Kreutzmann, A postmortem study S. Junghanns, M. Wolz, H. Reichmann, A. Storch E.D. Louis, J.E. Axelrad, L.S. Honig, I. Flores, G.W. (Dresden, Saxony, Germany) Ross, R. Pahwa, K.E. Lyons, P.L. Faust, J.P.G. 953 The effect of oxcarbazepine on essential tremor Vonsattel (New York, New York, USA) N. Yardimci, S. Benli (Ankara, Turkey)

101 965 Tremor associated to chronic inflammatory demyelinating peripheral neuropathy (CIDP): Treatment with Pregabalin H. Alonso-Navarro, A. Fernández-Díaz, M. Martín- Prieto, J.J. Ruiz-Ezquerro, T. López-Alburquerque, F.J. Jiménez-Jiménez (Salamanca, Spain) 966 Isolated tongue tremor after removal of cerebellar pilocytic astrocytoma: Functional analysis with Subtracted ictal SPECT coregistered to MRI study S.J. Kim, W.Y. Lee, J.Y. Kim, B.J. Kim, D.W. Seo (Seoul, Republic of Korea) 967 Provoking Parkinsonian tremor J. Raethjen, K. Austermann, F. Papengut, G. Deuschl (Kiel, Germany) 968 Clinical features of Parkinsonian tremor F. Papengut, J. Raethjen, G. Deuschl (Kiel, Germany) 969 Thalamic stimulation induced gustatory dysfunction in a patient with essential tremor J. Roggendorf, J. Vent, M. Maarouf, C. Haense, A. Thiel, G.R. Fink, R. Hilker (Koeln, Germany) 970 Reconstruction of the petrosal bone for treatment of kinetic tremor due to cerebellar herniation and torsion of cerebellar outflow pathways T. Kinfe, O. Sedlaczek, W. Bergler, C. Blahak, M. Hennerici, J.K. Krauss (Hannover, Germany) 971 Long duration accelometry to assess efficacy of oral 1-octanol in patients with essential tremor F.B. Nahab, S. Baines, D. Ippolito, M. Hallett (Bethesda, Maryland, USA) 972 Palatal tremor and ataxia associated with sporadic adult-onset Alexander’s disease N. Jodoin, C. Vandendries, D. Grabli, G. Bruneteau, D. Rodriguez (Paris, France) 973 Experience in therapy of essential tremor (ET) combined with arterial hypertension (AH) by prolonged beta-adrenoblockators (Dilatrend, Carvedilol): The pilot study D.V. Pokhabov, V.G. Abramov (Krasnoyarsk, Russian Federation)

102 Membership Information Full Membership Benefits • A subscription to the print, DVD, and online journal, Movement Disorders, including supplemental publications, such as “Management of Parkinson’s Disease: An Evidence-Based Review and Pediatric Movement Disorders” CD-ROM. • A unique selection of educational opportunities, including live and online CME/CPD activities and reference material on topics in Movement Disorders such as The Movement Disorder Society’s Guide to Botulinum Toxin Injections CD-ROM. • A reduction in fees charged for participation in the The Movement Disorder Society Society’s educational programs. Among these are The Movement Disorder Society the annual International Congress of Parkinson’s Disease and Movement Disorders, as well as regional programs, courses and workshops held each year. • A print directory listing mailing addresses, telephone and fax numbers, and e-mail addresses for all members. • A Members Only Section of the MDS Web site at www.movementdisorders.org, including a searchable Membership Directory. • A quarterly newsletter entitled Moving Along, highlighting current news and views in the field of Movement Disorders. • Participation in the election of International and Regional Section Leadership Representatives. Non-Members Applying for MDS Membership Non-Members may apply for MDS membership as part of their International Congress registration. The registration fee includes MDS membership at a reduced rate ($50 savings) with limited benefits through 2007, and full Visit us on the Web at membership status, including the print journal, in 2008. New MDS member applicants will be contacted by www.movementdisorders.org the MDS International Secretariat to provide additional For further information, please contact: information. The Movement Disorder Society 2007-2008 will be another exciting year for MDS and we International Secretariat look forward to bringing you news of these and other new 555 East Wells Street, Suite 1100 initiatives through the Movement Disorders journal, the Milwaukee, WI 53202 USA Moving Along newsletter and the MDS Web site. Tel: + 1 414-276-2145 Fax: + 1 414-276-3349 E-mail: [email protected] Web site: www.movementdisorders.org 103